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Abstract 
 
Chemical Tools for Investigating Galectin Dynamics 
 
by 
 
Brian Daniel Belardi 
 
Doctor of Philosophy in Chemistry 
 
University of California, Berkeley 
 
Professor Carolyn R. Bertozzi, Chair 
 
 
 Pattern recognition is an essential feature governing many biological processes, including 
metazoan development, infection, and tumorigenesis. Glycans form a unique pattern on the 
surfaces of cells. There, these branched, intricate structures are poised to direct communication 
between neighboring cells and tissues. How cells interpret the staggering complexity associated 
with the glycome, the repertoire of glycan structures expressed in cells and tissues, though is still 
not well understood. Galectins comprise one family of glycan-binding proteins that are thought 
to play a role in decoding glycomic patterns. They have been implicated in cell adhesion and 
signaling, proliferation, membrane organization, and transcript processing. Yet, the mechanistic 
underpinnings of the pleiotropic functions of galectins remain obscure due to challenges 
associated with studying lectin-glycan interactions. 
 Monitoring and modulating glycan patterns present on different cell surface 
glycoconjugates would greatly facilitate our understanding of galectin-dependent phenomena. 
Unfortunately, glycosylation is a post-translational modification that is dependent on the 
collective action of hundreds of enzymes. The final glycans appended to proteins and lipids are 
not directly encoded in the genome, and as such, there is no obvious means to tag or tailor 
complex, galectin ligands in vivo. This situation is further exacerbated by the properties of 
galectins themselves. Galectin-1, for instance, self-assembles in vitro and traverses cell 
membranes, occupying extracellular, cytosolic, and nuclear spaces. Therefore, isolating 
galectins’ dynamic organization in each subcellular context is imperative, yet non-trivial 
experimentally.   
 This dissertation describes the development of new chemical and biophysical tools for 
studying galectin dynamics and their contribution to cellular physiology and pathology. Chapter 
1 explores and summarizes recent advances in chemical methodology that report on mammalian 
lectin function in vivo. In Chapters 2 and 3, I present a platform for monitoring galectin-mediated 
cross-linking on living cells with synthetic glycoprotein mimics. Chapter 4 outlines a technique 
to image galectin ligands, i.e. specific protein glycoforms, in cultured cells and tissue slices. 
Finally, Chapter 5 is dedicated to clarifying galectin’s influence on mammary gland 
morphogenesis and breast cancer progression. Therein, I discuss harnessing the tools described 
in Chapters 1-4 to reveal an unprecedented, galectin-based mode of information transfer between 
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extracellular glycomic signatures and nuclear transcription machinery that drives mammary 
epithelial invasion.  
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Chapter 1. Chemical Methods for Probing the Dynamics of Mammalian Lectins In Vivo 
 
 
Introduction 
 
 The glycan appendages to proteins and lipids, collectively termed the glycome, are an 
information-rich set of molecular cues that influences almost every facet of molecular, cellular, 
and organismal biology, including, but not limited to, protein stability and function, cellular 
trafficking, signal transduction, cell-cell recognition, development, host defense and progression 
of pathology.1 The glycome exceeds the combinatorial complexity of other classes of 
biomolecules, e.g. proteins and nucleic acids.2 This diversity is due to the action of ~250 
glycosyltransferases that catalyze the addition of different glycan moieties onto their substrates 
with varying regio- and stereo-chemical specificities. While physical properties of these 
modifications can partially account for their biological effect, the overwhelming number of 
diverse glycan elaborations represents a molecular code that is interpreted by the local 
environment. In mammals, a class of glycan-binding proteins, lectins, is responsible for 
deciphering this glycan code.3,4 
 Lectin research during the past century has made significant strides towards the isolation 
of different lectin family members and the understanding of lectin binding preferences, 
hemagglutination activity and structure in vitro.5 This pursuit has been extremely productive as 
lectins are now routinely used as biological reagents in glycoprotein purification and cell staining 
as well as in biomedical-related applications. However, unraveling the in vivo glycan partners 
and functions of many mammalian lectins has been hampered by several features intrinsic to 
lectin-glycan interactions. First, studying the glycan partners for an individual lectin is 
exceptionally challenging using traditional tools. These ligands comprise a heterogeneous set of 
glycoconjugates with similar glycan compositions but disparate underlying protein and lipid 
scaffolds. Glycosylation, a post-translational modification, is not amenable to genetic 
manipulations, and as such, encoding a specific glycan structure with genetic engineering is not 
possible. As well, not all in vitro glycan ligands translate to an in vivo setting.6 In the context of a 
cell surface, it is probably only a subset of possible glycoprotein ligands, for instance, that 
actually interacts with a lectin-of-interest. The protein backbone is known to complicate glycan 
presentation, sometimes restricting glycan conformation and localization and even modulating 
affinity through cooperative interactions.7,8 Further still, lectins have convergently evolved to 
possess weak affinity for their monomeric glycan ligands (Kd’s of 100 uM to 1 mM). 
Multivalency, the presence of numerous glycan ligands on a single target, is responsible for the 
increased avidity of lectins for their targets.9,10 However, in vivo, these multiple glycan contacts 
may be heterogeneous and thus difficult to fully elucidate.  
 Another overlooked, but nonetheless vital feature, of lectin-glycan interactions relates to 
lectin dynamics. Early notions of mammalian lectin function dealt with glycan-binding proteins 
as docking sites for other cells and soluble glycoconjugates, i.e. sources of adhesion.11 Many 
lectins have the capacity to self-assemble though, either in solution or when embedded in the 
membrane, begging the question of what effect this ability has on glycan interactions.12 Aside 
from an increase in binding avidity, oligomeric lectins resemble adaptor proteins and can act as 
an organizing principle in vivo.  They can cluster their glycoconjugate ligands into functional 
domains or increase the probability that protein-protein associations transpire. As well, it is now 
clear that kinetic rate constants (kon and koff) for this assembly process vary under different 
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glycosylation and cellular conditions, tuning the influence of lectin multimerization.13 Since 
most lectin families are thought to lack regulatory domains or allosteric control, lectin trafficking 
and sub-cellular localization, and their respective dynamics, control how and when lectins exert 
their function. Unfortunately, traditional biological tools are not able to follow many of these 
time-dependent and sub-diffraction events in vivo. For example, tagging lectin monomers, which 
can be as small as ~15 kDa,14 with fluorescent proteins (molecular weights of ~25 kDa)15 can 
perturb lectin self-assembly, and visualizing this assembly with conventional microscopy 
obscures much of a lectin’s organizational properties.  
 Rapid advances in chemical methods have begun to meet the many challenges associated 
with unveiling lectin’s contributions in vivo. In this chapter, the focus will be on recent 
contributions that attempt to answer either 1) what native glycan structures mammalian lectins 
recognize or 2) what the dynamics of different lectins are and how they relate to lectin function. 
The various chemical strategies can be divided into three categories: metabolic cross-linking 
sugars, glycoprotein mimics, and site-selective tagging and imaging technologies (Figure 1.1). 
While this is by no means an exhaustive list of techniques for observing lectin binding and 
dynamics, these tools have transformed our understanding of lectin-glycan interactions in vivo 
and will continue to reveal unexpected features of mammalian lectins in the future.  
 
 
 
Figure 1.1. Recent chemical methods have begun to elucidate the binding partners and dynamic 
behavior of mammalian lectins in vivo. Metabolic cross-linking sugars can report on the in situ 
interactions between lectins and glycans by incorporating into endogenous cell surface 
glycoproteins. Glycoprotein mimics, on the other hand, are synthetic, multimeric structures 
capable of revealing the properties and biological consequences of lectin organization. New 
tagging and imaging technologies aim to complement these glycan-based strategies and promise 
to monitor lectin trafficking and organization in vivo. 
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Metabolic Cross-linking Sugars 
 
 A single lectin can associate with glycans derived from a variety of linkages, such as N-
linked and O-linked glycoproteins as well as glycolipids. N-linked glycosylation occurs co-
translationally or post-translationally in the endoplasmic reticulum (ER).1 The addition of a 
tetradecasaccharide to asparagine residues within the sequon, NXS/T, is accomplished through 
the action of a single enzyme complex, oligosaccharyltransferase (OST). Mucin-like O-linked 
glycans, on the other hand, are initiated post-translationally in the Golgi apparatus, where a 
member of the polypeptide N-acetylgalactosaminyltransferase (ppGalNAcTs) family modifies a 
serine or threonine residue with the monosaccharide, N-acetyl galactosamine (GalNAc).1 The 
early steps in these glycosylation pathways are quite distinct, generating unique glycan structures 
near the peptide backbone. However, as both types of glycoproteins in addition to 
glycospingolipids transit through the Golgi, later glycosyltransferases can act on each class of 
glycans and produce terminal glycosylation patterns that are similar or identical. Metabolic 
oligosaccharide engineering provides a means to target similar glycan structures associated with 
diverse scaffolds.  
 Metabolic engineering of glycosylation, first demonstrated by Reutter and co-
workers,16,17 relies on the native cellular biomachinery to incorporate non-natural glycans into 
native glycoconjugates. By extending the acyl side chain of N-acetylmannosamine (ManNAc), 
which is part of the salvage pathway of sialic acid, nonphysiological versions of sialic acid were 
shown to replace the native monomer in vivo.18 This idea was greatly expanded by Bertozzi and 
co-workers in a series of experiments.19,20 Chemical derivatives of ManNAc and sialic acid, 
bearing bioorthogonal functionalities, were found to be tolerated by the sialic acid biosynthetic 
enzymes, the CMP-sialic acid Golgi transporter, as well as by a number of sialyltransferases, to 
afford derivatives of cell surface sialoside structures. As well, the Bertozzi lab and others have 
incorporated unnatural reporter groups into glycans containing GalNAc,21 N-acetylglucosamine 
(GlcNAc),22 fucose,23 and xylose residues24. These pioneering efforts provided evidence that 
similar glycan structures on a variety of different protein and lipid scaffolds could be targeted 
using a metabolic-based approach. Recently, a number of reports have detailed the combination 
of metabolic labeling, where reporter groups attached to cell surface glycans are probed with 
fluorescent conjugates of bioorthogonal reaction partners, and Förster Resonance Energy 
Transfer (FRET) for imaging the precise location of specific glycoprotein ligands.25–27 These 
methods, while certainly expanding the scope of locating glycoconjugate ligands in vivo, are not 
necessarily reporting on bona fide lectin-glycan interactions. Binding events between lectins and 
glycans are plagued by transient non-covalent interactions with high dissociation constants and 
are thus not easily isolable. If possible, taking a snapshot of cellular interactions would provide a 
means to discriminate real from theoretical binding partners in vivo.  
 Carbenes and similar electron-deficient species, highly reactive functionalities, are 
known to undergo C-H and heteroatom-H insertion reactions, forming stable covalent adducts 
rapidly.28 Fast kinetics associated with these insertion reactions can be exploited to trap short-
lived binding events in biological samples.  Covalent cross-linking has recently been utilized to 
identify lectin-glycan interactions in vivo.  
 Siglec-2, or CD22, is a member of the sialic acid-binding immunoglobin-like lectin 
(siglec) family and modulates immune cell activation.29 The sialic acid binding domain of CD22, 
an integral membrane protein, is located in the extracellular space. The other functional domain 
of CD22 is cytosolic and has an immunoreceptor tyrosine-based inhibitory motif (ITIM) that 
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when phosphorylated recruits SH2 domain-containing phosphatase 1.30 This response inhibits 
downstream signaling associated with B-cell receptor (BCR) triggering and establishes a 
threshold for activation, which limits autoimmunity. On resting B cells, however, it was 
hypothesized that cis interactions with other cell surface glycoproteins masked CD22’s lectin 
domain, preventing CD22 and BCR co-localization. To determine the precise cis interactions of 
CD22, Han et al. derivatized the C-9 position of sialic acid with an azidoaryl species (9-AAz-
NeuAc).31 Azidoarenes form nitrenes after UV light exposure and subsequent expulsion of 
nitrogen and can capture proximal proteins by C-H insertion. To identify the exact glycoprotein 
partners in vivo, BJAB K20 cells, a B cell line deficient in sialic acid, were fed 9-AAz-NeuAc. 
After establishing that the azido functionality survived metabolic incorporation by performing a 
Staudinger ligation between cell surface azides and a phosphine-biotin probe, cells were first 
treated with 9-AAz-NeuAc and then irradiated with UV light to induce cross-linking. After 
immunoprecipitation of CD22 from cell lysates, different antibodies were used to test for 
glycoproteins that mask CD22 on B cell surfaces. Interestingly, the only glycoprotein found to 
cross-link CD22 was other CD22 molecules. Glycoproteins that bound soluble CD22 fusion 
constructs in vitro, for example CD45 and CD19, were not cross-linked to CD22 in vivo, 
emphasizing the power of this metabolic-based approach. In addition, the cross-links were found 
be high molecular weight (>400 kDa) species, suggesting that CD22 associates with itself and 
forms multimers on the cell surface. This last finding also reflects the unique dynamics of CD22 
in vivo. CD22’s cytosolic domain has a motif that is recognized by a component of clathrin-
coated pits and therefore may reinforce CD22 self-association and microdomain formation on 
resting B cells.  
 Paulson and co-workers wanted to also apply this same photocross-linking strategy to the 
trans ligands of CD22.32 During B cell engagement, glycoproteins on apposing cells unmask 
CD22, changing its dynamics. Subsequent localization to regions enriched in BCR downregulate 
immune signaling. The authors generated a list of potential glycoprotein candidates that interact 
during B cell-B cell contact by first incubating K20 cells with 9-AAz-NeuAc in serum-free 
media. Intact cells were then treated with the soluble CD22-Fc chimera, a surrogate for B cells, 
and exposed to UV light. After lysis, cross-linked species were isolated by a Protein G-resin and 
separated by gel electrophoresis. In-gel trypsin digestion and liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) identified 24 proteins, whose peptides had high spectral counts 
compared to non-UV radiation exposed cells. To corroborate their trans ligand list as well as 
increase the number of identified candidates through stable isotope labeling by amino acids in 
cell culture (SILAC), 9-AAz-NeuAc positive cells were grown either in media containing light 
([12C]lysine and [12C,14N]arginine) or heavy ([13C]lysine and [12C,15N]arginine) amino acid 
isotopes. Both populations were separately incubated with CD22-Fc and only the heavy isotope-
fed cells were irradiated. After combining both populations, purifying CD22 cross-linked 
species, and performing an on-bead trypsin digest, multi-dimensional protein identification 
technology-tandem mass spectrometry (MuDPIT-MS/MS) was used to discriminate and quantify 
proteins that were more abundant after photocross-linking. This complementary method yielded 
19 proteins, all of which were annotated as glycoproteins, and when combined with the previous 
list, resulted in 27 possible glycoprotein trans ligands of CD22. The authors proceeded to 
examine each of these candidates in a cell-cell contact photocross-linking experiment. K20 cells 
were labeled with 9-AAz-NeuAc and overlaid onto Chinese Hamster Ovarian (CHO) cells 
expressing V5-tagged CD22. After UV exposure, lysates were formed and CD22 was 
immunoprecipitated with α-V5. After probing the cross-linked species for the presence of each 
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of glycoprotein candidate, three glycoproteins were found to be interacting with CD22 in trans: 
IgM, CD45, and Basigin. Of these, IgM was the only ligand that showed robust cross-linking. In 
a series of knockdown studies, the authors provided striking evidence that both CD22 and IgM 
dynamics are altered during B cell-B cell contact as the partners redistribute and localize 
preferentially to the sites of cell contact in a lectin- and glycan-dependent manner. Again, this 
work emphasizes how both glycan structure and dynamics are intimately involved in dictating 
binding partners in vivo.  
 There are limitations associated with functionalizing C-9 of sialic acid. This position can 
undergo further modifications, such as 9-O-acetylation, 9-O-lactylation, and 9-phosphorylation,33 
which precludes 9-AAz-NeuAc’s use in situations where elaborated versions of sialic acid are 
under investigation. Tanaka et al. circumvented this problem by replacing the acetyl group of 
ManNAc with an N-acyl diazirine photo-labile functionality.34 Diazirines are known to generate 
carbenes after UV illumination and therefore cross-link binding partners that are in close 
association. Another liability with 9-AAz-NeuAc is its low incorporation levels in wildtype cell 
lines, but a smaller structural perturbation, such as a diazirine unit, should compete with the 
endogenous pool of sialic acid. In addition to K20 cells, wildtype K88 cells fed the fully 
protected diazirine-ManNAc analogue, Ac4ManNDAz, incorporated SiaDAz into cell surfaces 
glycans, and once there, SiaDAz cross-linked siglec CD22. This result provided further evidence 
that CD22 appears to form cis multimers on wildtype resting B cells. Kohler and coworkers went 
on to show that the chain length of N-acyl diazirines was crucial for proper incorporation.35 
ManNDAz derivates containing two (2me), three (3me), or four (4me) methylene chain units 
were synthesized and evaluated for replacement of endogenous sialic acid and subsequent cross-
linking capability (Figure 1.2). In Daudi B cells, only Ac4ManNDAz (2me) was found to cross-
link CD22, which defines the maximal structural perturbation permissible during metabolic 
transformation. This is just one example of how the ability to construct molecules can pinpoint 
the necessary properties for probing lectin-glycan interactions. 
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Figure 1.2. Structures of metabolic cross-linking sugars that upon UV exposure generate 
nitrenes or carbenes (red). These intermediates then react with lectins in vivo to form stable 
covalent adducts.  
 
 In less than a decade, metabolic cross-linking sugars have unearthed surprising features 
of CD22 on B cells. Many glycoproteins are modified with an N-acetylneuraminic acid α(2,6) 
galactose structure (Neu5Ac-α(2,6)-Gal), but among the plethora of possible binding partners of 
the lectin CD22, only CD22 and IgM appear to govern cis and trans interactions in vivo, 
respectively. The Kohler lab has recently expanded the library of cross-linking sugars to other 
glycan monomers,36 and we anticipate that many of these derivatives will be used to detect 
additional mammalian lectin-glycan interactions in the future. We also envision research towards 
inverting the current placement of the cross-linking functional group. If the cross-linking moiety 
is placed within the lectin, then this may provide a means to efficiently capture in vivo 
glycoprotein ligands, particularly in cases where the carbohydrate specificity of a lectin is not 
well understood. Incorporation of photoreactive benzophenones into proteins has already been 
accomplished in mammalian cells through unnatural amino acid incorporation.37 This technology 
could easily be expanded to the recognition domain of most lectins in vivo.  
 
Glycoprotein Mimics 
 
 Many glycoproteins, especially mucin-type O-linked glycoproteins, are heavily 
elaborated biomolecules with repeating motifs of glycosylation. The glycan signatures displayed 
across a single protein backbone can vary dramatically, making analysis of lectin-glycoprotein 
function difficult. Chemists have harnessed biomimicry for decades in order to construct 
molecular surrogates that emulate the essential features of biomolecules but differ in tunable 
composition and properties.38 Three general classes of glycoprotein mimics have been 
successfully synthesized and used to bind mammalian lectins both in vitro and in vivo: 
glycopolymers,39 linear polymers with pendant glycans; glycodendrimers,40 highly branched 
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architectures with terminal glycan residues; and glycoparticles,41 cross-linked organic polymers 
or spherical inorganic materials that are functionalized with glycans through various surface 
chemistries. As opposed to the native heterogeneous glycoforms of proteins, these synthetic 
glycoconjugates offer the ability to incorporate homogeneous glycans structures into a repeating 
sequence. This section will focus on glycopolymers as mimics of glycoproteins, since recent 
synthetic methods, offering unparalleled control over their construction, have yielded profound 
insights into lectin biology.  
 The original synthesis of glycopolymers dates back to the 1970’s.42 Since then, 
glycopolymers have found widespread use as inhibitors, for instance during bacterial infection43, 
and as tools for describing the binding modes of multivalency in vitro.44–46 In the past decade, 
chemical biologists have continued to push glycopolymers into the biological milieu.47 Free 
glycopolymers resemble soluble, secreted glycoproteins, and owing to improved synthetic 
methodology, it is now possible to prepare glycopolymers that mimic membrane-bound 
glycoproteins. With these tools in hand, a number of questions relating to lectin dynamics are 
now accessible and have been addressed for three large families of lectins, namely C-type 
lectins, siglecs, and galectins. 
  Selectins, calcium-dependent lectins (C-type lectins), are critical mediators of cell 
adhesion, especially of immune cell homing.48 The three selectins, P, L, and E- selectins, are 
expressed on different cell types, platelets, leukocytes, and endothelium, respectively. During the 
inflammatory response, leukocytes roll along endothelial cells, adhere to the vascular substrate 
and extravasate into the damaged tissue. As a corollary, the overexpression of L-selectin can lead 
to enhanced leukocyte migration and inflammatory damage, and thus L-selectin density is tightly 
regulated on leukocyte surfaces. The interaction between L-selectin and GlyCAM-1, an O-linked 
glycoprotein, plays a major role in leukocyte rolling along the endothelial wall. Since GlyCAM-
1 possesses sulfated versions of the sialyl Lewis x epitope (sLex), Neu5Ac-α2-3Gal-β1-4(Fuc-α 
1-3)GlcNAc, Mowery et al. were interested in how the differential sulfation of this epitope 
affected L-selectin signaling and regulation.49 The authors employed a type of living 
polymerization, ring opening metathesis polymerization (ROMP), to produce well-defined 
glycoprotein mimics. Living polymerization is a chain-growth method that suppresses the rate of 
termination compared to the rate of propagation, thereby rendering macromolecules with precise 
degrees of polymerization (DOP) and polydispersities (PDI).50 ROMP involves strained cyclic 
olefins and the use of transition metal complexes, containing ruthenium or molybdenum, to 
mediate their polymerization.51 Starting from functionalized norbornenes, different 
glycopolymers bearing sialyl Lewis x or mono- and disulfated analogs of galactose, Lewis x, and 
sialyl Lewis x were prepared (DOP = 15). Acting as soluble glycoprotein mimics, the 
glycopolymers were tested for their ability to downregulate L-selectin on lymphoid cells. The 
3’,6-disulfo Lewis x glycopolymer caused the most significant decrease in surface L-selectin 
levels after binding. Consistent with these results, glycopolymer treatment resulted in soluble L-
selectin in the supernatant, therefore indicating that shedding, or proteolytic release, of L-selectin 
was responsible for the lectin’s downregulation. None of the monovalent glycan equivalents 
promoted L-selectin shedding. The data together provide evidence that clustering of L-selectin 
by disulfated glycoprotein mimics on the cell surface signals it’s proteolytic release. It also 
appears that sulfation and therefore Coulombic forces as opposed to sialylation of glycoprotein 
ligands are more important factors in L-selectin shedding in vivo.  
 To address how spacing of these glycan epitopes along a glycoprotein might modulate 
the signaling of L-selectin clusters, well-defined glycoconjugates were formed using alanine-rich 
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recombinant polypeptides.52 Glycan conjugation to glutamic acid residues at defined positions 
yielded well-defined, α-helical glycoprotein mimics. Specifically, disulfated galactosyl amines 
were coupled to the polypeptide backbone with HBTU and arranged at two different distances, 
1.7-3.5 nm and 3.5-5.0 nm. Jurkat T cells were incubated with these glycopolypeptides, and the 
amount of L-selectin shedding was determined by an enzyme-linked immunosorbent assay 
(ELISA) for the protein. As anticipated, monovalent glycans and an unstructured 
glycopolypeptide did not induce L-selectin shedding. However, while the 1.7-3.5 nm construct 
resulted in L-selectin cleavage, the 3.5-5.0 nm glycopolypeptide, unexpectedly, did not. Once 
again, this discrepancy in shedding highlights how the dynamics of selectin organization on cell 
surfaces has functional consequences. Formation of L-selectin clusters are thought to lead to 
calmodulin (CaM) release by the cytoplasmic tail of the protein, which is then followed by a 
conformational change that causes the protein to be susceptible to sheddase activity. Results 
from glycoprotein mimics outlined above add another parameter that influences signaling and 
shedding of L-selectin. L-selectin monomers must be within sufficient proximity to one another 
after binding for signaling to occur, a spatial requirement that appears necessary for subsequent 
shedding.  
 Dendritic cell-specific ICAM-3-grabbing nonintegrin (DC-SIGN) is a member of the C-
type lectin class and carries out a multitude of functions on DCs through interactions with high 
mannose glycans and fucosylated Lewis-type antigens on ICAM-3 and ICAM-2.53 DC-SIGN 
stabilizes immunological synapases during T-cell engagement and can mediate trans-endothelial 
migration. It was also thought to be involved in antigen uptake and processing. A glycomimetic 
was subsequently developed that could undergo DC-SIGN-mediated uptake.54 Bovine serum 
albumin (BSA), acting as a polymeric backbone, was decorated with mannose mimetics bearing 
either native mannosyl or fucosyl residues using lysine chemistry (~16 copies per BSA). 
Fluorophore-functionalized BSA glycoconjugates were administered to Raji cells, a B cell line, 
stably transfected with the gene for DC-SIGN (Raji/DC-SIGN). The Raji/DC-SIGN cells, but not 
the wt Raji cell line, internalized all three glycoconjugates, including the unnatural mannose 
mimetic-BSA. The glycoprotein surrogates also stimulated JNK signaling in response to 
interaction with DC-SIGN. Phosphorylation of JNK was not seen in other studies of DC-SIGN 
binding, leading to the proposal that DC-SIGN reorganization and perhaps clustering is 
necessary for signaling to take place. C-type lectin-dependent uptake may be a general feature in 
antigen processing as polyacrylamide (PAA)-GalNAc glycopolymers are readily internalized by 
DCs through Macrophage Galactose-type C-type Lectin 2 (MGL2), resulting in their 
presentation in DCs.55  
  
 As discussed above, CD22 belongs to the siglec family of lectins. An important siglec on 
B cells, CD22 downregulates immune cell activation via recruitment of SHP-1 phosphatase to 
the site of receptor signaling. Cis α2,6-linked sialic acid-CD22 interactions were shown to mask 
CD22 on resting B cells. But one question remained: what are the properties of trans ligands that 
promote escape from masked CD22 multimers? Collins et al. examined this question by 
constructing a series of sialoside glycoprotein mimics.56 Two different molecular mass 
biotinylated PAA polymers, 30 kDa and 1000 kDa, were used as starting materials for the 
attachment of sialosides, including NeuAc and its C-9-biphenyl derivative (BPC-NeuAc) as well 
as the native N-glycolylneuraminic acid (NeuGc) and its C-9-biphenyl derivative (BPA-NeuGc). 
Aromatic groups at the C-9 position of sialic acid had been previously shown to increase affinity 
toward CD22.57 The prepared glycopolymers were added to either BJAB or Daudi B cells, and 
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flow cytometry was used to detect glycopolymer binding. Only the 1000 kDa BPC-NeuAc-PAA 
and BPA-NeuGc-PAA polymers adhered to the B cell surface. The native sialoside polymers, 
NeuAc-PAA and NeuGc-PAA, in addition to the 30 kDa glycopolymers did not exhibit cell 
surface retention. A simple interpretation of these findings is that CD22 exists in a dynamic 
‘equilibrium’ on the surface of B cells. If presented with ligands possessing a sufficient threshold 
of affinity, the CD22 binding ‘equilibrium’ favors unmasking, whereas if the glyconconjugate 
ligands are too weak, then the CD22 ‘equilibrium’ favors self-association. Only in the case when 
CD22 is presented with highly multivalent glycopolymers, 1000 kDa, containing high affinity 
glycan derivatives, i.e. BPC-NeuAc and BPA-NeuGc, does unmasking occur. The authors go on 
to provide evidence that the CD22-bound PAA glycopolymers undergo clathrin-mediated 
endocytosis into early endosomes that is dynamin dependent.58  
 In an elegant follow-up report, the synergistic aspects of engaging both CD22 and BCR 
simultaneously and the resulting perturbation on BCR downstream signaling were studied with 
glycoprotein mimics.59 Taking advantage of a well-defined, ROMP-derived N-hydroxy 
succinimidyl (NHS) ester polymer (DOP = 250), the backbone was elaborated with either BCR 
ligands (DNP), CD22 ligands (CD22L) or both (DNP/CD22L). By tethering both BCR and 
CD22 ligands to the same polymer backbone, the dynamics of BCR and CD22 would be 
restricted to membrane regions enriched with the two transmembrane proteins. Consistent with 
previous observations, CD22L glycopolymers did not bind to B cell surfaces, which is further 
evidence that the native CD22L glycan structure does not displace endogenous cis CD22 
interactions. As anticipated, both DNP-containing polymers adhered to B cell surfaces. To 
examine the regulatory consequences of clustering both BCR and CD22, calcium ion influx was 
monitored by a ratiometric calcium-chelating dye as a proxy for BCR signaling. Cells treated 
with DNP polymer displayed an increase in cytosolic calcium ion concentration. The 
DNP/CD22L copolymer, on the other hand, had no such effect.  No calcium influx was observed 
for the copolymer, and downstream BCR signaling targets, such as Syk and PLC γ2, had reduced 
phosphorylation compared with DNP polymer-treated cells (Figure 1.3). Interestingly, incubation 
with the DNP polymer or the DNP/CD22L copolymer produced similar early signaling patterns 
in B cells; both Lyn and CD22 became phosphorylated upon polymer engagement. The authors 
proposed that after BCR attachment, the increase in local concentration of polymer on the 
membrane facilitates CD22 trans association. Collectively, the data also indicate that co-
clustering of BCR and CD22 on the cell surface elicits early B cell activation but attenuates 
downstream signaling effectors. The copolymer data strongly suggest that CD22 dynamics can 
be modulated by the glycosylated state of antigen, which could be an innate form of self-
recognition. This insight would have been difficult to obtain without the aid of homogeneous 
glycoprotein mimics.  
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Figure 1.3. A soluble copolymer, glycoprotein mimic engages both BCR and CD22 
simultaneously. Glycopolymer binding reorganizes CD22 to sites of BCR activation and blocks 
downstream signaling. The CD22 ligands are composed of sialic acid residues, suggesting that 
sialylation may be a molecular form of ‘self’ in mammals.  
 
 To further explore the influence of B cell siglecs, such as CD22 and Siglec-G, on 
tolerance in the context of a living organism’s immune system, polyacrylamide (PA) copolymers 
were synthesized bearing both a BCR ligand (NP) and either a native CD22 ligand (NeuGc) or a 
high-affinity, unnatural CD22 ligand (bNeuGc).60 Mice immunized with NP-PA produced a 
strong antibody, IgM and IgG3, response as expected. In contrast, mice immunized with either 
the NP-PA-NeuGc copolymer or the NP-PA-bNeuGc copolymer failed to elicit high anti-NP 
titers. These results agree with the previous cell-based findings. To test whether glycopolymer 
antigen challenge shaped the organism’s subsequent immune response, mice that had been 
treated with sialylated antigen were then immunized with unsialylated NP-PA. Drastically 
reduced antibody titer was observed, a hallmark of antibody suppression and immune tolerance. 
Tolerance induction was associated with suboptimal B cell proliferation and arrest of plasma cell 
differentiation. Additionally, long-term tolerance was correlated with the strength of siglec 
binding as NP-PA-bNeuGc copolymers produced the highest immune tolerance. CD22 and 
Siglec-G can thus confer a graded output when presented with different glycosylated antigens.  
 Yet, what mechanisms are responsible for producing a spectrum of B cell activation?  
Kiessling and coworkers decided to explore how the dynamics of lectin trafficking could be 
responsible for B cell signaling regulation.61 To accomplish this, B cells were incubated with 
DNP polymer or DNP/CD22L copolymers, and BCR endocytosis was tracked by fluorescence 
microscopy. The cell surface half-life of BCR was significantly longer for cells treated with DNP 
polymer compared to cells treated with DNP/CD22L copolymer. Co-clustering of BCR and 
CD22 on B cell surfaces triggered endocytosis, which resulted in accumulation of BCR in early 
BCR CD22 
= BCR Ligand 
= Sialylated, CD22 Ligand 
Soluble Glycoprotein Mimic 
Attenuated B Cell Activation 
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endosomes after DNP/CD22L copolymer incubation. Glycosylation-dependent internalization 
was mediated by dynamin and initiated by early phosphorylation of BCR and CD22 through 
Lyn. This mechanism of BCR regulation provides a means for B cell’s to tailor their BCR levels 
based on glycoprotein antigen and in turn increase the threshold of B cell activation to 
subsequent antigen encounter.  
 Through the use of soluble, sialylated glycoprotein mimics, the intimate details of B cell 
siglecs have emerged. Glycopolymers have served as homogeneously glycosylated replacements 
for glycoprotein antigens in these experiments. As a result, a picture of sialylation as a form of 
“self” has been partly resolved mechanistically; copolymers presenting both BCR and CD22 
ligands also provided evidence that self-recognition can lead to long-term immune tolerance in 
vivo.  
 
 Immune cells other than B cells also possess unique repertoires of siglecs. One example 
is natural killer (NK) cells that act as early responders to foreign entities, leading to cell death 
and clearance.62 NK cells prominently express Siglec-7 and to a lesser extant Siglec-9.63 Early 
work by Nicoll et al. used soluble glycopolymers to establish that similar to CD22, Siglec-7 is 
indeed masked on NK cells by the disialylated ganglioside GD3.64 But how siglecs on NK cells 
respond during cell-cell contact had not been fully elucidated. To engineer cell surfaces with 
chemically defined glycoprotein mimics, the Bertozzi lab developed a strategy to synthesize a 
glycopolymer functionalized with a lipid at one terminus.65 This enabled the passive insertion of 
glycopolymers into cell membranes and expanded the potential to not only investigate secreted 
glycoproteins but membrane-bound glycoproteins as well. Hudak et al. harnessed this 
technology to modify targets cells of NK cell-mediated lysis.66 As an integral part of the innate 
immune response, NK cells act to contain the growth and metastasis of tumor cells. Aggressive 
cancers though are able to evade NK cells through the release of activating receptors or 
expression of inhibitory motifs. One such motif is hypersialylation. The prevailing assumption 
was that cell surface sialylation on cancer cells presents a physical barrier to NK cell 
engagement. But owing to the presence of siglecs on NK cell surfaces, lectin binding had also 
been hypothesized to contribute to NK cell protection. To isolate the molecular basis of NK cell 
inhibition, a lipid-functionalized poly(methylvinylketone) polymer was elaborated with a large 
panel of aminooxy glycan structures. Jurkat cells, a hyposialylated cell line that are known to be 
susceptible to NK cell killing, were decorated with polymers and then incubated with either 
purified NK cells or peripheral blood mononuclear cells (PBMC). NK cytotoxicity of Jurkat cells 
was strongly inhibited by sialic acid containing glycopolymers but not polymers lacking the 
terminal sugar or polymers possessing similar charge, acetic acid, or polarity, glycerol. Function-
blocking antibodies were then used to prevent any specific interactions occurring with cell 
surface sialic acid residues. The anti-Siglec-7, but not the anti-Siglec-9, antibody completely 
abolished any cytotoxicity protection that sialic acid polymers afforded. With this striking 
finding in hand, fluorescence micrographs were taken and revealed that Jurkat cells displaying 
the sialic acid glycopolymer caused the reorganization of Siglec-7 on the surface of NK cells. 
Initially, Siglec-7 is distributed uniformly on the surface, but after engagement the lectin is 
concentrated at cell-cell synapses. Subsequent immunoprecipitation of NK Siglec-7 showed 
glycopolymer-dependent phosphorylation and SHP recruitment, which points to phosphatases as 
the signaling regulator of NK cell degranulation. Based on results from glycoengineered cells, 
the authors concluded that hypersialylation of aggressive cancer cells is a form of 
microevolutionary immunoevasion that ultimately changes Siglec-7 dynamics on NK cells. 
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  Galectins, another family of carbohydrate binding proteins, differ considerably in 
topology from selectins and siglecs.67 These proteins are soluble, and several family members 
are thought to have divergent functions both extracellularly and intracellularly. Whereas siglecs 
and selectins bind sialylated structures, galectins recognize a different class of glycans, N-
acetyllactosamine residues. Moreover, the prototype and chimera-type galectins have the ability 
to self-assemble in solution while the tandem repeat-type galectins have two carbohydrate 
recognition domains (CRDs) that are fused together through a flexible linker peptide. Stemming 
from their oligomeric nature, it was proposed that galectins may form a lattice-like structure with 
glycoproteins on cell surfaces.68 These galectin microdomains could act as adaptors, assembling 
proteins and lipids based on their glycosylation state, and modulate the biochemical activity of 
glycoprotein ligands. Work by Dennis and coworkers provided experimental support for this 
model with Mgat5-knockdown cells and mice lacking the N-acetylglucosaminyltransferase 
responsible for adding LacNAc branches onto N-glycans.69 Limiting the number of galectin 
ligands on cell surface glycoproteins altered the internalization rates of a number of growth 
factor receptors, thereby indicating that galectin lattices may extend the cell surface residence 
time of certain glycoproteins. The observed increase in surface half-life of the glycoprotein 
receptors in turn affected the duration and thus the strength of signal transduction in response to 
growth factor binding. 
 Unfortunately, direct experimental validation of galectin-glycoprotein lattices had eluded 
researchers. Without a means of detection, physical properties, such as size and lifetime, were 
largely undefined for galectin-mediated aggregation, which impeded further studies on the 
differences between family members in maintaining membrane organization. To address this 
experimental deficiency, membrane-anchored glycopolymers and fluorescence spectroscopy 
were leveraged to verify the existence of galectin lattices.70 One requirement of fluorescence 
spectroscopy, a time-dependent technique well suited for studying dynamic systems, is the well-
defined placement and stoichiometry of a fluorescent dye within a macromolecular architecture. 
Reversible addition-fragmentation chain transfer (RAFT) polymerization, another type type of 
living polymerization, offers the opportunity to individually manipulate both ends of a polymer 
chain while also affording predictable DOP.71,72 Lactosyl and cellobiosyl (negative control) 
acrylamide monomers were therefore subjected to RAFT polymerization conditions in the 
presence of a lipid-functionalized chain transfer agent. Fluorescent glycoprotein mimics were 
prepared by end group modification, yielding glycopolymers containing either a single FRET 
donor or acceptor fluorophore. After embedding donor and acceptor glycopolymers (1:1) into 
living ldlD CHO cell membranes, fluorescence lifetime of the donor fluorophore was monitored 
in real-time for a period of 40 min. A decrease in fluorescence lifetime of the donor-
functionalized lactosyl polymer was observed in the presence of galectin-1, but inhibiting 
galectin-1 binding or changing the polymer’s glycans (cellobiosyl polymers) abolished the FRET 
signature. Moreover, the diffusion time, a parameter that can be measured by Fluorescence 
Correlation Spectroscopy and related to clustering, for the lactosyl glycopolymer increased only 
in the presence of galectin-1. By examining the data in real time, it appears that galectin-1 
mediates a dynamic cross-linking of membrane glycoprotein mimics on the minutes timescale 
and results in extended galectin networks, which are themselves stable for tens of minutes.  
 Now considered invaluable tools in the chemical biologist’s toolkit, glycoprotein mimics 
have been utilized in vivo to understand the flow of information from a glycosylated biomolecule 
to a lectin and the resulting cellular decision-making that is altered by carbohydrate binding. 
What has emerged is a picture of lectins whose functions are highly dependent on changes in 
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dynamics that occur upon ligand binding. Following glycoprotein mimic association, lectins 
redistribute, form signaling clusters, and process signals, all of which are regulated by the nature 
of the glycan partners themselves. Glycoprotein mimics have been instrumental in defining the 
parameters that affect lectin-mediated signaling and membrane organization both in cell culture 
and in organismal studies. Present mimics, however, lack the signaling domains associated with 
many glycoprotein ligands. In the future, it would be interesting to combine mucin-type 
polymeric structures with functional domains through semi-synthesis. Using this approach, 
questions regarding the feedback between lectin dynamics and glycoprotein function can start to 
be assessed.  
 
Site-selective Tagging and Imaging Technologies 
 
 Proteins are often organized in biological systems on both the molecular and 
supramolecular scale. Changes in conformation or oligomeric state have significant implications 
for a protein’s role in carrying out a specified set of functions in the cell. These different 
configurations can completely alter the binding properties of proteins, acting like on-off switches 
in some cases. An interesting example is actin, which was once thought to have a simple well-
defined function and organization. Now there is ample evidence that it can exist as a soluble 
monomer in the cytoplasm/nucleus or assemble dynamically to form different oligomeric and 
polymeric species, such as fibers and bundles, all of which have vastly different cellular effects: 
monomeric nuclear actin can associate with transcription regulators and control gene expression, 
whereas filamentous actin acts as scaffolding for trafficking and cell motility.73 As demonstrated 
in the sections above, lectin organization and dynamics have a surprising, nontrivial influence on 
cellular function. Yet, imaging the molecular details of lectin organization in a complex 
biological sample and following lectin dynamics are major challenges. First, to visualize a single 
protein molecule with optics requires a means to “break” the diffraction limit of light since the 
length scale of lectins is typically 5-10 nm, well below the diffraction limit, ~200 nm. Protein 
dynamics further complicates observation due to the short timescales associated with molecular 
diffusion and polypeptide conformational changes. These features necessitate fast detectors, i.e. 
hardware, to capture such events. Second, most proteins do not possess tags that distinguish their 
location from others in the dense, crowded cytoplasm or extracellular matrix. Labeling with 
fluorescent protein fusions or contrast agents can aid in visualization, but CRDs are small and 
globular and selecting the proper technique is of the utmost importance to avoid perturbing the 
lectin’s intrinsic characteristics. Advances in both protein modification and imaging 
methodology and hardware have recently begun to address the visualization of lectin 
organization. In the following section, we outline the very few examples in the literature that 
focus on mammalian lectins. Our intent is to spark additional research in this burgeoning area.  
 Leukocytes home to sites of damage and inflammation through L-selectin bonds with 
sialylated glycans on endothelial cells. This phenomenon is surprising because the attachment of 
leukocytes is enhanced under flow. While certainly a counterintuitive finding, it was originally 
rationalized by changes in cell surface area or number of adhesions under shear force. But to 
rigorously examine the molecular basis of leukocyte trafficking, a technique capable of 
observing short adhesion events was required. Yago et al. met this challenge by immobilizing the 
L-selectin ligand, P-selectin glycoprotein ligand-1 (PSGL-1), on a substrate and measuring the 
biophysical parameters that govern adhesion under flow with fast microscopy detectors (250-500 
frames per second).74 The authors monitored off-rates (koff), among other parameters, for the L-
 15 
selectin-PSGL-1 interaction in neutrophils under various tether forces. They observed decreases 
in koff as shear force was increased. This behavior is known as a catch bond, where bond lifetime 
lengthens under force. In this case, advances in instrumentation were pivotal for assigning the 
first biological function of catch bonds, i.e. flow enhancement of leukocyte attachment. This 
work also provides credence to the notion that lectin dynamics, e.g. force-induced conformation 
changes, are important for large-scale biological transformations, like leukocyte rolling and 
extravasation.    
 DC-SIGN, as previously discussed, is a C-type lectin that is involved in antigen uptake 
and processing in dendritic cells. Its cell surface organization has garnered significant attention 
due to the fact that DC-SIGN is involved in recognizing glycan epitopes on the surface of large 
pathogens, including Human Immunodeficiency Virus (HIV), Ebola virus, Candida albicans, 
Leishmania and others. In fact, DC-SIGN microdomains were first detected using wide-field 
microscopy and estimated to be between 300 and 1500 nm in size. Given the optical resolution 
of traditional microscopy and dimensions of viral particles (~80-100 nm), researchers were 
interested in whether DC-SIGN formed smaller clusters on the surface of immature dendritic 
cells. Super-resolution microscopy is a suite of techniques that allows spatial localization of 
individual molecules with 10’s of nm resolution. To examine DC-SIGN’s organization, Blink 
Microscopy, a super-resolution method, was creatively applied to estimate the cluster size of 
DC-SIGN.75 Blink Microscopy relies on driving the majority of fluorophores in a densely-
labeled sample into a dark state through a combination of redox reagents, leaving a few dyes 
fluorescing for short on times (~ms). By fitting the point spread function, the centroid of the 
fluorophore can be calculated and precisely localized with subdiffraction resolution. DC-SIGN 
was imaged using immunofluorescence with an ATTO655 dye that can be cycled in and out of a 
dark state in the presence of ascorbic acid and N,N-methylviologen. DC-SIGN appeared to be 
organized into nanodomains with a mean full width at high maximum (FWHM) value of 76 nm. 
By analyzing the number of blink localizations per cluster, the occupancy was calculated to be 
~12 molecules, or three tetramers of DC-SIGN, indicating that the cluster was sparsely occupied. 
This finding was also consistent with the ability of lipid molecules to easily diffuse through DC-
SIGN membrane domains. The multivalency associated with DC-SIGN and its limited density in 
clusters suggests an effective mechanism to ensure entry of weakly binding antigens that only 
require a single interaction for uptake, e.g. HIV.  
 Galectin-3 (Gal-3) is the only member of the galectin family that belongs to the chimera 
subtype. This protein has been reported to oligomerize in vitro upon binding glycan ligands, 
forming pentamers in solution.13 The N-terminal stalk region of Gal-3 is thought to be 
responsible for and the site of self-assembly between individual Gal-3 monomers. This presents a 
unique problem, though, for tracking Gal-3’s oligomerization in a biological sample. If both the 
N-terminus and the C-terminus, which contains the carbohydrate recognition domain, are 
absolutely essential for Gal-3’s function, then tagging Gal-3 with a large fluorescent protein 
fusion would disrupt critical interactions at either of these domains. Despite this limitation, 
Nieminen et al. were still interested in observing Gal-3 oligomerization using FRET in the 
context of neutrophil-endothelial cell interfaces.76 While FRET is a suitable reporter of Gal-3 
assembly, the question of Gal-3 modification remained. To address this, a small organic donor or 
acceptor fluorophore, Alexa Fluor 488- or Alexa Fluor 555-cadaverine, was conjugated to the C-
terminus of Gal-3 in a site-specific manner by the enzyme, transglutaminase. The peptide tag for 
transglutaminase, 7 amino acids in this example, did not alter Gal-3’s glycan binding properties 
even after fluorophore ligation. By precisely placing the dye at end of Gal-3’s primary structure, 
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robust FRET signals were observed in unprimed neutrophils and in the context of neutrophil-
endothelial cell adhesions. On the other hand, Gal-3 monomers modified non-specifically at 
randomly distributed lysine residues showed limited FRET. Together, these results suggest that 
Gal-3 is oligomerized within the glycocalyx on cell surfaces. This study also emphasizes the 
unmet need and demand for developing methods capable of site-selectively modifying lectins 
without perturbing activity or quaternary lectin structure. For instance, in very recent work, Gal-
3 has been tethered with a SNAP-tag that allows for modification with a myriad of 
benzylguanine derivatives, opening the door for a range of markers useful for observing lectin 
dynamics/organization.77 
 Finally, fluorescent amino acids are beneficial from an imaging perspective since they are 
small in size and can be placed at many points throughout the protein backbone - characteristics 
that are important for following lectin dynamics. Fluorescence is also extremely sensitive to the 
local environment and has been used extensively to detect binding events in vivo. Based on these 
advantages, Hohsaka and coworkers recently pioneered the incorporation of fluorescent amino 
acids into lectins.78,79 Through both cell-free and amber stop codon suppression methods, 
BODIPY fluorescent amino acids were efficiently installed in maltose-binding protein as well as 
in a sialic acid-binding protein (Figure 1.4). In both examples, placement of the fluorophore near 
the glycan-binding site created a fluorogenic lectin, i.e. fluorescence of the amino acid is 
quenched by a nearby tryptophan residue in the absence of ligand, but when maltose or 
sialyllactose was administered fluorescence turns “on.” These examples are encouraging since 
they suggest that fluorescent amino acids may be well suited to visualize small lectins in vivo, 
obfuscating addition of protein fusions or peptide tags to a lectin’s sequence. They also illustrate 
a path to selectively visualize lectins that are engaged with their glycoprotein ligands as opposed 
to ‘free’ protein.  
 
 
 
Figure 1.4. Fluorescent amino acids that have been incorporated into maltose-binding protein 
and a sialic acid-binding protein.  
 
 Chemical tools have revolutionized the way molecules are imaged and tracked inside 
complex biological milieu. Many of these techniques are just now being applied to lectins. 
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Lectins assemble, disassemble, form cross-linked ‘bridges’ between glycoproteins and adjacent 
cells, and generally act in complex, multimeric forms. Non-traditional methods are needed to 
observe the debated details of these processes in vivo. Recently, new hardware and chemical 
reagents have revealed, for instance, the nature of lectin binding under force and the spatial 
organization of lectin domains in membranes. We believe that by leveraging new contributions 
in protein modification and better imaging hardware/techniques our present understanding of 
lectin dynamics and binding behavior will give way to a more refined description. As well, we 
hope that in the future researchers will take advantage of single molecule techniques, such as 
single particle tracking, coupled with site-specific fluorophore-lectin conjugates to resolve lectin 
dynamics in different subcellular compartments, an unexplored frontier.  
 
Conclusion 
 
 Chemists have transformed the field of glycobiology by contributing a number of 
methods to interrogate mammalian lectin dynamics in vivo. These tools have come in a variety of 
molecular forms, ranging from small molecule metabolites to large macromolecular agents. 
Cross-linking sugars have revealed extraordinary features of CD22 that were wholly inaccessible 
using typical molecular biology techniques. The fact that CD22 is segregated into 
homomultimers in resting B cells has shed light on the in vivo consequences of lectin 
reorganization for tuning immune cell activation. Glycoprotein mimics have, for instance, 
clarified a novel glycan-based mechanism of NK cytotoxicity evasion by cancer cells. Escaping 
immunosurveillance was, not surprisingly, predicated on glycan-siglec interactions. And new 
imaging methods, such as super-resolution microscopy, have settled long-standing questions 
concerning DC-SIGN membrane domains. By precisely locating individual DC-SIGN 
molecules, DC-SIGN clusters were found to be composed of only 12 molecules, which explains 
their ability to efficiently mobilize and capture viral particles. However, in vivo specificity is still 
undefined for the vast majority of lectins and only recently have researchers begun to appreciate 
that supramolecular assembly and subcellular dynamics of lectins profoundly dictate function 
and cell behavior. We believe that chemical tools will be indispensible for elucidating how 
lectins interpret glycomic changes in the future. Our hope is that this review will stimulate 
further interest and work in this new, exciting area at the interface of chemistry and biology.  
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Chapter 2. Well-Defined Glycoprotein Mimics for Exploring Galectin Recognition 
 
 
Introduction 
 
 Elucidating the diverse functions of the glycome, the collection of all complex 
carbohydrate structures expressed in cells and tissues, is one of the most difficult and sought-
after challenges that has emerged in the post-genomic era.1-3 Intricate glycan structures adorn the 
exterior of the cell membrane and mediate cellular interactions with circulating proteins, 
extracellular matrix components, pathogens, and other cells. These interactions have 
physiological consequences in terms of diseases, inflammatory responses, and differentiation of 
various cell types.4-14 The ability to modulate such extracellular interactions would facilitate our 
understanding of the roles cell surface glycans play in various biological processes.  
 Galectins are one family of glycan-binding proteins that recognize N- and O-linked 
glycans bearing the terminal disaccharide, N-acetyllactosamine.15 Characterizing the 
organizational, signaling, and cell fate consequences of galectin binding is a difficult task in the 
context of a complex biological sample. Galectin ligands form a set of secreted and membrane-
bound glycoproteins that have numerous cellular functions, many of which are critical to cellular 
homeostasis.16 These galectin-binding glycoproteins are characterized by their heterogeneity: a 
glycoprotein exists in many different glycoforms that differ from protein-to-protein as well as 
from site-to-site on a single peptide backbone. To study specific glycan-galectin interactions in 
vivo requires a technique to tailor the glycan structures appended to glycoproteins. 
Unfortunately, glycosylation, a post-translational modification, is refractory to genetic 
manipulations, and perturbing the cellular glycomic profile globally can affect other properties 
associated with proteins, e.g. folding and stability, that are not related to galectin binding.17,18  
 Synthetic glycopolymers have proven to be powerful functional surrogates for natural 
glycoconjugates, particularly in situations where the complexity and heterogeneity of the native 
biomolecules undermines experimental inquiry.19-24 For decades, chemists have made use of 
various glycopolymer architectures to study glycan-receptor interactions related to the immune 
response,25,26 viral infection,27,28 bacterial signaling29 and neurobiology,30 and recently we 
employed synthetic glycopolymers as ligands for microarray-based studies of glycan binding31,32 
proteins and for cell-surface functionalization33. 
 We sought to emulate the features of native glycoproteins by constructing glycopolymer-
based mimics capable of binding galectins. Membrane glycoproteins possess multiple domains 
that are linked to one another in a linear fashion. MUC1, an O-linked mucin glycoprotein, for 
instance, consists of a a cytosolic recognition domain, transmembrane domain, an SEA domain, 
and a heavily glycosylated, repeating motif.34 Glycopolymers were designed to mirror this 
feature and possess the following attributes (Figure 2.1): (1) a lipid anchor at one terminus for 
membrane insertion and display of the polymers on cell surfaces, (2) a polymer backbone 
containing pendant glycans that are specific for galectin, and (3) a tag at the other end for 
tracking mimics in the biological milieu. Herein, we describe the development of a living 
polymerization method enabling the facile dual end-functionalization of a well-defined 
glycopolymer. 
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Figure 2.1. Glycoprotein mimic design. A well-defined glycopolymer differentially 
functionalized at both termini is targeted. The mimic possesses the ability to insert into cell 
membranes and bind galectins.  
 
Results and Discussion 
  
 Conventional free radical polymerization (FRP) suffers from recombination and chain 
transfer processes, resulting in polymers with uncontrollable lengths and high polydispersities. 
Using FRP, there is no obvious means to form linear polymers with two different end groups. 
However, a number of living polymerization methods involving radical propagation, known as 
controlled radical polymerizations (CRP), have recently been developed that minimize 
termination events during the polymerization reaction.35 This approach affords tunable chain 
lengths and uniformly distributed polymers as well as the opportunity to tailor the polymer with 
different functional groups at the termini. We thus envisioned controlling the polymerization of a 
glycosyl monomer with a lipid-functionalized species capable of producing a multi-domain 
linear polymer.  
 
Synthesis of a lactosyl methacrylate 
 
 The dissociation constant (Kd) for lactose-galectin interactions is comparable to that with 
N-acetyllactosamine,36 and polymers decorated with lactose residues have recently demonstrated 
the propensity to form complexes with galectins.37-40 For instance, a lactosyl pseudopolyrotaxane 
has previously been shown to bind to galectin-1 with a 10-fold enhancement on a per saccharide 
basis.41 We therefore focused our early efforts on preparing a lactosyl monomer for CRP because 
of lactose’s commercial availability. We first examined the most direct synthetic route to prepare 
a lactosyl methacrylate monomer. The Lewis acid-catalyzed glycosylation of per-O-acetylated 
lactose with 2-hydroxyethyl methacrylate under varying temperatures, concentrations, and 
ultrasonication methods were unsuccessful. And while the lactosyl methacrylate compound was 
accessed via the glycosyl bromide donor under Koenigs-Knorr conditions, this route was 
unrealistic for large-scale preparation due to low yields and major side products.  
 We next designed a synthetic route based on the Schmidt glycosylation reaction. Lactose 
would first be fully acetylated and then regioselectively deprotected at the anomeric oxygen. The 
anomeric position would then be further manipulated to the trichloroacetimidate glycosyl donor. 
Biophysical+
Probe+
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In the final two transformations, Schmidt glycosylation would be performed with 2-hydroxyethyl 
methacrylate and followed by global deprotection. We anticipated one drawback from this 
scheme, namely that the ester within the methacrylate may be labile under the standard acetate 
deprotection conditions in the final step. Nevertheless, we attempted this concise scheme 
realizing we would likely need to find mild conditions for ester cleavage in the final step. 
 β-Lactose (9) was fully acetylated by reaction with acetic anhydride and pyridine. After 
poor yields were observed for the regioselective deacetylation using ethylenediamine and acetic 
acid, the per-O-acetylated lactose was deacetylated at the anomeric position with the use of mild 
ammonium acetate in a tetrahydrofuran and methanol mixture (1:1). Treating heptaacetate 2.2 
with trichloroacetonitrile and 1,8-diazobicyclo[5.4.0]undec-7-ene (DBU) led to lactosyl imidate 
2.3, the glycosyl donor. Glycosylation was performed with 2-hydroxyethyl methacrylate and 
trimethylsilyl trifluoromethanesulfonate as the Lewis acid promoter. The final step towards 
lactosyl methacrylate was to selectively deprotect the acetyl groups without cleavage of the ester 
bond in the methacrylate portion of the target. A common procedure for this deprotection step is 
treatment with a catalytic amount of sodium methoxide in methanol. This condition was 
investigated by monitoring the reaction over thirty minutes and analyzing its progress via thin-
layer chromatography. It was evident that Zemplén conditions were too harsh and cleaved the 
methacrylate on a rapid time scale. Therefore, a milder deprotection procedure was pursued. 
Numerous attempts to preserve the methacrylate group with typical organic bases failed. 
However, when protected 2.4 was treated with a solution of saturated ammonia in methanol 
(50%), the desired product was produced in a period of 4 h in low yield. 
 
Scheme 2.1. Synthesis of a lactosyl methacrylate monomer. 
 
 
 
Preparation of lipid-functionalized initiators and chain transfer agents 
 
 To examine the CRP of 2.5 with a lipid-functionalized species, we decided to rely on two 
widely used methods known for their functional group tolerance, atom transfer radical 
polymerization (ATRP) and reversible addition-fragmentation chain transfer (RAFT) 
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polymerization.  ATRP is typically initiated by an alkyl halide in the presence of a transition 
metal complex.42 We sought to construct an ATRP initiator with a lipid functionality conjugated 
to a tertiary bromide initiator. This strategy would ultimately install the hydrophobic group at 
one end of the polymer chain. 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE) was 
chosen as the phospholipid based on literature precedent for cell surface incorporation.33 DPPE 
was reacted with acid bromide 2.6 to form lipid-ATRP initiator 2.7. It was necessary to perform 
the reaction with a 1:1 stoichiometry between acyl bromide and the reactive phospholipid since 
higher equivalents of the electrophile produced inseparable difunctionalized lipid.  
 
Scheme 2.2. Preparation of lipid-functionalized ATRP initiator. 
 
 
 
 RAFT polymerization is mediated by a chain transfer agent, usually a thiocarbonylthio 
compound, that reacts rapidly and reversibly with alkyl radicals to control chain growth.43 Unlike 
ATRP, in which the equilibrium between propagating and dormant chains is governed by the 
transition metal and its coordinated ligands, RAFT is primarily regulated by the judicious choice 
of chain transfer agent (CTA). Accordingly, we designed both a dithioester and a 
trithiocarbonate CTA appended with DPPE to facilitate membrane insertion.  
 Access to the lipid-functionalized dithioester was achieved through a series of reactions 
to yield a carboxylic acid CTA that could be further elaborated with DPPE. The synthesis 
commenced by reacting benzyl bromide with elemental sulfur and sodium methoxide to form 
sodium dithiobenzoate 2.8. 2.8 was subsequently oxidized using potassium ferricyanide to 
di(thiobenozyl) disulfide. Disulfide 2.9 was taken forward to the dithiocarboxylic acid by 
treatment with 4,4’-azobis(4-cyanovaleric acid) (ACVA) under radical conditions. The 
phospholipid was then attached to the CTA by first converting 2.10 to the pentafluorophenyl 
(PFP) ester using pentafluorophenyl trifluoroacetate (PFP-TFA) and Hünig’s base. 2.11 was 
finally coupled with DPPE to afford the lipid-functionalized dithioester 2.12 in excellent yield. 
Lipid-functionalized trithiocarbonate 2.13 was prepared using a similar strategy.  
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Scheme 2.3. Constructing lipid dithioester CTA 2.12 and trithiocarbonate CTA 2.13. 
 
 
 
CRP of lactosyl methacrylate 
 
 Controlled polymerization of lactosyl methacrylate 2.5 was tested using the lipid-ATRP 
initiator as well as with the two lipid-CTA. No polymerization occurred under any Cu-catalyzed 
conditions with lipid-initiator 2.7. As well, short lactosyl oligomers were the only product of 
RAFT polymerization with trithiocarbonate CTA 2.13, and these short chains precipitated in the 
reaction vessel over time. We therefore focused on lipid-functionalized dithioester CTA 2.12. A 
mixture of 1,4-dioxane and water (4:1) was found to solubilize both the CTA and the free 
lactosyl monomer. Our attempts at polymerization at 70 °C with 4,4’-azobis(4-cyanopentanoic 
acid) as the radical initiator were successful. By following the reaction over time, polymerization 
appeared to proceed with a linear correlation between molecular weight and monomer 
conversion (Table 2.1, entry 1). Additionally, low polydispersity indices were obtained for the 
growing polymer chains at all time points, and the reaction kinetics were defined by a pseudo-
first order dependence on lactosyl monomer concentration (Figure 2.2). Taken together, the data 
indicate that the polymerization was controlled and produced well-defined, lipid-terminated 
glycopolymers with a degree of polymerization (DP) of 25.  
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Scheme 2.4. RAFT polymerization of lactosyl methacrylate 2.5. 
 
 
 
 
Table 2.1. RAFT polymerization of 2.5 with 2.12 as the RAFT agent. Polymerization was 
performed in 1,4-dioxane/water mixture (4:1) at 70 °C. 
 
Entry [M]0/[CTA]/[Init] Time (min) Mn (GPC) Conv. (NMR) PDI (GPC) 
1 50:2:1 80 
 
1,100 0.09 1.25 
251 
 
2,400 0.31 1.23 
436 
 
3,900 0.56 1.22 
1020 
 
6,000 0.95 1.22 
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Figure 2.2. Pseudo-first order kinetics for entry 1. 
 
Synthesis of glycosyl acrylamides 
 
 Plagued by low yields of 2.5, we were unable to prepare sufficient quantities of 
glycopolymer for further biological studies. To overcome this issue, we transitioned from a 
methacrylate to a monomer with a more stable amide linkage, i.e. a lactosyl acrylamide. We 
reasoned that the acrylamide unit would remain intact under the basic conditions necessary for 
ester cleavage during the final step of monomer synthesis. Starting from the per-O-benzoylated 
lactosyl trichloroacetimidate 2.15, we formed the protected acrylamide monomer under Schmidt 
conditions as before. We next examined whether the large-scale preparation of lactosyl 
acrylamide was possible. Treating 2.16 with catalytic amounts of sodium methoxide afforded the 
deprotected glycomonomer 2.17 in excellent yield. Encouraged by these findings, we also tested 
whether this synthetic strategy could be applied to other glycan structures. Cellobiose, the C-4’ 
epimer of lactose, was chosen as a structurally similar control ligand for our investigations based 
on its reported lack of binding to galectin.44 We successfully synthesized cellobiosyl acrylamide 
2.20 in short order using the same strategy used for the lactosyl acrylamide. With gram-scale 
quantities of acrylamide monomers in hand, we turned our attention to their polymerization using 
RAFT. 
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Scheme 2.5. Synthesis of glycosyl acrylamides.  
 
 
 
RAFT polymerization of glycosyl acrylamides 
 
 We first attempted the RAFT polymerization of acrylamide 2.17 by employing 
dithioester CTA 2.12 and trithiocarbonate CTA 2.13. For both reactions, controlled 
polymerization proved elusive.  In the case of trithiocarbonate CTA 2.13, we noted precipitation 
of the growing polymer chain at early time points. This led us to hypothesize that non-covalent 
association and subsequent aggregation between the two terminal hydrophobic domains impeded 
continued propagation. As such, we imagined tailoring the trithiocarbonate structure at the ‘Z’ 
position to a shorter alkyl chain, minimizing its hydrophobicity. Synthesis of a short alkyl CTA 
species, i.e. ethyl, commenced by treating ethanethiol with carbon disulfide and 2-
bromoisobutyric acid sequentially in a one-pot procedure. Carboxylic acid 2.21 was then 
transformed to the PFP ester before ligating with DPPE, yielding lipid-functionalized CTA agent 
2.22. 
 
Scheme 2.6. Installation of short ethyl chain at ‘Z’ position of lipid-functionalized CTA. 
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 The polymerization of lactosyl acrylamide 2.17 in the presence of CTA 2.22 was 
performed in a mixture of water and N,N-dimethylformamide to ensure homogeneity. This 
reaction indeed generated glycopolymer 2.23 with a low PDI of ~1.2 and in high conversion 
(>90%). By varying the ratio between monomer and CTA, we were able to construct 
glycopolymers with predictable DPs of ~25, 50, and 100 (Figure 2.3). We also subjected 
acrylamide 2.20 to identical RAFT conditions in order to incorporate cellobiosyl residues into 
the polymers. Again, a well-defined cellobiosyl glycopolymer 2.24 resulted with the use of ethyl 
CTA 2.22, which was important for optimal conversion and PDI.  
 
Scheme 2.7. RAFT polymerization of glycosyl acrylamides in the presence of CTA 2.22. 
 
 
 
 
 
 
Figure 2.3. Size exclusion chromatography traces of poly(lactosyl acrylamide) lipid-terminated 
glycopolymers. Polymerizations were performed with [M]0:[CTA] ratios of 100:1 (green), 50:1 
(blue), 25:1 (red).  
 
Conclusion 
 
 Well-defined glycopolymers, possessing a phospholipid at one end, were synthesized by 
RAFT polymerization. A lipid-functionalized CTA agent was utilized to control polymerization 
reactions of glycosyl acrylamide monomers. The final polymers mimic the essential features of 
membrane-bound glycoprotein ligands of galectins. The lipid domain permits the cell surface 
incorporation of the glycopolymer into cell membranes, while the polymer portion functions to 
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interface with galectins native to extracellular environments. A unique feature of this living 
polymerization system is the ability to form dual end functionalized macromolecules. 
Glycopolymers 2.23 and 2.24 are well suited for post-polymerization functionalization as the 
trithiocarbonate remains intact as the polymer end-group. A number of transformations are now 
at the disposal of chemists to convert the trithiocarbonate moiety to synthetically useful 
intermediates for further elaboration.45  
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Experimental Procedures 
 
General methods 
 
 All of the chemical reagents were of analytical grade, obtained from commercial 
suppliers, and used without further purification, unless otherwise noted. All of the reactions were 
performed in a N2 atmosphere. Liquid reagents were added with a syringe. Dry methanol was 
purchased from Alfa Aesar in a sealed bottle. All other solvents were purified via packed 
columns as described by Pangborn et al.46 Unless otherwise noted, sodium sulfate was used as a 
drying agent and solvent was removed with a rotary evaporator at reduced pressure. Thin layer 
chromatography was performed on 60 Å glass back silica gel plates and visualized by staining 
with anisaldehyde or by absorbance of UV light at 245 nm. Flash chromatography was carried 
out with 60 Å 230-400 mesh silica gel. Unless otherwise noted, 1H, 13C{1H}, 19F and 31P{1H} 
NMR spectra were obtained with 300, 400 or 500 MHz Bruker spectrometers. Chemical shifts 
(δ) are reported in parts per million and standardized against solvent peaks. IR spectra were 
obtained using thin films of NaCl plates. Polymer Mn was calculated by comparing the area 
under the peak corresponding to the anomeric proton to that of the methyl protons on the 1,2-
dipalmitoyl-sn-glycero-3-phosphoethanolamine unit (1H NMR). High resolution electrospray 
ionization (ESI) mass spectra were obtained from the UC Berkeley Mass Spectrometry Facility. 
UV-Vis spectra were acquired on a Thermo Scientific NanoDrop 2000 Spectrophotometer and 
used to determine percent modification of fluorophore labeling. Aqueous size exclusion 
chromatography was performed using a Viscotek TDA 302 SEC fitted with a Shodex SB-803 
HQ column and using differential refractive index detection. The mobile phase used was an 
aqueous solution of NaNO3 (0.1M) at a flow rate of 1.0 mL min-1 and at a constant temperature 
of 40 oC. Conventional calibration was achieved using narrow PEG standards. Polydispersity 
indices were determined using the Omnisec for Windows software. 
 
Synthesis 
 
1,2,3,6-Tetra-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-D-galactopyranosyl)-D-glucopyranose 
(2.1). A mixture of lactose (2.00 g, 5.84 mmol) and acetic anhydride (8.82 mL, 93.5 mmol) in 
pyridine (20.0 mL) was stirred at room temperature overnight. A 150 mL portion of CH2Cl2 was 
added to the mixture and extracted with three 150 mL portions of 1.0 N HCl. The organic layer 
was then washed with 150 mL portions of H2O, satd. NaHCO3, and brine. The resulting solution 
was dried over MgSO4 and then concentrated. Purification by flash chromatography (1:1 
EtOAc/hexane) afforded 2.1 (3.36 g, 85%). All spectroscopic data agreed with the literature.47 1H 
NMR (300 MHz, CDCl3): δ 5.67 (d, J = 8.1 Hz, 1H), 5.34 (dd, J = 3.4, 1.2 Hz, 1H), 5.23 (t, J = 
9.0 Hz, 1H), 5.16 – 4.98 (m, 4H), 4.97 – 4.89 (m, 2H), 4.52 – 4.38 (m, 2H), 4.20 – 4.01 (m, 1H), 
3.92 – 3.79 (m, 1H), 3.79 – 3.68 (m, 1H), 2.21 – 1.90 (8 x s, 24H). 
 
Lactose heptaacetate (2.2). A flame-dried RB flask was charged with compound 2.1 (1.00 g, 
1.47 mmol) and ammonium acetate (227 mg, 2.94 mmol). The mixture was dissolved in 5.00 mL 
of dry THF/MeOH (1:1) and allowed to react overnight. The mixture was diluted in 100 mL of 
CH2Cl2, extracted with three portions of 100 mL of H2O, and dried over NaSO4. The crude 
product was purified by flash chromatography (9:1 à 1:3 hexane/EtOAc) to give 2.2 as a white 
solid (770 mg, 83%). All spectroscopic data matched the literature.47 1H NMR (400 MHz, 
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CDCl3): δ 5.51 (t, J = 9.7 Hz, 1H), 5.35 (dd, J = 8.5, 3.5 Hz, 2H), 5.10 (ddd, J = 10.2, 7.9, 5.9 
Hz, 1H), 4.99 – 4.90 (m, 1H), 4.86 – 4.77 (m, 1H), 4.53 – 4.45 (m, 2H), 4.20 – 4.03 (m, 4H), 
3.87 (t, J = 6.9 Hz, 1H), 3.80 – 3.72 (m, 1H), 2.21 – 1.93 (7 x s, 21H). 
 
Lactosyl trichloroacetimidate (2.3). Compound 2.2 (1.28 g, 1.91 mmol) was dissolved in dry 
CH2Cl2 (20.0 mL) and placed in an ice bath. Trichloroacetonitrile (959 µL, 9.57 mmol) was 
added dropwise, and the mixture was stirred for 5 min. 1,8-Diazabicyclo[5.4.0]undec-7-ene (114 
µL, 0.765 mmol) was then added dropwise over 2 min and allowed to react for 2 h. The dark 
orange-brown mixture was then diluted with CH2Cl2 and concentrated in vacuo. The crude 
residue was purified by flash chromatography (5:1 à 1:1 hexane/EtOAc with 1% TEA) to yield 
compound 2.3 as a white solid (1.34 g, 90%). All spectroscopic data agreed with the literature.48 
1H NMR (500 MHz, CDCl3): δ 8.66 (s, 1H), 6.51 – 6.45 (m, 1H), 5.55 (t, J = 9.2 Hz, 1H), 5.38 – 
5.32 (m, 1H), 5.09 (ddd, J = 30.0, 10.1, 3.2 Hz, 2H), 4.95 (dt, J = 8.1, 3.1 Hz, 1H), 4.55 – 4.41 
(m, 2H), 4.20 – 4.03 (m, 4H), 3.93 – 3.83 (m, 2H), 2.20 – 1.91 (7 x s, 21H). 
 
Per-O-acetylated lactosyl ethyl methacrylate (2.4). A flame-dried RB flask containing a stir 
bar and 4 Å molecular sieves was charged with compound 2.3 (1.34 g, 1.71 mmol) and dry 
CH2Cl2 (22.0 mL). To this suspension was added 2-hydroxyethyl methacrylate (250 µL, 2.06 
mmol), and the mixture was stirred for 30 min at rt. The RB flask was then transferred to a -20 
oC bath and trifluoromethylsilyl trifluoromethanesulfonate (124 µL, 0.686 mmol) was added 
dropwise over 2 min. The mixture was allowed to react for 70 min, and trimethylamine was 
subsequently added to quench the reaction. After the mixture was first warmed to rt and then 
concentrated, the crude material was purified by flash chromatography (9:1 à 1:1.5 
hexane/EtOAc) to afford 2.4 as a white crystalline solid (765 mg, 60%). 1H NMR (500 MHz, 
CDCl3) δ 6.05 (s, 1H), 5.53 (s, 1H), 5.32 – 5.23 (m, 1H), 5.13 (t, J = 9.2 Hz, 1H), 5.04 (dd, J = 
10.5, 7.7 Hz, 1H), 4.90 (dd, J = 10.4, 3.5 Hz, 1H), 4.84 (t, J = 8.7 Hz, 1H), 4.48 (d, J = 7.9 Hz, 
1H), 4.46 – 4.39 (m, 2H), 4.28 – 4.16 (m, 2H), 4.10 – 3.99 (m, 3H), 3.99 – 3.91 (m, 1H), 3.86 – 
3.79 (m, 1H), 3.78 – 3.70 (m, 2H), 3.59 – 3.51 (m, 1H), 2.15 – 1.83 (8 x s, 24H). 13C NMR (125 
MHz, CDCl3): δ 170.32, 170.12, 170.02, 169.74, 169.53, 169.07, 167.07, 136.05, 125.87, 
101.07, 100.56, 76.22, 72.76, 72.68, 71.49, 70.96, 70.67, 69.10, 67.48, 66.63, 63.40, 61.97, 
60.82, 20.83, 20.79, 20.63, 20.50, 18.26. IR: 2961, 1754, 1635, 1433, 1370, 1223, 1169, 1056 
cm-1. ESI-HRMS: Calcd. for C32H44O20Na+ [M+Na]+: 771.2318, found: 771.2291. 
 
Lactose methacrylate (2.5). A dry RB flask was charged with compound 2.4 (500 mg, 0.668 
mmol) and a stir bar. Dry MeOH (10.0 mL) was added, and the mixture was stirred for 15 min. 
A solution of satd. NH3 in MeOH (10.0 mL) was then added, and the mixture was allowed to 
react at rt for 4 h. The mixture was diluted in MeOH and concentrated. The crude residue was 
purified by flash chromatography (1:4 MeOH/CHCl3), diluted in H2O, and lyophilized to give 
compound 2.5 as a white solid (110 mg, 36%). 1H NMR (400 MHz, D2O): δ 6.15 (s, 1H), 5.71 
(s, 1H), 4.52 (d, J = 8.0 Hz, 1H), 4.42 (d, J = 7.7 Hz, 1H), 4.40 – 4.31 (m, 2H), 4.19 – 4.10 (m, 
1H), 4.03 – 3.66 (m, 7H), 3.66 – 3.48 (m, 5H), 3.30 (t, J = 8.3 Hz, 1H), 1.91 (s, 3H). 13C NMR 
(125 MHz, CDCl3): δ 168.84, 137.73, 126.44, 105.09, 104.52, 80.57, 77.08, 76.50, 76.39, 74.82, 
74.64, 72.55, 70.30, 68.65, 65.25, 62.48, 61.90, 18.41. IR: 3365, 2924, 1745, 1635, 1462, 1378, 
1249, 1160, 1056 cm-1. ESI-HRMS: Calcd. for C18H30O13Na+ [M+Na]+: 477.1579, found: 
477.1563.  
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Lipid-functionalized ATRP Initiator (2.7). A flame-dried RB flask was charged with DPPE 
(100 mg, 0.145 mmol) and CHCl3 (20.0 mL) and stirred at 65 oC for 20 min in order to fully 
dissolve DPPE in CHCl3. The mixture was allowed to cool to rt, and the flask was placed in an 
ice-bath. Triethylamine (60.4 µL, 0.434 mmol) and 2-bromoisobutyryl bromide (17.9 µL, 0.145 
mmol) were added dropwise, and the mixture was stirred overnight and warmed to rt. The 
reaction mixture was acidified by adding 25 mL of CHCl3 and 40 mL of 0.02 M citrate/0.02 M 
phosphate buffer (pH 5.5) and stirred for 30 min. The aqueous phase was extracted three times 
with portions of 40 mL of CHCl3 and discarded. The combined organic phases were dried over 
anhydrous sodium sulfate, and solvent was removed in vacuo. The crude material was purified 
by flash chromatography (1:19 MeOH/CHCl3 with 1% AcOH) to afford 2.7 as a white solid 
(120. mg, 98%). 1H NMR (400 MHz, CDCl3): δ 7.92 (s, 1H), 5.27 – 5.15 (m, 1H), 4.37 (dd, J = 
12.0, 3.2 Hz, 1H), 4.15 (dd, J = 12.1, 6.6 Hz, 1H), 3.55 – 3.46 (m, 2H), 2.27 (td, J = 7.6, 5.1 Hz, 
4H), 1.94 (s, 6H), 1.64 – 1.50 (m, 4H), 1.36 – 1.12 (m, 48H), 0.86 (t, J = 6.7 Hz, 6H). 13C NMR 
(100 MHz, CDCl3): δ 173.64, 173.27, 172.32, 70.46, 63.85, 62.81, 61.37, 45.69, 34.42, 34.23, 
32.16, 32.05, 31.19, 29.84, 29.67, 29.49, 29.28, 25.05, 25.00, 22.81, 14.25, 8.69. 31P NMR (161 
MHz, CDCl3): δ 0.40. IR: 3384, 2918, 2850, 1742, 1665, 1535, 1467, 1371, 1223, 1063, 665 cm-
1. ESI-HRMS: C41H79O9NBrPNa+ [M+Na]+: 862.4568, found: 862.4545. 
 
Di(thiobenzoyl) disulfide (2.9). In a 250 mL RB flask, a 25% solution of sodium methoxide in 
methanol (45.7 mL, 200. mmol), elemental sulfur (6.40 g, 200. mmol), and dry methanol were 
combined rapidly. Benzyl bromide (11.9 mL, 100. mmol) was then added dropwise over 1 h at 
rt. After the addition, the mixture was refluxed at 67 oC for 14 h. After this time, the reaction 
mixture was placed in an ice bath. The precipitated salt was removed by filtration and the solvent 
was removed in vacuo. To the residue was added H2O (100 mL). The solution was filtered a 
second time and then transferred to a 1 L separatory funnel. The crude sodium dithiobenzoate 
solution was washed with three portions of 40 mL diethyl ether. Diethyl ether (40 mL) and 1.0 N 
HCl (100 mL) were added, and dithiobenzoic acid was extracted into the ethereal layer. H2O (60 
mL) and 1.0 N NaOH (120 mL) were added, and sodium dithiobenzoate was extracted to the 
aqueous layer. This washing process was repeated two more times to finally yield a solution of 
sodium dithiobenzoate. Due to the propensity of sodium dithiobenzoate to degrade, it was 
immediately used in the next step. Potassium ferricyanide(III) (6.58 g, 20.0 mmol) was dissolved 
in H2O (100.0 mL). The potassium ferricyanide solution was then added dropwise to the sodium 
dithiobenzoate via an addition funnel over a period of 1 h under vigorous stirring. The pink 
precipitate was filtered and washed with deionized water until the washings became colorless. 
The solid was dried in vacuo, and the product was recrystallized from ethanol to yield compound 
2.9 as a pink solid (6.56 g, 43% over 2 steps). All spectroscopic data matched the literature.49 1H 
NMR (400 MHz, CDCl3): δ 8.09 (d, J = 7.5 Hz, 1H), 7.62 (t, J = 7.4 Hz, 2H), 7.46 (t, J = 7.8 Hz, 
1H). 
 
Dithioester RAFT agent (2.10). In a flame-dried RB flask, compound 2.9 (590. mg, 1.93 mmol) 
and 4,4′-azobis(4-cyanovaleric acid) (809 mg, 2.89 mmol) were dissolved in 12.0 mL of ethyl 
acetate. The mixture was then refluxed at 80 oC for 20 h and concentrated. The crude material 
was purified by flash chromatography (2:3 EtOAc/hexane) and recrystallized from benzene to 
give 2.10 as a red solid (345 mg, 64%). All spectroscopic data matched the literature.50 1H NMR 
(500 MHz, CDCl3): δ 7.91 (dd, J = 7.5, 1.3 Hz, 1H), 7.58 (t, J = 7.5 Hz, 1H), 7.44 – 7.37 (m, 
1H), 2.82 – 2.70 (m, 2H), 2.68 – 2.59 (m, 1H), 2.51 – 2.41 (m, 1H), 1.95 (s, 3H). 
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PFP-dithioester RAFT agent (2.11). A flame-dried RB flask was charged with compound 2.10 
(100. mg, 0.358 mmol) and CH2Cl2 (3.00 mL). The mixture was stirred in an ice bath, followed 
by the dropwise addition of diisopropylethylamine (156 µL, 895 mmol) and pentafluorophenyl 
trifluoroacetate (74.0 µL, 429 mmol). The mixture was then stirred at 0 oC for 1.5 h and 
concentrated in vacuo. The residue was purified by flash chromatography (1:9 à 1:4 
EtOAc/hexane) to give 2.11 as a red solid (102 mg, 64%). All spectroscopic data matched the 
literature.51 1H NMR (400 MHz, CDCl3): δ 7.93 (d, J = 8.1 Hz, 1H), 7.59 (d, J = 7.4 Hz, 1H), 
7.42 (t, J = 7.7 Hz, 2H), 3.15 – 2.96 (m, 2H), 2.83 – 2.71 (m, 1H), 2.60-2.52 (m, 1H), 1.99 (s, 
3H). 19F NMR (376 MHz, CDCl3) δ -151.69 (d, J = 17.3 Hz, 2F), -156.45 (t, J = 21.7 Hz, 1F), -
161.05 (d, J = 19.6 Hz, 2F). 
 
Lipid-functionalized dithioester RAFT agent (2.12). A flame-dried RB flask was charged with 
compound 2.11 (100. mg, 0.225 mmol), DPPE (155 mg, 0.225 mmol) and a solution of 
chloroform/methanol (20:1, 5.00 mL). Diisopropylethylamine (196 µL, 1.12 mmol) was added 
and the mixture was stirred at 65 oC. After 5 h, the mixture was allowed to cool to rt and 
concentrated. The crude solid was purified by flash chromatography (1:19 à 1:4 MeOH/CHCl3 
with 1% AcOH), azeotroped with toluene to remove excess acetic acid, and dried in vacuo 
overnight to give compound 2.12 as a red solid (200. mg, 93%). 1H NMR (400 MHz, CDCl3): δ 
10.78 (s, 1H), 7.89 (d, J = 7.7 Hz, 2H), 7.54 (t, J = 7.4 Hz, 1H), 7.44 (s, 1H), 7.37 (t, J = 7.7 Hz, 
2H), 5.25 – 5.16 (m, 1H), 4.33 (dd, J = 12.1, 3.5 Hz, 1H), 4.14 (dd, J = 11.9, 6.5 Hz, 1H), 4.04 – 
3.89 (m, 4H), 3.71 (q, J = 7.0 Hz, 1H), 3.61 (p, J = 6.6 Hz, 1H), 2.68 – 2.52 (m, 3H), 2.50 – 2.37 
(m, 1H), 2.36 – 2.20 (m, 4H), 1.92 (s, 3H), 1.66 – 1.46 (m, 4H), 1.42 – 1.14 (m, 48H), 0.86 (t, J 
= 6.6 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ 177.44, 173.75, 173.42, 171.72, 144.71, 133.01, 
128.63, 126.78, 118.78, 70.20, 64.56, 63.87, 62.52, 53.58, 46.17, 41.92, 34.36, 34.23, 34.19, 
32.03, 31.43, 29.82, 29.78, 29.64, 29.48, 29.26, 25.00, 24.04, 22.80, 21.00, 18.22, 14.23, 11.86. 
31P NMR (161 MHz, CDCl3): δ 0.36. IR: 3384, 2918, 2850, 1740, 1653, 1558, 1467, 1378, 1225, 
1050, 982, 869 cm-1. ESI-HRMS: C50H85O9N2PS2Na+ [M+Na]+: 975.5326, found: 975.5348. 
 
Lipid-functionalized trithiocarbonate RAFT agent (2.13). A flame-dried RB flask equipped 
with stir bar was charged with compound PFP-trithiocarbonate RAFT agent52 (100 mg, 0.188 
mmol) and DPPE (130. mg, 0.188 mmol). A solution of dry CHCl3/MeOH (20:1, 5.00 mL) was 
added, followed by diisopropylethylamine (164 µL, 0.940 mmol). The mixture was stirred at 65 
°C for 5 h. The mixture was diluted with chloroform, concentrated, and the residue was purified 
by flash chromatography (1:19 à 1:9 MeOH/CHCl3 with 1% AcOH) to give 2.13 as a yellow 
solid (135 mg, 69%). 1H NMR (500 MHz, CDCl3): δ 5.29 – 5.18 (m, 1H), 4.40 – 4.28 (m, 1H), 
4.22 – 4.05 (m, 4H), 3.95 – 3.86 (m, 1H), 3.63 – 3.47 (m, 2H), 2.88 – 2.77 (m, 2H), 2.32 (dt, J = 
14.7, 7.6 Hz, 4H), 2.23 – 1.85 (m, 12H), 1.35 – 1.17 (m, 66H), 0.88 (t, J = 6.6 Hz, 9H). 13C NMR 
(100 MHz, CDCl3): δ 173.88, 173.56, 173.43, 148.76, 57.35, 37.23, 34.49, 34.30, 32.10, 29.95, 
29.86, 29.71, 29.56, 29.47, 29.40, 29.26, 29.19, 27.91, 25.76, 25.15, 25.07, 22.86, 14.29. 31P 
NMR (161 MHz, CDCl3): δ 0.22. IR: 3368, 2919, 2850, 2360, 1739, 1654, 1522, 1467, 1363, 
1243, 1072, 814 cm-1. ESI-HRMS: C54H105O9NPS3+ [M+H]+: 1038.6684, found: 1038.6677. 
 
Polymerization of lactose methacrylate (2.14). Polymerizations were carried out using 
standard Schlenk techniques. Lipid-functionalized dithioester RAFT agent 2.12 (7.08 mg, 
0.00735 mmol), lactose methacrylate 2.5 (84.5 mg, 0.45 mmol), 4,4′-azobis(4-cyanovaleric acid) 
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(1.04 mg, 0.00372 mmol), dioxane-d8 (640. µl) and D2O (160. µl) were added to the Schlenk 
tube. The solution was degassed three times using freeze-pump-thaw cycles. The Schlenk flask 
was placed in a 70 oC bath to start the polymerization, and aliquots were removed periodically 
for kinetic analysis. The reactions were stopped by exposure to oxygen. The conversion for the 
lactosyl monomer was calculated by comparing the integrals of the alkene proton peaks of the 
monomer (6.15 ppm, 1H) and those of the backbone methyl protons on the glycopolymer (0.50-
1.00 ppm, 3H). The solvent was removed and H2O added to the samples for GPC analysis. 
 
2-N-acryloyl-aminoethoxy (2,3,4,6-tetra-O-benzoyl-β-D-galactopyranosyl)-(1→4)-2,3,6-tri-
O-benzoyl-β-D-glucopyranoside (2.16). A flame-dried RB flask containing a stir bar and 4 Å 
molecular sieves was charged with compound 2.1653 (0.522 g, 0.429 mmol) and dry CH2Cl2 (9.0 
mL). To this suspension was added N-(2-hydroxyethyl)acrylamide (49.4 µL, 0.472 mmol), and 
the mixture was stirred for 30 min at rt. The RB flask was then transferred to a 0 oC bath and 
boron trifluoride diethyl etherate (54.4 µL, 0.429 mmol) was added dropwise over 2 min. The 
mixture was allowed to react for 90 min, and trimethylamine was subsequently added to quench 
the reaction. After the mixture was first warmed to rt and then concentrated, the crude material 
was purified by flash chromatography to afford 2.16 as a white crystalline solid (0.492 g, 98%). 
1H NMR (400 MHz, CDCl3): δ 8.06 – 7.86 (m, 12H), 7.73 (dd, J = 8.5, 1.4 Hz, 2H), 7.67 – 7.25 
(m, 17H), 7.25 – 7.11 (m, 4H), 6.08 (dd, J = 17.0, 1.5 Hz, 1H), 5.94 (t, J = 5.6 Hz, 1H), 5.82 (dd, 
J = 10.0, 9.1 Hz, 1H), 5.78 – 5.67 (m, 3H), 5.49 – 5.34 (m, 3H), 4.92 (d, J = 7.9 Hz, 1H), 4.73 – 
4.62 (m, 2H), 4.48 (dd, J = 12.2, 4.2 Hz, 1H), 4.26 (t, J = 9.5 Hz, 1H), 3.94 (t, J = 6.7 Hz, 1H), 
3.89 – 3.80 (m, 2H), 3.80 – 3.63 (m, 3H), 3.58 – 3.49 (m, 1H), 3.42 – 3.30 (m, 1H). 13C NMR 
(125 MHz, CDCl3): δ 165.99, 165.68, 165.49, 165.47, 165.42, 165.32, 164.89, 133.69, 133.64, 
133.62, 133.57, 133.54, 133.42, 133.39, 130.52, 130.10, 129.93, 129.85, 129.79, 129.77, 129.67, 
129.58, 129.48, 129.45, 129.08, 128.91, 128.76, 128.74, 128.71, 128.67, 128.40, 128.38, 126.37, 
101.42, 101.11, 75.95, 73.33, 72.66, 71.96, 71.83, 71.51, 69.98, 69.46, 67.58, 62.24, 61.14, 
39.13, 29.83. HRMS (ESI): calcd. for C66H57O19NNa+ [M+Na]+, 1190.3417; found, 1190.3464. 
 
2-N-acryloyl-aminoethoxy (β-D-galactopyranosyl)-(1→4)-β-D-glucopyranoside (2.17). A 
flame-dried RB flask was charged with compound 2.16 (3.07 g, 2.63 mmol) and a stir bar. Dry 
MeOH (75 mL) was added, and the mixture was stirred for 15 min. A solution of 0.5 M sodium 
methoxide in MeOH (2.10 mL) was then added, and the mixture was allowed to react overnight 
at rt until the product had precipitated.  Compound 2.17 was isolated by vacuum filtration as a 
white solid (1.06 g, 92%). 1H NMR (400 MHz, CDCl3): δ 6.25 (dd, J = 17.1, 9.8 Hz, 1H), 6.17 
(d, J = 17.0 Hz, 1H), 5.74 (d, J = 9.9 Hz, 1H), 4.44 (dd, J = 22.6, 7.9 Hz, 2H), 4.03 – 3.86 (m, 
3H), 3.85 – 3.66 (m, 5H), 3.66 – 3.41 (m, 7H), 3.30 (t, J = 7.6 Hz, 1H). 13C NMR (100 MHz, 
CDCl3): δ 171.11, 132.29, 129.91, 105.37, 104.70, 80.74, 77.79, 77.20, 76.72, 75.21, 74.94, 
73.38, 70.98, 70.90, 63.48, 62.46, 41.84. HRMS (ESI): calcd. for C17H29O12NNa+ [M+Na]+, 
462.1582; found, 462.1591. 
 
2-N-acryloyl-aminoethoxy (2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→4)-2,3,6-tri-O-
benzoyl-β-D-glucopyranoside (2.19). A flame-dried RB flask containing a stir bar and 4 Å 
molecular sieves was charged with compound 2.1854 (3.75 g, 3.09 mmol) and dry CH2Cl2 (60.0 
mL). To this suspension was added N-(2-hydroxyethyl) acrylamide (390. mg, 3.39 mmol), and 
the mixture was stirred for 30 min at rt. The RB flask was then transferred to a 0 oC bath and 
boron trifluoride diethyl etherate (390. µL, 3.09 mmol) was added dropwise over 2 min. The 
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mixture was allowed to react for 90 min, and trimethylamine was subsequently added to quench 
the reaction. After the mixture was first warmed to rt and then concentrated, the crude material 
was purified by flash chromatography to afford 2.19 as a white crystalline solid (2.33 g, 65%). 
1H NMR (500 MHz, CDCl3): δ 7.99 – 7.91 (m, 10H), 7.80 – 7.70 (m, 4H), 7.60 – 7.37 (m, 13H), 
7.31 – 7.20 (m, 8H), 6.09 (dd, J = 16.9, 1.6 Hz, 1H), 5.90 (t, J = 5.7 Hz, 1H), 5.86 – 5.63 (m, 
3H), 5.53 (dd, J = 9.9, 7.8 Hz, 1H), 5.45 – 5.33 (m, 3H), 4.97 (d, J = 7.9 Hz, 1H), 4.71 – 4.62 (m, 
2H), 4.45 (dd, J = 12.1, 4.4 Hz, 1H), 4.23 (t, J = 9.5 Hz, 1H), 4.06 (dd, J = 11.6, 2.7 Hz, 1H), 
3.88 – 3.77 (m, 4H), 3.69 – 3.60 (m, 1H), 3.58 – 3.47 (m, 1H), 3.39 – 3.29 (m, 1H). 13C NMR 
(125 MHz, CDCl3): δ 165.95, 165.78, 165.73, 165.49, 165.45, 165.41, 165.10, 164.84, 133.60, 
133.54, 133.44, 133.37, 130.53, 129.90, 129.86, 129.82, 129.74, 129.71, 129.54, 129.53, 129.40, 
129.02, 128.69, 128.66, 128.64, 128.62, 128.57, 128.45, 128.38, 126.36, 101.29, 100.98, 76.36, 
73.35, 72.86, 72.53, 72.50, 72.12, 72.02, 69.46, 62.76, 62.21, 39.13, 29.82, -1.72. HRMS (ESI): 
calcd. for C66H57O19NNa+ [M+Na]+, 1190.3417; found, 1190.3469. 
 
2-N-acryloyl-aminoethoxy (β-D-glucopyranosyl)-(1→4)-β-D-glucopyranoside (2.20). A 
flame-dried dry RB flask was charged with compound 2.19 (2.24 g, 1.92 mmol) and a stir bar. 
Dry MeOH (55 mL) was added, and the mixture was stirred for 15 min. A solution of 0.5 M 
sodium methoxide in MeOH (1.53 mL) was then added, and the mixture was allowed to react 
overnight at rt.  The mixture was neutralized using DOWEX 50WX8-100 resin, filtered and 
concentrated to give compound 2.20 as a white solid (761 mg, 90%). 1H NMR (400 MHz, D2O): 
δ 6.24 (dd, J = 17.2, 9.8 Hz, 1H), 6.15 (d, J = 17.0 Hz, 1H), 5.72 (d, J = 10.0 Hz, 1H), 4.45 (d, J 
= 7.1 Hz, 2H), 4.02 – 3.83 (m, 3H), 3.82 – 3.64 (m, 4H), 3.64 – 3.51 (m, 4H), 3.51 – 3.23 (m, 
5H). 13C NMR (100 MHz, D2O) δ 168.66, 129.81, 127.43, 102.53, 102.21, 78.54, 75.93, 75.43, 
74.71, 74.15, 73.10, 72.81, 69.40, 68.43, 60.51, 59.93, 39.36. HRMS (ESI): calcd. for 
C17H29O12NNa+ [M+Na]+, 462.1582; found, 462.1591. 
 
S-Ethyl-S’-(α,α’-dimethyl-α’’-acetic acid)trithiocarbonate (2.21). A flame-dried RB flask was 
charged with K3PO4 (1.00 g, 4.71 mmol) and dry acetone (22 mL). Ethanethiol (0.350 mL, 4.71 
mmol) was added and the mixture was stirred for 10 min. Carbon disulfide (0.612 mL, 10.1 
mmol) was then added dropwise and the mixture was stirred for 10 min. After the solution turned 
bright yellow, 2-bromo isobutyric acid (0.787 g, 4.71 mmol) was added and the mixture was 
stirred overnight. The mixture was concentrated and the crude material was dissolved in CH2Cl2 
(25 mL). The organic layer was washed with 1 N HCl (25 mL), water (25 mL), and brine (25 
mL), dried with sodium sulfate, and concentrated. The residue was purified by flash 
chromatography to afford 2.21 as a yellow solid (803 mg, 76%). 1H NMR (400 MHz, CDCl3): δ 
10.43 (s, 1H), 3.29 (q, J = 7.4 Hz, 2H), 1.72 (s, 6H), 1.33 (t, J = 7.4 Hz, 3H). 13C NMR (100 
MHz, CDCl3): δ 220.67, 179.42, 55.69, 31.42, 25.32, 13.02. HRMS (ESI): calcd. for C7H11O2S3- 
[M-H]-, 222.9927; found, 222.9931. 
 
Lipid-functionalized trithiocarbonate chain transfer agent (2.22). A flame-dried RB flask 
was charged with compound 2.21 (161 mg, 0.718 mmol) and dry CH2Cl2 (8 mL). The mixture 
was stirred in an ice bath, followed by the dropwise addition of N,N-diisopropylethylamine (312 
µL, 1.80 mmol) and pentafluorophenyl trifluoroacetate (150. µL, 0.861 mmol). The mixture was 
then stirred at 0 oC for 2 h and concentrated in vacuo. The crude material was dissolved in 
hexanes and filtered through a silica plug. A flame-dried RB flask equipped with a stir bar was 
charged with the filtered PFP ester and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (491 
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mg,  0.710 mmol). A solution of dry CHCl3/MeOH (20:1, 7.00 mL) was added, followed by 
diisopropylethylamine (520 µL, 2.96 mmol). The mixture was stirred overnight at 65 °C, allowed 
to cool to rt, and concentrated. The crude solid was purified by flash chromatography, 
azeotroped with toluene to remove excess acetic acid, and dried in vacuo overnight to give 
compound 2.22 as a yellow solid (0.526 g, 82%). 1H NMR (400 MHz, CDCl3): δ 11.15 (s, 1H), 
7.46 – 7.37 (m, 1H), 5.19 (s, 1H), 4.35 (d, J = 11.5 Hz, 2H), 4.24 (t, J = 5.8 Hz, 1H), 4.12 (dd, J 
= 11.7, 6.7 Hz, 2H), 4.00 – 3.87 (m, 4H), 3.65 – 3.51 (m, 2H), 3.50 – 3.40 (m, 2H), 3.25 (q, J = 
7.3 Hz, 2H), 3.06 – 2.95 (m, 2H), 2.26 (dd, J = 11.9, 6.9 Hz, 4H), 1.99 (s, 1H), 1.73 – 1.62 (m, 
6H), 1.61 – 1.50 (m, 5H), 1.45 – 1.15 (m, 42H), 0.85 (t, J = 6.4 Hz, 6H). 13C NMR (100 MHz, 
CDCl3): δ 220.51, 173.55, 173.14, 172.73, 70.40, 70.32, 64.29, 64.26, 63.76, 63.73, 62.70, 57.29, 
53.24, 41.72, 41.37, 41.32, 34.36, 34.19, 32.01, 31.31, 29.80, 29.75, 29.62, 29.45, 29.42, 29.24, 
25.82, 25.01, 24.96, 22.78, 18.64, 17.47, 14.22, 12.90, 11.95. 31P NMR (160 MHz, CDCl3): δ -
1.57 (s). HRMS (ESI): calcd. for C44H83O9NPS3- [M-H]-, 896.4973; found, 896.4975. 
 
RAFT polymerization of glycosyl acrylamides. Polymerizations were carried out using 
standard Schlenk techniques. Lipid-functionalized CTA 2.22 (4.09 mg, 4.55 µmol), lactosyl 
ethyl acrylamide 2.17 or cellobiosyl ethyl acrylamide 2.20 (0.100 g, 228 µmol), 4,4′-azobis(4-
cyanovaleric acid) (319 µg, 1.14 µmol), DMF (200 µl) and H2O (800 µl) were added to the 
Schlenk tube. The solution was degassed by sparging with N2 for 30 min. The Schlenk flask was 
placed in a 70 oC bath to start the polymerization. After 16 h, the reactions were stopped by 
exposure to oxygen. The conversion for the glycosyl monomer was calculated by comparing the 
integrals of the alkene proton peaks of the monomer (5.7 ppm, 1H) and those of the backbone 
methylene protons on the glycopolymer (1.87- 1.00 ppm, 2H). Glycopolymers were purified by 
dialysis against H2O for 72 h and lyophilized.  
 
Lactosyl glycopolymer (2.23). According to the above procedures, polymer 2.23 was obtained 
as a light yellow solid (87 mg, 93%). Conversion (NMR) = 0.95. Mn (NMR) = 20670. PDI 
(SEC) = 1.21. 1H NMR (500 MHz, D2O): δ 4.67 – 4.25 (m, 45H), 4.23 – 2.94 (m, 354H), 2.48 – 
1.87 (m, 24H), 1.87 – 1.36 (m, 34H), 1.36 – 0.97 (m, 23H), 0.83 (t, J = 6.5 Hz, 3H). 
 
Cellobiosyl glycopolymer (2.24). Polymer 2.24 was prepared using the above procedure to yield 
a light yellow solid (91 mg, 89%). Conversion (NMR) = 0.98. Mn (NMR) = 22490. PDI (SEC) = 
1.22. 1H NMR (500 MHz, D2O): δ 4.60 – 4.36 (m, 49H), 4.26 – 3.04 (m, 411H), 2.51 – 1.87 (m, 
27H), 1.87 – 1.36 (m, 40H), 1.36 – 1.00 (m, 22H), 0.93 – 0.76 (m, 3H). 
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Chapter 3. Investigating Cell Surface Galectin-Mediated Cross-linking on Glycoengineered 
Cellsa 
 
 
Introduction 
 
 Many cellular processes are regulated by multimerization of cell surface proteins and 
lipids.1 In many systems, biomolecules assemble into higher-order clusters through direct 
protein-protein interactions. However in some cases, auxiliary proteins provide scaffolding for 
oligomeric assemblies via recognition of post-translational modifications.2 The galectins, a 
family of secreted glycan-binding proteins, are thought to serve such a function by interacting 
with specific glycan structures covalently bound to cell surface proteins and lipids.3 Evidence 
that both the galectins as well as many of their native ligands are multivalent has led to the 
proposal of a “galectin lattice” model, in which galectins can segregate membrane-associated 
glycoproteins and glycolipids into discrete microdomains.4 Galectin-mediated assemblies have 
been implicated in the regulation of cell signaling, adhesion, migration, and proliferation,5  and 
their dysfunctions have been associated with autoimmune disease6 and cancer.7  As well, Dennis 
and coworkers have proposed that galectin lattices can regulate the cell surface half-lives of 
glycoproteins by retarding their endocytosis.8 
 Despite compelling evidence for the galectins’ role in modulating the behaviors of cell 
surface molecules, galectin-mediated ligand cross-linking has not been directly observed on live 
cells. A majority of studies addressing the galectins’ crosslinking ability have relied on in vitro 
binding assays.9 In one cell-based study, Nieminen et al. demonstrated that galectin-3 exists in a 
multivalent state, a requirement for cross-linking, on neutrophil and endothelial cell surfaces 
through Förster resonance energy transfer (FRET) imaging.10 However, the effects of galectin 
binding on ligand multimerization have not been directly addressed in cell-based systems, a 
challenge that is exacerbated by the nature of the galectins’  endogenous ligands: they comprise a 
heterogeneous collection of glycoconjugates that share related glycan structures but disparate 
underlying scaffolds. There is no straightforward means to selectively label such a complex 
ligand mixture with biophysical probes that would enable studies of their oligomerization. 
Specific glycoproteins, such as integrins,11 mucins,12  the T cell receptor,6 and EGFR,8  have 
been found to bind galectins in	   biochemical assays. In principle, the influence of galectins on 
these proteins’ cell-surface behavior can be monitored using GFP fusions and fluorescent 
antibodies. But on live cells, it is likely that only a subset of their heterogeneous glycoforms 
engage galectins and form oligomers, which complicates analyses focusing only on the protein 
component of the ligand. 
 Here we present a new platform for investigating galectin-mediated cross-linking on live 
cell surfaces utilizing membrane-associated GPs as chemically defined ligands (Figure 3.1). The 
GPs were designed to possess the following attributes: (1) galectin-binding glycans distributed 
across the polymer backbone similarly to galectin-binding mucin glycoproteins,12 (2) a lipid 
anchor at one end, and (3) a FRET donor or acceptor fluorophore at the other end. The lipid tail 
enables insertion of the GP into live cell membranes and control of polymer orientation at the 
cell surface.13 The fluorescent dyes allow simultaneous monitoring of GP cross-linking by FRET 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
a Geoffrey P. O’Donoghue and Adam W. Smith contributed to work presented in this chapter. 
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as well as detection of higher-order assemblies by fluorescence correlation spectroscopy (FCS). 
Using this experimental platform we found direct evidence for the formation of cell-surface 
ligand clusters in the presence of galectin-1. More broadly, the method should facilitate 
interrogation of the galectin-lattice model in the physiologically relevant context of cell surfaces. 
 
 
 
Figure 3.1. An experimental platform for probing galectin-mediated ligand cross-linking on live 
cell surfaces. Synthetic GPs were adorned with galectin-binding glycans (blue hexagons) and 
functionalized with a lipid on one end and either a FRET donor or acceptor dye on the other. The 
GPs were inserted into live cell membranes, and their fluorescence lifetimes (τFL) and diffusion 
times (τD) were monitored. The galectin-dependent decrease in τFL and increase in τD provided 
evidence of cell-surface GP cross-linking and oligmerization.  
 
Results and Discussion 
 
Glycoengineering cell surfaces 
 
 Well-defined GPs were synthesized by reversible addition-fragmentation chain transfer 
(RAFT) polymerization (Chapter 2), which enables the dual end-functionalization of the polymer 
chain. The trithiocarbonate end groups of 2.23 and 2.24 were cleaved with sodium borohydride, 
and the resulting free sulfhydryl groups were conjugated with maleimide-functionalized Alexa 
Fluor 488 (donor lactosyl GP 3.1 and donor cellobiosyl GP 3.2) or Alexa Fluor 555 (acceptor 
lactosyl GP 3.3 and acceptor cellobiosyl GP 3.4). These fluorescent lipid-functionalized GPs 
were used in all subsequent experiments. 
 We next sought to display polymers 3.1 and 3.2 on live cells for galectin binding studies. 
Most cell types express endogenous glycoproteins that possess galectin-binding N-
acetyllactosamine (LacNAc, Galβ1,4GlcNAc) residues.14  In this initial study, we tried to 
minimize the impact of endogenous ligands on galectin-GP interactions by choosing a cell line 
that is deficient in galactosides, the ldlD Chinese Hamster Ovary (CHO) cell mutant.15 ldlD  
CHO cells were incubated with 3.1 or 3.2 for 50 min at rt and imaged using fluorescence 
microscopy to assess cell surface incorporation. Consistent with previous studies,13 both GPs 
produced robust fluorescence localized at the cell membrane as well as within endocytic vesicles 
(Figure 3.2B and F, and Figures 3.3, 3.4, and 3.5). 
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Figure 3.2. Fluorescence microscopy of ldlD CHO cells treated with GP 3.1 (A−D) or 3.2 (E−H) 
followed by fluorescently labeled Galectin-1, Gal-1-555 (D and G). Hoechst 33342 was used to 
stain the nuclei (A and E). Galectin-1 binding was observed on cells incubated with GP 3.1 (C) 
but not with GP 3.2 (G). 
 
 
 
Figure 3.3. Fluorescence microscopy of ldlD CHO cells incubated with lipid-terminated 
fluorescent glycopolymers. The signal (green) demonstrates cell surface incorporation of 
glycopolymers 3.1 and 3.2. Hoechst 33342 (blue) was used to stain the nuclei. 
 
 
 
Figure 3.4. Fluorescence microscopy of ldlD CHO cells incubated with glycopolymer 3.1 and 
imaged at different time points. The glycopolymer cell surface signal (green) diminishes over 
time, consistent with endocytosis of the lipid-terminated glycopolymers. Hoechst 33342 (blue) 
was used to stain the nuclei. 
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Figure 3.5. Fluorescence microscopy of ldlD CHO cells first incubated with glycopolymer 3.1 
and then with an early endosome marker, Dextran Alexa Fluor 647. The glycopolymer signal 
(green) colocalizes with the dextran signal (red), providing evidence that the lipid-functionalized 
glycopolymers undergo endocytosis and traffic to early endosomes. 
 
Galectin-1 binds to glycopolymer-functionalized cells 
 
 For our initial studies we chose galectin-1, a homodimer with two carbohydrate 
recognition domains (CRDs) at opposite poles of its 3-D structure.16 The distance between the 
two CRDs is ~5 nm, well below the Förster radius, R0, for the FRET pair Alexa Fluor 488 and 
555. To explore galectin-1’s ability to bind GPs 3.1 and 3.2 when displayed on live cells, 
galectin-1 was fluorescently labeled with Alexa Fluor 555 (generating Gal-1-555) as previously 
described.17 ldlD CHO cells previously treated with either 3.1 or 3.2 were incubated with labeled 
galectin-1, imaged using fluorescence microscopy or analyzed by flow cytometry. 
 Cells displaying lactosyl GP 3.1 showed significant Gal-1-555 binding (Figure 3.2C), 
whereas cells displaying cellobiosyl GP 3.2 did not (Figure 3.2G), mirroring the known 
monomeric ligand preference of galectin-1. Flow cytometry analysis of cells treated similarly 
gave comparable results (Figure 3.6), although a low amount of Gal-1-555 binding to cell-
associated GP 3.2 was observed. It is likely that galectin-1’s interaction with cellobiose, though 
too weak to detect at the monomer level, becomes discernible with multivalent polymers. 
Overall, these results show that cells deficient in endogenous ligands can be engineered using 
synthetic GPs to bind galectin-1. 
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Figure 3.6. Flow cytometry analysis of galectin-1 binding to ldlD CHO cells incubated with 
glycopolymer 3.1, glycopolymer 3.2, or no glycopolymer. Error bars indicate the standard 
deviation.  
 
Monitoring galectin-mediated cross-linking on live cells 
 
 The impact of galectin-1 binding on the oligomerization state and mobility of bound GPs 
was assessed using fluorescence lifetime measurements by time-correlated single-photon 
counting (TCSPC) and FCS. The principle of the experiment is as follows. GPs 3.1 and 3.2 
possess identical backbone and glycan structures but disparate dyes that constitute a FRET pair. 
The GP pair can be codisplayed on cell membranes in a 1:1 ratio. In the ns regime, fluorescence 
lifetime measurements can probe for galectin-1-mediated cross-linking since the depletion of 
excited states of donor 3.1 by proximal acceptor 3.3 (d < R0) decreases the overall fluorescence 
lifetime (τFL) of 3.1.18 Further, FCS operates by performing an autocorrelation analysis on the 
fluorescence fluctuations in an ~1 fL excitation volume over many time scales, ns to s.19 A 
diffusion time (τD) parameter can be extracted from the autocorrelation function, ultimately 
quantifying the relative mobility of the GPs on the cell surface. The formation of GP clusters 
would be implied by observed increases in diffusion time. 
 ldlD CHO cells were first incubated with GPs 3.1 and 3.3 (1:1 ratio), and the time-
resolved fluorescence intensity of donor 3.1 was monitored on single live cells with a ps laser 
pulse at 10 MHz in the presence or absence of unlabeled galectin-1.20 Fluorescence lifetime and 
diffusion time were calculated at 10-min intervals. In the absence of galectin-1, donor 3.1’s 
fluorescence lifetime increased with time (Figure 3.7). We attribute this phenomenon to 
endocytosis of the GPs, as evident in our microscopy images. As a consequence, the GPs’ 
density on the cell surface decreases over time, which would reduce the background level of 
FRET among unclustered GP molecules. Indeed, at lower temperatures at which endocytosis is 
slower (11− 13 ° C), the fluorescence lifetime of donor 3.1 increased at a slower rate (Figure 
3.8). 
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Figure 3.7. Fluorescence lifetime measurements of GPs on ldlD CHO cells. (A) Fluorescence 
lifetime, Δτ(t), measurements of donor 6 in the absence (dotted) or presence (solid) of galectin-1 
as a function of time. Δτ(t) represents the difference between τ(t) and τ(0). Error bars indicate the 
standard deviation. (B) The difference in fluorescence lifetime (Δτ) between t = 20 and t = 0 min, 
averaged over six different cells. *P < 0.01; **P < 0.005. Gal-1: unlabeled galectin-1; Lac: 200 
mM lactose. Error bars indicate the standard error. 
 
 
 
Figure 3.8. The difference in fluorescence lifetime (τD) of donor 3.1 on ldlD CHO cells between 
t = 20 and t = 0 min, averaged over six different cells. Error bars indicate standard error.  
 
 Next, we monitored the fluorescence lifetime of donor 3.1 after adding galectin-1 to cells 
labeled with 3.1 and 3.3. We observed a marked decrease in fluorescence lifetime of donor 3.1 
over a period of 40 min (Figure 3.7A). We repeated the experiment on six different cells and 
observed similar results; the average changes in fluorescence lifetime are shown in Figure 3.7B. 
These observations suggest that cross-linking of donor 3.1 and acceptor 3.3 by galectin-1 
enhanced FRET and, consequently, decreased the fluorescence lifetime of donor 3.1. We 
performed a comparable experiment using the cellobiosyl GP FRET pair 3.2 and 3.4. Despite the 
presence of galectin-1, the fluorescence lifetime of donor 3.2 increased with time, consistent with 
endocytosis and little cross-linking. The observed increase was not as dramatic as that observed 
in the absence of galectin-1, probably reflecting GP 3.2’s weak interaction with the protein as 
previously observed by flow cytometry (Figure 3.6). Importantly, the galectin-1-dependent 
decrease in fluorescence lifetime of GP 3.1 was entirely inhibitable by soluble lactose (200 mM) 
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(Figure 3.7B). In the presence of this galectin-1 competitor, no significant galectin-1-mediated 
cross-linking was observed. Additional evidence for a direct interaction between galectin-1 and 
donor 3.1 was demonstrated through a FRET experiment with fluorescently labeled galectin-1 
(Figure 3.8). 
 
Measuring diffusion time of glycopolymers in the presence of galectin-1 
 
 Using the same data acquired for fluorescence lifetime measurements, diffusion times 
were calculated for donor 3.1 over the 40-min time course in the presence or absence of galectin-
1. Examples of autocorrelation functions (A and B) and diffusion time values (C) are shown in 
Figure 3.9. In the absence of galectin-1, diffusion times for donor 3.1 were relatively stable 
(Figure 3.9C), indicating that the mobility of 3.1 on living cells does not change significantly 
over time. Notably, the diffusion time for donor 3.1 noticeably increased over time after addition 
of galectin-1. This dramatic galectin-1-dependent decrease in donor 3.1’s mobility provides 
evidence for oligomerization on the cell surface. As before, we averaged the diffusion time 
values from six different cells and calculated the difference between those values at t  = 20 and 0 
min (Figure 3.9D). The data confirm that galectin-1 increased the diffusion time of donor 3.1, 
which is indicative of reduced mobility and oligomerization of the GP. Free lactose abrogated 
galectin-1’s influence on mobility, consistent with a glycan-binding mechanism of 
oligomerization. In the presence of 200 mM lactose, the change in diffusion time mirrored that of 
donor 3.1 in the absence of galectin-1. 
 
 
 
Figure 3.9. FCS of GP 3.1 on ldlD CHO cells. Autocorrelation curves for donor 3.1 in the 
absence (A) or presence (B) of galectin-1 at 0 min (blue) and 20 min (green). (C) Diffusion time, 
τD, for donor 3.1 in the absence (dotted) or presence (solid) of galectin-1. (D) The difference in 
diffusion time (ΔτD) of donor 3.1 at t = 20 and 0 min averaged over six different cells. *P < 0.05. 
Gal-1: unlabeled galectin-1; Lac: 200 mM lactose. Error bars indicate the standard error. 
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Galectin deforms glycoengineered membranes in giant unilamellar vesicles 
 
 Having established that galectins assemble glycoconjugates into large, stable cross-linked 
networks on the cell surface, we wanted to understand the consequences of network formation on 
membrane curvature.  We subsequently inserted GP 3.1 into a simplified membrane system 
composed of giant unilamellar vesicles (GUVs). GUVs are large liposomal structures that are 
similar to cell membranes but lack cytosolic components.21 They are also large enough (10-100 
µm) that membrane deformation can be visualized by fluorescent microscopy. We first incubated 
GP 3.1 with 1-palmitoyl-2-oleoylphosphatidylcholine (POPC)-based GUVs to functionalize the 
outer leaflet of the membrane with the GP. Using epifluorescence microscopy, we found that the 
GP uniformly labeled the vesicle without affecting membrane curvature (Figure 3.10A). Upon 
addition of galectin-3, however, we noted significant membrane bending and deformation of the 
vesicle structure (Figure 3.10B). Ordered domains, membrane tubes, and endocytic vesicles were 
all observable and dependent on galectin-mediated cross-linking. These results indicate that 
galectin clusters can both reinforce and oppose membrane curvature depending on geometric 
constraints. Taken together, our data suggest that galectins are able to form extended networks 
on cells surfaces and influence the mechanics and organization of the underlying membrane.  
 
 
 
Figure 3.10. Fluorescence microscopy of GUVs first incubated with GP 3.1 (A) and then treated 
with recombinant galectin-3. Galectin cross-linking of GPs (green) bends POPC membranes.  
 
 
Conclusion 
 
 In conclusion, we have established a new methodology for investigating galectin-glycan 
interactions on live cell membranes using fluorescently labeled GPs in conjunction with FRET 
and FCS. To our knowledge, we have also provided the first experimental evidence for galectin-
1-mediated cross-linking from the perspective of the bound ligand. Studies are underway 
addressing the ability of different members of the galectin family to induce such cross-linking. 
The information should shed light on the dimensions and dynamics of putative galectin lattices 
on the cell surface as well as the effects of the glycan structure and presentation on galectin 
recognition and crosslinking. This approach could ultimately provide insight into how the 
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various galectin members exert different signaling and organizational functions through cell 
surface interactions. Beyond galectin biology, we envision applications in the study of glycan-
receptor interactions between two cells, wherein changes in oligomerization of receptor-bound 
GPs might reveal the preferred cluster size of the associated glycan-binding protein. As well, the 
platform can be extended to cell-surface interactions not involving glycans, as the polymers are 
wholly synthetic and can be adorned with any ligand type. 
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Experimental Procedures 
 
General methods 
 
 All of the chemical reagents were of analytical grade, obtained from commercial 
suppliers, and used without further purification, unless otherwise noted. All of the reactions were 
performed in a N2 atmosphere. Liquid reagents were added with a syringe. Unless otherwise 
noted, 1H NMR spectra were obtained with 500 MHz Bruker spectrometers. Chemical shifts (δ) 
are reported in parts per million and standardized against solvent peaks. Polymer Mn was 
calculated by comparing the area under the peak corresponding to the anomeric proton to that of 
the methyl protons on the 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine unit. UV-Vis 
spectra were acquired on a Thermo Scientific NanoDrop 2000 Spectrophotometer and used to 
determine percent modification of fluorophore labeling. Aqueous size exclusion chromatography 
was performed using a Viscotek TDA 302 SEC fitted with a Shodex SB-803 HQ column and 
using differential refractive index detection. The mobile phase used was an aqueous solution of 
NaNO3 (0.1M) at a flow rate of 1.0 mL min-1 and at a constant temperature of 40 oC. 
Conventional calibration was achieved using narrow PEG standards. Polydispersity indices were 
determined using the Omnisec for Windows software. 
 Alexa Fluor 488 C5 maleimide, Alexa Fluor 555 C2 maleimide, Alexa Fluor 647 
succinimidyl ester, Dextran Alexa Fluor 647 and Hoechst 33342 nuclear stain were obtained 
from Invitrogen Life Technologies, Inc. Dulbecco’s phosphate-buffered saline pH 7.4 (PBS), 
Ham’s F-12 media, and fetal bovine serum (FBS) were obtained from HyClone Laboratories. 
Tissue culture plates were obtained from Corning, and glass slides mounted with 8-tissue culture 
wells were obtained from Nunc. Flow cytometry analysis was performed on a BD FACSCalibur 
flow cytometer with at least 104 live cells for each sample. Cell viability was determined by 
gating the samples on the basis of forward scatter and side scatter. The average fluorescence 
intensity was calculated from three, separate replicate samples. Fluorescence microscopy was 
performed on a Zeiss Axiovert 200M inverted microscope. Images were acquired by using a 
CoolSNAP HQ charged-coupled device camera. SLIDEBOOK software was used to control the 
microscope and the camera and for image analysis. 
 Förster Resonance Energy Transfer (FRET) and Fluorescence Correlation Spectroscopy 
(FCS) experiments were performed on an inverted microscope (Nikon Eclipse Ti; Technical 
Instruments, Burlingame, CA). Illumination light for the FRET donor was produced by a 10 
MHz, <100 picosecond pulsed diode laser (LDH-P-C-485; PicoQuant GmbH, Berlin, Germany) 
operating at 488 nm. A single mode fiber was used to reshape the diode laser emission to 
produce a Gaussian beam profile. Laser power at the sample was set to 1.5 µW by directly 
modulating the laser power at the laser head using a pulsed diode laser driver (PDL 800-B; 
PicoQuant GmbH, Berlin, Germany). Several turning mirrors were used to center and shape the 
focused diode laser beam using both a solution of Alexa Fluor 488 and a DOPC (Avanti Polar 
Lipids Inc., Alabaster, Al) supported lipid bilayer doped with a small percentage of TopFluor-PS 
lipids (Avanti Polar Lipids Inc., Alabaster, Al) as a visual indicator of beam quality. Images were 
recorded using an EM-CCD (iXon 597DU; Andor, Inc., South Windsor, CT). A dichroic 
beamsplitter (z405/488/561rpc; Chroma Technology Corp., Bellows Falls, VT) reflected light 
through the objective (Nikon 1.49 N.A. TIRF; Technical Instruments, Burlingame, CA). 
Fluorescence emission was collected on a 50 µm active area single photon avalanche detector 
(PDM Series from Micro Photon Devices; Optoelectronic Components, Quebec, Canada). 
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Bandpass emission filters were FF01-520/44-25 (Semrock Inc., Rochester, NY) and 
z405/488/561M (Chroma Technology Corp., Bellows Falls, VT). Photon arrival times were 
measured using an event timer (PicoHarp 300; PicoQuant GmbH, Berlin, Germany) and channel 
router (PHR 800; PicoQuant GmbH, Berlin, Germany) controlled using the PicoHarp software 
(PicoQuant GmbH, Berlin, Germany). Photon data were analyzed using custom written 
MATLAB scripts (The Mathworks, Natick, MA).  
 
Synthesis 
 
Alexa Fluor functionalization of glycopolymers. A RB flask was charged with glycopolymer 
2.23 or glycopolymer 2.24 (18.0 mg, 0.871 µmol) and H2O (10 mL). Sodium borohydride (196 
mg, 5.20 mmol) was added to the mixture, and the reaction was stirred for 2 h. Sodium 
borohyride was removed by dialysis against H2O for 72 h. The reduced glycopolymer (2.5 mg, 
0.13 µmol) was then dissolved in 100 mM Tris buffer (0.4 mL, pH 7.5) and degassed by 
sparging with N2 for 15 min. Tris(2-carboxyethyl)phosphine hydrochloride (0.4 mg, 1.3 µmol) 
was added. After 1 h, Alexa Fluor 488 C5 maleimide or Alexa Fluor 555 C2 maleimide (1.0 mg, 
1.3 µmol) was added to the reaction mixture. The reaction was stirred overnight at rt in the dark. 
The fluorescent glycopolymer was purified by dialysis against H2O for 120 h in the dark and 
subsequently lyophilized.  
 
Donor lactosyl glycopolymer (3.1). Polymer 3.1 was prepared using the above procedure to 
yield an orange solid (2.55 mg, 92%, 92% Alexa Fluor modification).  Mn (NMR) = 21290. PDI 
(SEC) = 1.34. See 1H NMR in Appendix.  
 
Donor cellobiosyl glycopolymer (3.2). Polymer 3.2 was prepared using the above procedure to 
yield an orange solid (2.71 mg, 90%, 99% Alexa Fluor modification). Mn (NMR) = 23050. PDI 
(SEC) = 1.51. See 1H NMR in Appendix. 
 
Acceptor lactosyl glycopolymer (3.3). Polymer 3.3 was prepared using the above procedure to 
yield a purple solid (2.44 mg, 86%, 97% Alexa Fluor modification). Mn (NMR) = 21820. PDI 
(SEC) = 1.35. See 1H NMR in Appendix. 
 
Acceptor cellobiosyl glycopolymer (3.4). Polymer 3.4 was prepared using the above procedure 
to yield a purple solid (2.55 mg, 83%, 98% Alexa Fluor modification). Mn (NMR) = 23580. PDI 
(SEC) = 1.52. See 1H NMR in Appendix. 
 
Cell culture 
 
 ldlD Chinese hamster ovary (CHO) cells were cultured in Ham’s F-12 media 
supplemented with 10% FBS, 100 units/mL penicillin and 100 µg/mL streptomycin. The cells 
were maintained at 37 °C and 5% CO2 in a water-saturated incubator and counted using a 
hemocytometer. Cell densities were maintained between 1 x 105 and 2 x 106 cells per mL. 
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Fluorescence microscopy 
 
 Human galectin-1 was recombinantly expressed and purified according to Pace et al.22 
Gal-1-555 was prepared from galectin-1 and Alexa Fluor 555 succinimidyl ester following the 
procedure from Stowell et al.17  ldlD CHO cells were seeded at a density of 1 x 105 cells per mL 
on slides mounted with 8-tissue culture wells in 0.3 mL media. After 2 d, the cells were washed 
with PBS + 1% FBS (2 x 0.5 mL) and then treated with either 6 or 7 (400 µg/mL) in PBS + 1% 
FBS (0.2 mL). The cells were incubated for 50 min at rt. The cells were then washed with PBS + 
1% FBS (3 x 0.4 mL) and incubated with Gal-1-555 (25 µM) in PBS + 1% FBS (0.2 mL) for 40 
min at rt and stained with Hoechst 33342 (200 µg/mL) for 5 min. The cells were then washed 
with PBS + 1% FBS (3 x 0.4 mL) and imaged in PBS + 1% FBS (0.2 mL).  
 
FRET and FCS data collection and analysis 
 
 ldlD CHO cells were seeded at a density of 1 x 105 cells per mL on slides mounted with 
8-tissue culture wells in 0.3 mL media. After 2 d, the cells were washed with PBS + 1% FBS (2 
x 0.5 mL) and then treated with either 6 (200 µg/mL) and 8 (200 µg/mL) or 7 (200 µg/mL) and 9 
(200 µg/mL) in PBS + 1% FBS (0.2 mL). The cells were incubated for 50 min at rt. The cells 
were then washed with PBS + 1% FBS (4 x 0.4 mL) and imaged in PBS + 1% FBS (0.2 mL). 
Cells were first imaged using reflection interference contrast microscopy until three viable cells 
with suitable size and morphology were found. These cell positions were saved, and each cell 
was sequentially centered with respect to the focused laser beam. Six 20 s photon streams were 
collected from the same position inside each cell. This sequence was repeated for the three 
different cells at 10 min intervals after galectin-1 (25 µM) addition.  
 Each cell produced photon streams that were then manipulated to yield both a photon 
arrival histogram and fluorescence correlation curve for each time point before/after galectin-1 
addition. The fluorescence lifetime reported for each cell at a particular time point is the decay 
constant from a single exponential fit of that cells photon arrival histogram. τD was chosen as a 
measure of mobility instead of the diffusion coefficient, because cell membranes often exhibit 
anomalous (time-dependent) diffusion.23 τD was calculated to be the half-life of the decay of the 
fluorescence correlation curve.  
 
Galectin-1 binding analysis by flow cytometry 
 
 Galectin-1 was labeled with Alexa Fluor 647 succinimidyl ester according to Stowell et 
al.17 A suspension of 1 x 106 ldlD CHO cells was pelleted by centrifugation (1300 rpm for 3 
min). The supernatants were decanted, and the cells were washed (2 x 0.5 mL) with PBS + 1% 
FBS (FACS buffer). After resuspension in FACS buffer (0.2 mL), the cells were incubated with 
6 or 7 (400 µg/mL) for 50 min at rt. The cells were then pelleted again by centrifugation and 
washed (2 x 0.5 mL) with FACS buffer. ldlD CHO cells treated with either 6 or 7 were 
subsequently resuspended in FACS buffer (0.2 mL) and incubated with Gal-1-647 (25 µM) for 
40 min at rt. The cells were pelleted again, and the supernatant was decanted. The labeled cells 
were washed (3 x 0.5 mL) and resuspended in FACS buffer (0.4 mL) for analysis by flow 
cytometry. 
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Endocytosis analysis by fluorescence microscopy 
 
 ldlD CHO cells were seeded at a density of 1 x 105 cells per mL on slides mounted with 
8-tissue culture wells in 0.3 mL media. After 2 d, the cells were washed with PBS + 1% FBS (2 
x 0.5 mL) and then treated with 6 (400 µg/mL) in PBS + 1% FBS (0.2 mL). The cells were 
incubated for 50 min at rt. The cells were either (1) stained with Hoechst 33342 (200 µg/mL) for 
5 min, washed with PBS + 1% FBS (3 x 0.4 mL) and imaged in PBS + 1% FBS (0.2 mL), (2) 
washed with PBS + 1% FBS (3 x 0.4 mL), incubated in media for 60 min at 37 oC and 5% CO2, 
stained with Hoechst 33342 (200 µg/mL) for 5 min, washed with PBS + 1% FBS (3 x 0.4 mL) 
and imaged in PBS + 1% FBS (0.2 mL), or (3) stained with Dextran Alexa Fluor 647 (1 mg/mL) 
and Hoechst 33342 (200 µg/mL) for 5 min at 37 oC, washed with PBS + 1% FBS (3 x 0.4 mL) 
and imaged in PBS + 1% FBS (0.2 mL). 
 
Giant Unilamellar Vesicle Functionalization 
 
 1-Palmitoyl-2-oleoylphosphatidylcholine (POPC)-based GUVs, prepared by 
electroformation, were incubated with GP 3.1 (100 µg/mL) overnight at rt in HEPES buffer. 
GUVs were then isolated by centrifugation (420 x g) and washed (3 x 50 µL) with HEPES. An 
aliquot of GUV suspension (10 µL) was then removed and imaged by fluorescence microscopy 
with a flow cell. GP-functionalized GUVs were then treated with recombinant galectin-3 in 
HEPES for 1.5 h before addition to flow chamber. Membrane curvature was then assessed by 
fluorescence microscopy in HEPES (10 µL).  
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Chapter 4. Imaging the Glycosylation State of Cell Surface Glycoproteins by Two-Photon 
Fluorescence Lifetime Imaging Microscopya 
 
 
Introduction 
 
 A cell surface protein’s glycosylation state can profoundly influence its biological 
capabilities and can report on the physiological state of the underlying cell.1-7 Thus, visualization 
of particular protein glycoforms is an important though challenging goal. Most protein-directed 
imaging methods (e.g. green fluorescent protein (GFP) tags, fluorescent antibodies) are not 
sensitive to the glycosylation state of a protein. Our research group previously developed a 
method or imaging certain glycan structures on native glycoproteins by metabolic labeling with 
functionalized sugars. However, this glycan-targeted imaging method cannot reveal the identity 
of proteins to which the labeled glycans are attached.8-10 Imaging of a specific protein glycoform 
will require integration of the identifies of both the protein and the glycan. 
 Other groups have recently made strides towards this goal. Söderberg and coworkers 
used proximity ligation to detect a specific glycoform of the tumor marker MUC2.11 More 
recently, Haga et al. used azido sugar labeling of GFP-tagged proteins to image cell surface 
glycoproteins by Förster resonance energy transfer (FRET) fluorescence microscopy.12 Due to 
their reliance on GFP-tagged proteins, however, this method cannot image endogenous 
glycoproteins or proteins that are not amenable to fluorescent protein fusion. Even so, there are 
some limitations to a traditional FRET-based technique. The distance between the donor and 
acceptor fluorophores in a FRET experiment is related to the efficiency of energy transfer and 
typically precludes the use of two large macromolecules, such as immunoglobulin G (IgG; >10 
nm).13 Another compounding factor for imaging of specific protein glycoforms is the 
discrepancy between protein copy number and glycan abundance. The difference in abundance 
between common types of glycans and a specific protein can be orders of magnitude on the cell 
surface.14 This large difference in relative number can complicate analyses in imaging 
applications. For example, in a typical FRET-based experiment, the donor fluorophore is excited, 
and emission from the acceptor fluorophore is monitored. In the case of high acceptor 
fluorophore concentration, acceptor bleedthrough can occur causing a false positive FRET signal 
(Figure 4.1). 
 
 
 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
a Adam de la Zerda, David R. Spiciarich, and Sophia L. Maund contributed to work in this chapter. 
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Figure 4.1. Förster Resonance Energy Transfer (FRET) fluorescence microscopy of U87MG 
cells. Integrin αVβ3 was labeled with a donor fluorophore, while the sialic acid residues were 
labeled with an acceptor fluorophore. FRET is observed even in the absence of donor 
fluorophore. Scale bar: 50 µm.  
 
 Herein, we present a new approach to image endogenous protein glycoforms using a 
combination of azido sugar labeling and two-photon fluorescence lifetime imaging microscopy 
(FLIM). We rely on a small (<7 nm) targeting moiety, an antigen-binding fragment (Fab), to 
introduce the donor fluorophore and locate the protein component. We applied our previously 
developed glycan labeling strategy to introduce the acceptor fluorophore. In this scheme, cells 
were first incubated with an azido sugar, peracetylated N-azidoacetylmannosamine 
(Ac4ManNAz), which is processed by the cellular machinery and incorporated into glycoproteins 
as azido sialic acid (SiaNAz). Subsequent bioorthogonal reaction with a cyclooctyne–
fluorophore15,16 conjugate delivers the acceptor fluorophore within a minimal distance (Figure 
4.2). 
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Figure 4.2. A technique for imaging the glycosylation state of glycoproteins through the use of 
metabolic labeling and two-photon fluorescence lifetime imaging microscopy (FLIM). Cells or 
tissues are fed the azido sugar, Ac4ManNAz, which is metabolized to SiaNAz, and SiaNAz is 
then incorporated in sialylated glycoproteins. The azide functionality is reacted with an 
appropriate bioorthogonal probe bearing an acceptor fluorophore to report on the localization of 
sialic acid residues. In a subsequent step, the protein scaffold of the glycoprotein is targeted with 
a donor fluorophore-labeled Fab fragment. The presence of both the FRET donor and acceptor 
fluorophores on a specific glycoprotein is monitored by changes in the fluorescence lifetime (τ) 
of the donor after two-photon excitation on a per-pixel basis. 
 
Results and Discussion 
 
SiaNAz residues incorporate into integrin αVβ3 
 
 A common method for circumventing acceptor bleedthrough is to focus on the donor 
fluorophore’s emission in a FRET experiment. Energy transfer between the donor and acceptor 
fluorophore results in two major changes to the donor’s physical properties. The first is reduction 
in emission from the donor. Imaging this photon reduction in a population of cells requires 
normalization by photobleaching of the acceptor to reveal the maximum amount of donor 
emission, a difficult and tedious task when the field of view contains numerous cells. The other 
change for the donor fluorophore upon energy transfer is a decrease in fluorescence lifetime.17 
This time-dependent property is advantageous since no further experimentation or sample 
manipulation is necessary. We sought to utilize the decrease in fluorescence lifetime of the donor 
fluorophore associated with FRET to monitor the sialylation state of a given glycoprotein 
through two-photon FLIM. 
 Overexpression of the integrin αVβ3 subtype is observed in variety of cancers and is often 
correlated with invasiveness due to its pro-angiogenic function.18 Integrin αVβ3 possesses four 
reported and nine potential N-glycosylation sites on the α subunit and two reported and four 
potential sites on the β subunit. Recently, several reports have suggested that the glycosylation 
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state of integrin αVβ3 can dramatically alter its migratory and angiogenic functions. In two 
separate reports, sialylation of integrin αVβ3 was found to be required for cell proliferation, 
migration, and regeneration in wound-healing assays.19,20 Panjwani and co-workers have shown 
that αVβ3’s glycosylation state also affects VEGF- and bFGF-mediated angiogenesis through an 
interaction with galectin-3.21 Motivated by the importance of αVβ3’s glycosylation state, we 
chose to pursue this integrin as a proof-of-concept glycoprotein for imaging its sialylation status. 
 We first investigated whether endogenous integrin αVβ3 is sialylated in the U87MG 
glioblastoma cell line, which is known to express the heterodimer complex at high levels.22 αVβ3 
was immunoprecipitated from U87MG lysate, and the presence of sialic acid on both subunits 
was assessed by lectin blotting. α2,3- and α2,6-linked sialosides can be distinguished by blotting 
with Maackia amurensis agglutinin (MAA) and Sambucus nigra lectins (SNA), respectively. 
After immunoprecipitation, we observed MAA binding to both integrin subunits, suggesting they 
are sialylated with α2,3-linked residues (Figure 4.3A). 
 
 
 
Figure 4.3. Incorporation of SiaNAz into integrin αVβ3 and U87MG cell surface 
glycoconjugates. A) Lectin blot of α and β subunits of immunoprecipitated αVβ3 with α2,6 
(SNA) and α2,3 (MAA) sialic acid binding lectins in the presence or absence of sialidase. B) 
Reactivity of αVβ3 subunits with phosphine-biotin. Cells were fed either Ac4ManNAz (Az) or 
Ac4ManNAc (Ac) for 3 days and incubated with phosphine-biotin, a probe for the presence of 
azides, in the presence or absence of sialidase. C,D) Fluorescence microscopy of U87MG cells 
treated with either Ac4ManNAz (C) or Ac4ManNAc (D) and then DIBAC-647 (C,D). Scale bars: 
50 µm. 
 
 Our FRET scheme is predicated on SiaNAz incorporation into the N-glycans of integrin 
αVβ3 (Figure 1). To confirm this, we supplemented cells with either Ac4ManNAz or Ac4ManNAc 
for 3 days. We then incubated cells with a biotin-conjugated phosphine, a bioorthogonal probe 
for the azido functionality.9 Cell lysates were subjected to immunoprecipitation with an anti-
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integrin αVβ3 antibody, and SiaNAz was detected by western blotting. Azide-dependent labeling 
was observed for both the alpha and beta chains of integrin αVβ3 (Figure 4.3B), suggesting that 
SiaNAz is present on both subunits of the heterodimer. We also confirmed that the azide-specific 
signal was indeed due to SiaNAz residues by digesting the lysates with sialidase, whereupon we 
observed a reduced signal on both integrin subunits (Figure 4.3B). 
 
Preparation and evaluation of Fab-594 and DIBAC-647 
 
 We next turned our attention to the selection of the proper FRET pair for the dual 
labeling strategy. Neuronal cell lines, such as U87MG, are known to exhibit strong flavin- and 
riboflavin-associated autofluorescence centered at 540-550 nm.23 To avoid cellular 
autofluorescence, we focused on donor fluorophores with emission above 600 nm. We ultimately 
chose the Alexa Fluor 594 (594) and Alexa Fluor 647 (647) fluorophore combination since 
Alexa Fluor 594’s emission maximum is 617 nm, and the Förster radius for the pair is 8.5 nm.  
 Preparation of the donor Fab fragment conjugate commenced by treating the monoclonal 
antibody against integrin αVβ3 (LM609 clone) with a peptidase that cleaves the full-length IgG 
between the Fab and Fc segments. The Fab fragment was separated from the Fc segment and 
unreacted IgG by incubation with protein A resin, and in a subsequent step the lysine residues 
were reacted with Alexa Fluor 594 N-hydroxysuccinimidyl ester to furnish the Fab–594 
conjugate. The acceptor cyclooctyne was also synthesized from commercially available reagents, 
dibenzoazacyclooctyne (DIBAC) amine and Alexa Fluor 647 N-hydroxysuccinimidyl ester. The 
ease of construction of both the donor, Fab-594, and the acceptor, DIBAC-647, targeting 
moieties underscores the versatility of this method and its applicability to other glycoprotein 
targets. 
 After the treatment of U87MG cells with Fab-594, we observed specific cellular labeling 
of membrane-associated αVβ3 that could be inhibited by the presence of full-length anti-αVβ3 IgG 
(Figure 4.4). We also sought to determine if DIBAC-647 was a faithful bioorthogonal probe for 
azides. Towards this end, we fed cells either Ac4ManNAz or Ac4ManNAc for 3 days and then 
incubated them with DIBAC-647. Cell-surface labeling occurred only in cells administered 
Ac4ManNAz (Figure 4.3C,D). 
 
 
 
Figure 4.4. Fluorescence microscopy of U87MG cells treated with Ac4ManNAz and Fab-594 in 
the absence (A) or presence (B) of anti-αVβ3 IgG. Scale bar: 50 µm.  
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Fluorescence lifetime imaging microscopy of integrin αVβ3’s sialylation state  
 
 After confirming the labeling of αVβ3’s protein backbone with the FRET donor Fab-594 
and SiaNAz residues with the FRET acceptor DIBAC–647, we focused on monitoring FRET 
using two-photon FLIM. The two-photon FLIM FRET technique entails exciting the donor 
fluorophore using near-IR/IR femtosecond pulses and monitoring the time-dependent 
fluorescence decay in the nanosecond regime.17 In the case when an acceptor fluorophore is in 
close proximity to the donor fluorophore, the excited state of the donor is depleted through 
energy transfer, which ultimately results in the reduced fluorescence lifetime (τ) of the donor 
molecule. We observed that Fab-594 had an in vitro characteristic τ value of 3.09 ns, which was 
determined by fitting the fluorescence decay of Fab–594 to a single exponential (Figure 4.5). In 
FLIM, the fluorescence emission for each pixel of an image is monitored in a time-dependent 
manner. The emission data are then fitted to extract the τ values, and these are displayed as a 
heat-map image.17 
 
 
 
Figure 4.5. Fluorescence decay histogram for Fab-594. The blue dots represent the arrival time 
of emitted photons with the single exponential fit (red line) overlaid. 
 
 FLIM images were obtained by incubating U87MG cells with either Ac4ManNAz or 
Ac4ManNAc for 3 days and then labeling cells with DIBAC-647 and Fab-594, sequentially. 
Cells that were treated with Ac4ManNAc had an average τ value of 2.91 ns (Figure 4.6A). The 
cell-surface regions had a relatively constant τ value, as represented by the deep blue color in the 
image in Figure 4.6A. On the other hand, in cells treated with Ac4ManNAz, the average τ value 
decreased to 2.60 ns (Figure 4.6B), which is consistent with cell-surface FRET24 between Fab-
594 and DIBAC-647; the cell-surface τ values appeared far more heterogeneous than in Figure 
4.6A, as evident by green and yellow clusters. Collectively, these data indicate that cell surface 
integrin αVβ3 is sialylated on U87MG cells. We further analyzed the τ values by constructing a 
histogram of the cell surface τ values for both Ac4ManNAc and Ac4ManNAz cell populations 
(Figure 3C). The decrease in the τ values from cells labeled with only the Fab-594 donor versus 
cells with both the Fab-594 donor and the DIBAC-647 acceptor was also accompanied by a 
switch from a unimodal (red) to a multimodal distribution (blue). These changes may reflect 
variations in the amount of sialylation on individual integrin αVβ3 molecules. As well, cells 
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lacking Fab-594 but labeled with the DIBAC-647 acceptor displayed minimal signal (Figure 
4.7A). 
 
 
 
Figure 4.6. FLIM imaging of sialylated integrin αVβ3. A,B) Two-photon FLIM images of 
U87MG cells treated with either Ac4ManNAc (A) or Ac4ManNAz (B), followed by DIBAC-647 
and Fab-594. FLIM images are the heat maps of τ values determined per pixel (see 
accompanying legend, right). C) Histogram of cell surface τ values for cells treated with either 
Ac4ManNAc (red bars) or Ac4ManNAz (blue bars) and then incubated with DIBAC-647 and 
Fab-594. Scale bars: 50 µm. 
 
FRET is integrin- and glycan-dependent 
 
 We further sought to evaluate whether the observed FRET arose from SiaNAz residues 
on integrin αVβ3 itself, or alternatively, from nearby sialic acid-modified glycoproteins or 
glycolipids. We reasoned that by adding an acceptor fluorophore to cell surfaces nonspecifically, 
while guaranteeing that the acceptor moiety was not bound to our integrin-of-interest, we could 
differentiate between sialylated integrin-dependent FRET and background FRET. Cells were 
first incubated with dipalmitoyl phosphatidylethanolamine (DPPE)-647, which incorporates the 
acceptor into cell membranes uniformly, and then followed with Fab-594 labeling. No decrease 
in τ values was observed in this case as cell surfaces appeared to maintain a similar hue to that of 
cells that only possess the Fab-594 fragment (Figure 4.7B,D). Thus, we reasoned that sialic acid 
residues on nearby proteins or lipids do not influence the FRET signal originating from αVβ3 
complexes. We also tested whether the observed FRET was a sialylation state-dependent 
phenomenon. We treated Ac4ManNAz-fed U87MG cells with a sialidase to cleave SiaNAz 
residues from cell surface glycoconjugates. The cells were further treated with DIBAC-647 and 
incubated with Fab-594. Sialidase treatment abolished the decrease in τ (Figure 4.7C,D), 
indicating that SiaNAz residues on integrin αVβ3 were critical for the observed FRET. 
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Figure 4.7. FLIM FRET is dependent on the proximity of the acceptor dye to Fab-594 and the 
target protein’s glycosylation state. FLIM images of A) Ac4ManNAz-fed U87MG cells treated 
with DIBAC-647 alone, B) U87MG cells modified with DPPE-647 and then incubated with Fab-
594, and C) Ac4ManNAz-fed U87MG cells first treated with sialidase and then incubated with 
DIBAC-647 and Fab-594. FLIM images are the heat maps of τ values determined per pixel (see 
accompanying legend, right). D) Histogram of cell surface τ values for cells treated with either 
Ac4ManNAc (black line), DPPE-647 (red line), Ac4ManNAz and sialidase (blue line), or 
Ac4ManNAz (green line) and then incubated with DIBAC-647 (black, blue, and green) and Fab-
594 (black, red, blue, and green). Scale bars: 50 µm. 
 
Imaging the glycosylation state of integrin αVβ3 in human prostate adenocarcinoma tissue slices 
 
 A unique attribute of this platform is that it can monitor the glycosylation state of 
endogeneous glycoproteins as well as image deep within a specimen, owing to the two-photon 
mode of excitation. We have previously shown that human prostate adenocarinoma tissue slices 
can metabolically incorporate azido sugars into their glycoproteins.25 Prostate cancers are known 
to undergo an upregulation in integrin αVβ3,26 which provided us an opportunity to apply our 
imaging technique to human tissue slices. Grade 3-4 precision-cut adenocarinoma tissue slices 
derived from an 8 mm core of a radical prostatectomy were cultured for 3 days in either 
Ac4ManNAz or Ac4ManNAc.We first determined that αVβ3 immunoprecipitated from tissue 
lysate, like αVβ3 derived from U87MG lysate, was recognized by MAA (Figure 4.8A) and 
incorporated SiaNAz residues into its glycans (Figure 4.8B). Using fluorescence microscopy, 
Fab-594 and DIBAC-647 were found to label prostate tissue slices in a αVβ3- and azide-
dependent manner (Figures 4.9 and 4.10), respectively. We next applied our FLIM FRET 
strategy to the tissue slices by first staining with DIBAC-647 and then with Fab-594. 
Ac4ManNAc-treated tissue slices displayed the characteristic Fab-594 τ value (Figure 4.11A,D), 
as evident by the blue color. The Ac4ManNAz-treated tissue slices showed a decrease in τ values 
(Figure 4.11B,D) that could be abrogated by treatment with sialidase (Figure 4.11C,D), again 
consistent with FRET and the presence of sialylated integrin αVβ3 embedded within the tissue 
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slices. These data show that we can probe protein glycosylation with increasing molecular 
precision. 
 
 
 
Figure 4.8. (A) Lectin blot of α and β subunits of immunoprecipitated αVβ3 from human prostate 
adenocarcinoma lysate with MAA in the presence or absence of sialidase. Reactivity of αVβ3 
subunits (B) from human prostate adenocarcinoma lysate (C) with phosphine-biotin. Prostate 
tissue slices were fed either Ac4ManNAz (Az) or Ac4ManNAc (Ac) for 3 days and incubated 
with phosphine-biotin in the presence or absence of sialidase. 
 
 
 
 
Figure 4.9. Fluorescence microscopy of human prostate adenocarcinoma tissue slices treated 
with Fab-594 in the absence (A) or presence (B) of anti-αVβ3 IgG. Fab-594 fluorescence (red) 
overlay with brightfield. Scale bar: 50 µm. 
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Figure 4.10. Confocal fluorescence microscopy of human prostate adenocarcinoma tissue slices 
treated with either Ac4ManNAz (A) or Ac4ManNAc (B) for 3 days and then incubated with 
DIBAC-647.  
 
 
 
Figure 4.11. FLIM images and lifetime histogram of grade 3-4 human prostate adenocarinoma 
tissue slices. Tissue slices were incubated with either Ac4ManNAc (A), Ac4ManNAz (B), or 
Ac4ManNAz and sialidase (C) and then treated with DIBAC-647 and Fab-594. FLIM images are 
the heat maps of τ values determined per pixel, (see accompanying legend, right). D) Histogram 
of τ values for tissues treated with either Ac4ManNAc (black line), Ac4ManNAz and sialidase 
(blue line), or Ac4ManNAz (red line) and then incubated with DIBAC-647 and Fab-594. Scale 
bars: 50 µm. 
 
Conclusion 
 
 In conclusion, we have developed a FLIM FRET-based method for visualizing the 
glycosylation state of specific glycoproteins. The method overcomes intrinsic limits of classic 
FRET imaging, which can be undermined by bleedthrough. As well, we can now also image 
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discrete protein glycoforms in whole tissue slices. The method therefore adds to a growing 
toolkit for characterizing cell surface glycomes with molecular precision. We plan on utilizing 
this technique in the future for imaging the cognate cell surface ligands for secreted lectins as 
well as for diagnostic purposes in monitoring the glycosylation status of specific glycoproteins. 
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Experimental Procedures 
 
General methods  
 
 All of the chemical reagents were of analytical grade, obtained from commercial 
suppliers, and used without further purification, unless otherwise noted. Alexa Fluor 594 
carboxylic acid, succinimidyl ester and Alexa Fluor 647 carboxylic acid, succinimidyl ester were 
obtained from Life Technologies, Inc. DIBAC-amine was purchased from Click Chemistry 
Tools. Ac4ManNAz and Ac4ManNAc were synthesized as previously described.27 All of the 
reactions were performed in a N2 atmosphere. Liquid reagents were added with a syringe. Unless 
otherwise noted, 1H and 13C{1H} spectra were obtained with either 400 or 500 MHz Bruker 
spectrometers. Chemical shifts (δ) are reported in parts per million and standardized against 
solvent peaks. High resolution electrospray ionization (ESI) mass spectra were obtained from the 
UC Berkeley Mass Spectrometry Facility. UV-Vis spectra were acquired on a Thermo Scientific 
NanoDrop 2000 Spectrophotometer. Reversed-phase HPLC was performed on a Varian system 
attached to an absorption detector using a C18 reverse phase column (5 µm, 250 x 4.6 mm, 
Agilent) for purifications. HPLC solvents were A: H2O with 0.1% TFA and B: MeCN with 0.1% 
TFA. Blot fluorescence was measured with a Typhoon 9410 imaging system (Amersham).  
 Dulbecco’s phosphate-buffered saline pH 7.4 (PBS), Dulbecco’s modified Eagle’s media 
(DMEM) without phenol red, and fetal bovine serum (FBS) were obtained from HyClone 
Laboratories. Antibodies and lectins were purchased from EMD Millipore, Jackson 
ImmunoResearch and Vector Laboratories. Tissue culture plates were obtained from Corning, 
and glass slides mounted with 4- and 8-tissue culture wells were obtained from Nunc. 
Fluorescence microscopy was performed on a Zeiss Axiovert 200M inverted microscope 
equipped with a 20x/0.75 Fluar air lens. Images were acquired by using a CoolSNAP HQ 
charged-coupled device camera (Roper Scientific). A 175 W Xenon lamp housed in a Sutter 
DG4 illuminator linked to the microscope by an optical fiber assured shuttering and illumination. 
SLIDEBOOK software (Intelligent Imaging Innovations, Inc.) was used to control the 
microscope and the camera and for image analysis.  
 Time-correlated single photon counting (TCSPC) data sets were acquired on an inverted 
Zeiss LSM510 NLO microscope with a Plan-Neofluar 40x/1.30 NA oil immersion lens equipped 
with a Becker & Hickl SPC-830 TCSPC controller. Samples were excited by two-photon, 
femtosecond 800 nm pulses generated by a 80 MHz Ti:sapphire laser (Coherent MiraSHG). 
Several turning mirrors were used to center and shape the focused laser beam using a fluorescent 
slide (Microscopy/Microscopy Education).  The non-descanned emission was collected from a 
back port, filtered through both a 700 nm shortpass (E700SP-2, Chroma) and a 615 nm bandpass 
filter (ET615/30m-2P, Chroma) and detected by a HPM-100-40 detector (Becker & Hickl) 
containing a hybrid Hamamatsu R10467-40 GaAsP photomultiplier tube. Images of 256 × 256 
pixels (256 time bins/pixel) were obtained and averaged over 10 acquisitions of 60 s. Photon data 
were analyzed using a combination of custom MATLAB (The Mathworks) scripts and 
SPCImage software (Becker & Hickl). 
 
Synthesis  
 
Dibenzoazacyclooctyne-647. A flame-dried RB flask containing a stir bar was charged with 
dibenzoazacyclooctyne amine (0.440 mg, 1.59 µmol), and dry DMF (44.0 µL). A solution of 
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Alexa Fluor 647 carboxylic acid, succinimidyl ester (1.00 mg) in dry DMF (456 µL) was added 
dropwise. To this suspension, DIPEA (0.700 µL, 4.00 µmol) was then added, and the mixture 
was stirred overnight at rt. After concentration, the crude solid was purified by reversed-phase 
HPLC using a gradient of 0% to 40% MeCN in H2O (0.1% TFA) over 45 min. The collected 
fractions were concentrated and lyophilized to yield a blue solid (1.10 mg). See 1H NMR 
spectrum below. HRMS (ESI): [M]3- found, m/z = 308.7328. λmax = 648 nm.  
 
Fab-594. Anti-integrin αVβ3 IgG (200 µg, LM609 clone) was concentrated and buffer exchanged 
into digestion buffer (Pierce), pH 10.0 with a 30k MWCO centrifugal filter (EMD Millipore) and 
treated with immobilized papain (Pierce) for 5.5 h at 37 oC. After filtration, unreacted IgG and 
Fc fragments were removed from the reaction mixture by treatment with immobilized protein A 
(Thermo) for 30 min at rt, followed by filtration. Cleavage and purification were assessed by 
SDS-PAGE under reducing conditions and indicated the presence of only Fab. Purified Fab was 
concentrated and buffer exchanged into PBS with a 10k MWCO centrifugal filter (EMD 
Millipore). After addition of Alexa Fluor 594 carboxylic acid, succinimidyl ester (3.67 µg, 4.48 
nmol) and 100 mM sodium bicarbonate, the mixture was rotated overnight at rt. Fab-594 was 
purified and concentrated with a 10k MWCO centrifugal filter, yielding a light pink solution 
(22.1 µM, DOL = 1.06). λmax = 590 nm.  
 
Cell culture 
 
 U87MG cells were cultured in DMEM media without phenol red and supplemented with 
10% FBS, 100 units/mL penicillin and 100 µg/mL streptomycin. The cells were maintained at 37 
°C and 5% CO2 in a water-saturated incubator and counted using a hemocytometer.  
 
U87MG lysate 
 
 U87MG cells were grown to 80-90% confluency on a 145 mm tissue culture dish. The 
cells were washed with two portions of PBS (10 mL). Lysis buffer (20 mM Tris-Cl, pH 7.5, 2 
mM EDTA, 150 mM NaCl, 1% Triton X-100, Roche protease inhibitors) was added and the cells 
were mechanically agitated. Lysate was then incubated at 4 °C for 20 min, followed by 
centrifugation at 12,000 x g for 40 min. The supernatant was removed, and the pellet was 
discarded. Protein concentration was determined using the BCA protein assay (Pierce), and the 
protein content was normalized across samples.  
 
Lectin blot   
 
 U87MG lysate was first treated with Protein A/G Ultralink Resin (Pierce) for 1 h at 4 °C. 
After centrifugation (2,500 x g, 3 min), the supernatant was removed and rotated overnight at 37 
°C with or without neuraminidase (1000 units, Clostridium perfringens, New England Biolabs). 
Anti-integrin αVβ3 antibody (5 µg) was subsequently added. The mixture was then rotated 
overnight at 4 °C. To this mixture, Protein A/G Ultralink Resin was administered and allowed to 
rotate for 4 h at 4 °C. Centrifugation was performed and the resin was washed (3X) with lysis 
buffer. Loading buffer was added to the resin and boiled at 95 °C for 5 min. SDS-PAGE was 
performed, followed by transfer to a nitrocellulose membrane. The membrane was first stained 
for protein with Ponceau. The membrane was then blocked with blocking buffer (0.5% Tween-
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20, DPBS containing calcium and magnesium) for 1 h at rt. The presence of sialic acid was 
probed with either SNA- or MAA-fluorescein lectin conjugates by incubating the membrane 
with either lectin at 1:1000 dilution in blocking buffer for 1 h at rt. After washing the membrane 
with blocking buffer (3X), the blot was imaged for fluorescence.  
 
Integrin αVβ3 azide incorporation 
 
 U87MG cells were cultured with either Ac4ManNAz or Ac4ManNAc (100 µM) for 3 
days in a 145 mm petri dish. After washing the cells twice with PBS (10 mL), lysates were 
formed according to the above procedure. Lysates were first treated with Protein A/G Ultralink 
Resin (Pierce) for 1 h at 4 °C. After centrifugation (2,500 x g, 3 min), the supernatant was 
removed and rotated overnight at 37 °C with or without neuraminidase (1000 units, Clostridium 
perfringens, New England Biolabs), followed by treatment with phosphine-biotin (250 µM) 
overnight at 37 °C. Anti-integrin αVβ3 antibody (5 µg) was added. The mixture was then rotated 
overnight at 4 °C. To this mixture, Protein A/G Ultralink Resin was administered and allowed to 
rotate for 4 h at 4 °C. Centrifugation was performed and the resin was washed (3X) with lysis 
buffer. Loading buffer was added to the resin and boiled at 95 °C for 5 min. SDS-PAGE was 
performed, followed by transfer to a nitrocellulose membrane. The membrane was first stained 
for protein with Ponceau. The membrane was then blocked with blocking buffer (5% BSA in 
0.05% Tween-20, DPBS) for 2 h at rt. The presence of biotin was probed with an anti-biotin, 
Alexa Fluor 647 antibody (1:3400 dilution, Jackson ImmunoResearch Laboratories) in blocking 
buffer for 1 h at rt. After washing the membrane with 0.05% Tween-20, DPBS (3X), the blot was 
imaged for fluorescence.  
 
Fluorescence microscopy 
 
 U87MG cells were cultured on slides mounted with 8-tissue culture wells in 0.3 mL 
containing Ac4ManNAz or Ac4ManNAc (100 µM). After 3 d, the cells were washed with DPBS 
+ 1% FBS (2 x 0.5 mL). To examine the labeling of SiaNAz residues, cells were then treated 
with DIBAC-647 (25 µM) in media for 1 h at 4 °C.  The cells were then washed with DPBS + 
1% FBS (3 x 0.4 mL) and fixed with 4% paraformaldehyde in PBS (0.2 mL) for 5 min at 4 °C 
and 15 min at rt. After washing with DPBS (4 x 0.2 mL), the cells were imaged in DPBS (0.2 
mL). To investigate Fab-594 specificity, cells were fixed with 4% paraformaldehyde in PBS (0.2 
mL) for 5 min at 4 °C and 15 min at rt; the cells were then washed with DPBS + 1% FBS (4 x 
0.2 mL). The cells were treated with either Fab-594 (500 nM) or Fab-594 and anti- αVβ3 IgG 
(500 nM each) in DPBS for 1 h at 4 °C. After washing with DPBS (3 x 0.4 mL), the cells were 
imaged in DPBS (0.2 mL).  
 
Fluorescence lifetime imaging microscopy (FLIM) 
 
 In a typical experiment, U87MG cells were cultured on slides mounted with 8-tissue 
culture wells in 0.3 mL containing Ac4ManNAz or Ac4ManNAc (100 µM). After 3 d, the cells 
were washed with DPBS + 1% FBS (2 x 0.5 mL). The cells were then treated with DIBAC-647 
in media for 1 h at 4 °C. After washing the cells with DPBS + 1% FBS (3 x 0.4 mL), the cells 
were fixed with 4% paraformaldehyde in PBS (0.2 mL) for 5 min at 4 °C and 15 min at rt. After 
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washing with DPBS (4 x 0.2 mL), the cells were incubated with Fab-594 (500 nM), followed by 
washing with DPBS (3 x 0.4 mL). The cells were imaged at rt in DPBS (0.2 mL). 
 Analysis of the acquired FLIM data was performed by first binning (3 pixels x 3 pixels) 
the time-dependent photon image and assigning a minimum threshold count of 50 recorded 
photons for modeling. Exponential fits (one-component) are obtained for the decay histogram 
with limits of 1 ns and 8 ns. Fluorescence lifetime values derived from the exponential fits are 
then displayed as a heat-map image. Cell surface lifetime values are also extracted using a search 
algorithm and displayed as a histogram.  
 
Metabolic labeling of human tissue slice cultures 
 
 Informed, signed consent was obtained from either the patient or next of kin for human 
samples. An 8 mm diameter core from a radical prostatectomy was embedded in agarose and 
segmented into thin slices (300 um thick) with an automated Krumdieck microtome. Tissue 
sections were retrieved, frozen, and evaluated for histopathology grading using hematoxylin and 
eosin stains.  These slices were loaded onto specially designed titanium screens and transferred 
to standard 6-well culture plates containing 2.5 ml of serum-free medium (PFMR-4A) 
supplemented with 10 ng/mL cholera toxin, 10 ng/mL epidermal growth factor, 40 µg/mL 
bovine pituitary extract, 100 µM phosphoethanolamine, 3 µM hydrocortisone, 30 nM selenous 
acid, 100 µg/mL gentamycin, 0.03 nM all-trans retinoic acid, 4 µg/mL insulin, 2.3 µM α-
tocopherol, and 50 nM synthetic androgen R1881 (in EtOH) and 50 µM Ac4ManNAz or 
Ac4ManNAc.  The dishes were rotated (1 rpm) on an inclined plane (30°) in a tissue culture 
incubator to permit full oxygenation of the tissue. Each day, the conditioned media was removed 
and replaced with fresh media. After three days, the conditioned media was again removed, and 
the slices washed with cold PBS prior to being snap-frozen in liquid nitrogen for storage.  
 
Human prostate tissue slice lysate 
 
 Prostate tissue slices were lysed in 1 mL of lysis buffer containing 20 mM Tris-Cl, pH 
7.4, 300 mM NaCl, 1% Triton X-100, and protease inhibitors (Calbiochem Inhibitor Cocktail III, 
EMD Millipore). The tissue was pulverized at 4 °C using a Tissue Tearor (setting 2, Biospec 
Products, Model #780CL-04) with cycles of 20 sec on/20 sec off for 3 min. Lysate was incubated 
at  4 °C for 30 min and the supernatant was collected after centrifugation at 10,000 rpm for 10 
min at 4 oC. The supernatant was collected, and a BCA protein assay (Pierce) was performed to 
determine protein concentration. The protein content was normalized across samples. 
 
Prostate tissue lectin blot 
 
 Prostate tissue lysate was first treated with Protein A/G Ultralink Resin (Pierce) for 1 h at 
4 °C. After centrifugation (2,500 x g, 3 min), the supernatant was removed and anti-integrin αVβ3 
antibody (5 µg) was subsequently added. The mixture was then rotated overnight at 4 °C. To this 
mixture, Protein A/G Ultralink Resin was administered and allowed to rotate for 4 h at 4 °C. 
Centrifugation was performed and the resin was washed (3X) with lysis buffer. Loading buffer 
was added to the resin and boiled at 95 °C for 5 min. SDS-PAGE was performed, followed by 
transfer to a nitrocellulose membrane. The membrane was first stained for protein with Ponceau. 
The membrane was then blocked with blocking buffer (0.5% Tween-20, DPBS containing 
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calcium and magnesium) for 1 h at rt. The presence of sialic acid was probed with a MAA-
fluorescein lectin conjugate by incubating the membrane with the lectin at 1:1000 dilution in 
blocking buffer for 1 h at rt. After washing the membrane with blocking buffer (3X), the blot 
was imaged for fluorescence.  
 
Prostate tissue azide incorporation  
 
 Prostate tissue lysates were formed according to the above procedure. The lysates were 
first treated with Protein A/G Ultralink Resin (Pierce) for 1 h at 4 °C. After centrifugation (2,500 
x g, 3 min), the supernatant was removed and rotated overnight at 37 °C with or without 
neuraminidase (1000 units, Clostridium perfringens, New England Biolabs), followed by 
treatment with phosphine-biotin (250 µM) overnight at 37 °C. Anti-integrin αVβ3 antibody (5 µg) 
was added. The mixture was then rotated overnight at 4 °C. To this mixture, Protein A/G 
Ultralink Resin was administered and allowed to rotate for 4 h at 4 °C. Centrifugation was 
performed and the resin was washed (3X) with lysis buffer. Loading buffer was added to the 
resin and boiled at 95 °C for 5 min. SDS-PAGE was performed, followed by transfer to a 
nitrocellulose membrane. The membrane was first stained for protein with Ponceau. The 
membrane was then blocked with blocking buffer (5% BSA in 0.05% Tween-20, DPBS) for 2 h 
at rt. The presence of biotin was probed with an anti-biotin, Alexa Fluor 647 antibody (1:3400 
dilution, Jackson ImmunoResearch Laboratories) in blocking buffer for 1 h at rt. After washing 
the membrane with 0.05% Tween-20, DPBS (3X), the blot was imaged for fluorescence.  
 
Prostate adenocarcinoma tissue slice fluorescence microscopy 
 
 Frozen tissue slices were placed on slides mounted with 4-tissue culture wells and 
allowed to thaw. Tissue slices were then washed with DPBS + 1% FBS (2 x 0.8 mL), followed 
by incubation with or without DIBAC-647 (25 µM) in DMEM media for 1 h at 4 °C. Tissues 
slices were subsequently washed with DPBS + 1% FBS (10 x 0.8 mL) and fixed with 4% 
paraformaldehyde in PBS (0.4 mL) for 5 min at 4 °C and 20 min at rt. After washing the tissues 
slices with DPBS (4 x 0.4 mL), the tissue slices were blocked with 10% Normal Goat Serum in 
DPBS (0.8 mL) for 1 h at rt. The blocking solution was removed, and the tissue slices were then 
treated with either Fab-594 (500 nM), Fab-594 and anti-αVβ3 IgG (500 nM each), or DPBS for 1 
h at 4 °C. The tissue slices were washed with DPBS (3 x 0.8 mL) and transferred to a concave 
microscope slide. After addition of DPBS (50 uL), a glass coverslip was used to seal the slide, 
and the tissue slices were imaged.  
 
Prostate adenocarinoma tissue slice FLIM 
 
 In a typical experiment, frozen tissue slices were placed on slides mounted with 4-tissue 
culture wells and allowed to thaw. Tissue slices were then washed with DPBS + 1% FBS (2 x 
0.8 mL), followed by incubation with DIBAC-647 (25 µM) in DMEM media for 1 h at 4 °C. 
Tissues slices were subsequently washed with DPBS + 1% FBS (10 x 0.8 mL) and fixed with 
4% paraformaldehyde in PBS (0.4 mL) for 5 min at 4 °C and 20 min at rt. After washing the 
tissues slices with DPBS (4 x 0.4 mL), the tissue slices were blocked with 10% Normal Goat 
Serum in DPBS (0.8 mL) for 1 h at rt. The blocking solution was removed, and the tissue slices 
were then treated with Fab-594 (500 nM) in DPBS for 1 h at 4 °C. The tissue slices were washed 
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with DPBS (3 x 0.8 mL) and transferred to a concave microscope slide. After addition of DPBS 
(50 uL), a glass coverslip was used to seal the slide.  
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Chapter 5. Glycomic Signatures Regulate Nuclear Galectin-1 to Pattern the Mammary 
Glanda 
 
 
Abstract 
 
 Branching morphogenesis in the mammary gland is achieved by the invasion of epithelial 
cells through a microenvironment consisting of stromal cells and dense extracellular matrix 
(ECM)1,2. Here we demonstrate that Galectin-1 (Gal-1), an endogenous lectin that recognizes N-
acetyllactosamine (LacNAc)-containing glycoconjugates, induces invasion and branching of 
mammary epithelia in vivo and in 3D organotypic cultures. The positive regulation of branching 
and invasion by Gal-1 was independent of its glycan-binding ability and instead was dependent 
on its localization within mammary epithelial nuclei. The nuclear translocation of Gal-1 was 
however dependent on a glycomic signature that was unique to the front of the mammary end 
bud. α2,6-sialylation (α2,6-SA) of terminal LacNAc residues in the end buds masked Gal-1 
ligands and promoted nuclear localization of Gal-1 and thereby epithelial invasiveness. 
Conversely, terminal LacNAc glycans, enriched in the epithelial ducts, sequestered Gal-1 in the 
extracellular environment, ultimately attenuating invasive potential. These findings suggest that 
the two glycomic signatures at the level of tissue microanatomy regulate the nuclear function of 
Gal-1. Our results also provide a novel glycan-lectin based mechanism through which the tissue 
microenvironment modulates the invasive behavior of mammary epithelia in a developmental 
context, suggesting a possible explanation of how malignant breast cells, which are rich in α2,6-
SA3 and Gal-1,4  could invade. 
 
Introduction 
 
 Gal-1 belongs to a small set of proteins that lacks a signal peptide but is secreted to the 
extracellular environment through unconventional mechanisms5. There, it interacts with 
glycoconjugates, modulating their surface organization and mediating cell-cell contact6. Within 
the cell, Gal-1 localizes to both the cytosol and the nucleus, where it appears to function 
independent of its glycan recognition7. To date, we have no explanation for the presumed distinct 
functions of Gal-1 in different subcellular contexts.   
 We and others have shown that tissue architecture is a dominant regulator of proliferation 
and invasion of cancer cells through their surrounding microenvironment8-10. While glycomic 
changes such as hypersialylation have long been shown to correlate with cell invasion, how 
glycan patterns and lectins mechanistically drive the invasion process remains obscure. 
Mammary epithelia also proliferate and invade their surrounding stroma during mammary gland 
development, although in a more controlled manner. Because Gal-1 is upregulated in invasive 
breast cancer, and tumorigenesis involves a radical change in glandular architecture, we 
hypothesized that Gal-1 could play a crucial role during the development of the mammary gland. 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
a Ramray Bhat contributed to work presented in this chapter. 
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Results and Discussion 
 
Gal-1 is concentrated in mammary gland end buds 
 
 Using immunofluorescence, we measured the levels of Gal-1 in murine mammary glands 
at distinct stages of development. Gal-1 levels were found to be highest during the early stages of 
branching morphogenesis (5 weeks post partum) (Figure 5.1a; Figure 5.2 shows weak to 
moderate levels of Gal-1 at other developmental stages of the mammary gland). Within 5-week 
glands, Gal-1 expression was highest in epithelial cells at the front of the end buds: bulbous 
microanatomical features that represent the invading fronts of the mammary arbor during the 
branching stage of development (Figure 5.1b). Gal-1 levels were low in the quiescent, 
noninvasive epithelia of mammary ducts even at this stage (Figure 5.1b). We also found a major 
difference in subcellular localization: Gal-1 in the end bud epithelia was predominantly nuclear, 
whereas, in the ductal cells, it was depleted from nuclei and instead showed weak levels in the 
cytosol and glycocalyx (Figure 5.1b). To understand whether Gal-1 levels were linked to the 
ability of mammary epithelia to invade into, and branch within, the mammary fat pad, we used 
laser scanning-based tissue autofluorescence/fluorescence imaging (LS-TAFI), an imaging 
technique that measures autofluorescence of thick tissues and accurately reconstructs three 
dimensional microanatomy11. Mammary gland whole-mounts from 5-week Gal-1-/- mice showed 
a decrease in branching and invasion of mammary epithelia within their fat pads compared to 
wildtype mammary glands (Figure 5.1c).  
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Figure 5.1. Nuclear Gal-1 drives mammary invasion and branching. a, Immunofluorescence 
micrographs of a five-week murine mammary gland stained with α-Gal-1 antibody (top) and 
DAPI (bottom). Scale bar, 100 µm. b, In the end bud, Gal-1 is enriched in the nucleus (top), 
whereas Gal-1 staining in the mammary duct is mainly extracellular (bottom). Scale bar, 10 µm. 
c, Autofluorescence micrographs of wildtype (left) and Gal-1-/- (right) murine mammary gland 
showing epithelial architecture (left panels). Scale bar, 1500 µm. Quantification of the number of 
terminal end buds (left graph), the number of branch points (middle graph), and the distance 
from lymph node (right graph) per gland for wildtype and Gal-1-/- murine mammary networks 
(N=3). d, Gal-1 KD Eph4 cells (top, left) ectopically expressing either NLS-GAL-1 (top, right), 
GAL-1 (bottom, left), or NES-GAL-1 (bottom, right) were cultured in a 3D collagen I (CL-I) 
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gel. Branching was observed only upon expression of GAL-1 or NLS-GAL-1. (Images taken 
with 20x objective). Inset fluorescence micrographs indicate the subcellular localization of each 
mYPet fusion construct. e, Quantification of GAL-1 nuclear:extranuclear ratio for each of the 
GAL-1 constructs. f, Quantification of the spatial network per cluster for each of the GAL-1 
constructs in 3D. Spatial network is defined as the sum of the branch lengths for each cluster. g, 
Gal-1 KD EpH4 cells ectopically expressing SEC-GAL-1 branch when cultured in a 3D CL-I gel 
(left panel). Scale bar, 100 µm. mYPet fluorescence of SEC-GAL-1 fusion construct is 
distributed between the extracellular space and the nucleus (right panel). Scale bar, 10 µm. For 
all bar graphs, error bars represent s.e.m. Statistical significance is given by *P < 0.05; **P < 
0.01; ***P < 0.001; ****P < 0.0001. 
 
 
 
Figure 5.2 Gal-1 levels at different developmental stages of mammary gland morphogenesis. 
Immunofluorescence micrographs of paraffin embedded sections of murine mammary glands 
during distinct stages of development, at 5 weeks but omitting the primary antibody, at 10 weeks, 
midpregnancy, lactation, and involution stained with α-Gal-1 antibody (upper panel) and DAPI 
(lower panel). Gal-1 levels are low after branching is complete and during pregnancy but 
increase moderately during lactation and during involution. Scale bar, 100 µm. 
 
Nuclear Gal-1 drives mammary gland branching and invasion 
 
 In order to probe whether the nuclear localization of Gal-1 at the end bud was required 
for epithelial invasion and branching, we relied on an organotypic 3D culture model of 
mammary epithelial cells. Upon addition of epidermal growth factor12-15, EpH4 mammary 
epithelial cells, embedded in collagen Type-1 (CL-1) matrix, invade into their surroundings and 
form branched structures.  Having confirmed the presence of endogenous Gal-1 within invading 
epithelia in 3D culture (Figure 5.3), we knocked down (KD) Gal-1 (Figure 5.4) and observed an 
abrogation of branching and invasion (Figure 5.1d).  We were able to rescue the invasive 
phenotype by overexpression of human Gal-1 (GAL-1). Having observed nuclear enrichment of 
Gal-1 in the end buds in vivo, we sought to evaluate invasion/branching in culture by 
overexpressing GAL-1 constructs tagged with specific localization signals: a nuclear localization 
signal (NLS) and a nuclear export signal (NES). The NLS tag directed nuclear localization of 
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GAL-1 and was able to rescue branching and invasion (Figure 5.1d and Figure 5.5), while 
expression of NES-GAL-1 resulted in the localization of GAL-1 to the cytoplasm and failed to 
rescue branching (Figure 5.1d and Figure 5.5). 
 
 
 
Figure 5.3. Gal-1 is concentrated in invading branches of EpH4 cells in 3D culture. Wildtype 
EpH4 cells exhibit branching and invasion when cultured in 3D CL-I gels and stained with α-
Gal-1 antibody and DAPI. The epithelia constituting the branches (bounded by trapezoid) show 
particularly high levels of Gal-1 when compared with the non-branching core (bounded by oval). 
Scale bar, 70 µm. 
 
 
 
Figure 5.4. shRNA-based Gal-1 knockdown. a, Immunoblot showing Gal-1 knockdown in 
lysates from EpH4 cells using one scrambled control shRNA and two separate shRNA clones 
against Gal-1. Ponceau staining of membrane indicates uniform loading. b, Immunofluorescence 
micrographs of control cells and cells transduced with Gal-1 shRNA lentivirus showing 
knockdown of Gal-1. Scale bar, 50 µm. 
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Figure 5.5. Localization of subcellular constructs and branching of EpH4 cells expressing 
subcellular constructs. a-b, Gal-1 KD Eph4 cells (top, left) ectopically expressing GAL-1 (top, 
right), NLS (bottom, left), or NES (bottom, right) tagged with mYPet or only mYPet (top, right) 
were cultured in 2D and in (b) 3D . c-d, Gal-1 KD Eph4 cells ectopically expressing SEC-GAL-
1 (top) fused to mYpet and SEC-mYpet (bottom) were cultured in (c) 2D and in (d)3D. Scale 
bar, 50 µm.  
 
 Endogenous Gal-1 is known to be secreted to the extracellular space through an 
unconventional secretion pathway16. But, we wanted to ensure that once translated within 
mammary epithelia, Gal-1 is first secreted to the extracellular space before it has the opportunity 
to traffic elsewhere. Therefore, we overexpressed GAL-1 with an extracellular secretion signal 
peptide (SEC) tag. SEC-GAL-1 was secreted and then relocalized back within the nucleus, and 
also rescued branching (Figure 5.1e; Figure 5.5, Figure 5.6 for confirmation of the nuclear 
localization of SEC-GAL-1 within mammary epithelia cocultured with SEC-GAL-1 expressing 
cells, and Figure 5.7 showing nuclear localization of exogenously added GAL-1). These data 
together suggest that nuclear Gal-1 is necessary and sufficient for invasion and branching and 
that Gal-1 is able to translocate from the extracellular space to the nucleus. 
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Figure 5.6. SEC-GAL-1 translocates to mammary epithelial nucleus in adjacent cells. Gal-1 KD 
EpH4 cells ectopically expressing NLS-mCherry were co-cultured with GAL-1 KD EpH4 cells 
ectopically expressing SEC-GAL-1 fused to mYpet. Fluorescent micrographs show 
colocalization of both mCherry and mYpet (white arrowheads). Scale bar, 50 µm.  
 
 
 
Figure 5.7. Nuclear translocation of exogenous GAL-1. Immunofluorescence micrographs of 
Gal-1 KD Eph4 cells cultured in 3D CL-I gels with exogenous GAL-1-Alexa Fluor 633 showing 
branching when stained with F-actin and DAPI. Scale bar, 50 µm. 
 
 Galectin-glycan recognition has previously been reported to influence cell invasion and 
migration17. Consequently, we investigated if mammary epithelial invasion was at all dependent 
on Gal-1’s interaction with its cognate glycan ligands by constructing the N46D mutant of GAL-
1, which attenuates glycan binding18. Overexpression of GAL-1 (N46D) in Gal-1 KD EpH4 cells 
rescued the branching phenotype in 3D similar to wildtype Gal-1 (Figure 5.8a). When these same 
cells were cultured in 2D, the mutant GAL-1 showed a greater degree of nuclear localization 
than wildtype Gal-1 (Figure 5.8b,c). This led us to hypothesize that cognate glycan ligands of 
Gal-1 may modulate the subcellular distribution of Gal-1 but are not required for Gal-1’s effect 
on branching. As well, we noted that endogenous nuclear Gal-1 levels were higher in cells 
	   88 
cultured in 3D, compared to cells cultured in 2D, emphasizing the importance of the cellular 
microenvironment in regulating the subcellular localization of Gal-1 (Figure 5.8d,e).  
 
 
 
Figure 5.8. Nuclear localization of Gal-1 is dependent on extracellular glycan ligands. a-b, 
Fluorescence micrographs of Gal-1 KD EpH4 cells ectopically expressing GAL-1 (left panel) 
and GAL-1 (N46D) (right panel) fusion proteins in 3D (a) or 2D (b) and stained with F-actin and 
DAPI. Cells expressing GAL-1 (N46D), a mutant with attenuated glycan binding, invade and 
branch when cultured in 3D. Scale bar, 100 µm. c, Quantification of GAL-1 nuclear:extranuclear 
ratio shows GAL-1 (N46D) is concentrated in the nucleus. d, Immunofluorescence micrographs 
of EpH4 cells cultured in 2D (left panel) or in a 3D CL-I gel (right panel) and stained with an α-
Gal-1 antibody and DAPI. Scale bar, 25 µm. e, Quantification of Gal-1 nuclear:extranuclear ratio 
for EpH4 cells cultured in 2D vs. 3D. f, Fluorescence micrographs of GAL-1 expressing EpH4 
cells grown on top of CL-I gels treated with either a soluble lactosyl GP, which binds Gal-1, or a 
soluble cellobiosyl GP, which does not interact with Gal-1. Scale bar, 50 µm. g, Quantification 
of the GAL-1 nuclear:extranuclear ratio for EpH4 cells treated with either the lactosyl GP or the 
cellobiosyl GP. h, Immunofluoresence micrographs of EpH4 cells cultured in 3D CL I gel in the 
presence or absence of either lactosyl GP or cellobiosyl GP and then washed and stained with F-
actin, DAPI and α-Gal-1 antibody. Scale bar, 100 µm. i, Quantification of the spatial network per 
cluster of EpH4 cells in the presence or absence of GPs. For all bar graphs, error bars represent 
s.e.m. Statistical significance is given by *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. 
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Gal-1 subcellular localization is dependent on glycan microenvironment 
 
 What controls the relative abundances of Gal-1 in the different cellular compartments? 
To answer this, we re-engineered the glycan microenvironment surrounding the cells using 
glycopolymers that mimic ECM glycoproteins19. We generated glycopolymers (GPs) 
functionalized with Gal-1 ligands (lactosyl GP) or control glycan structures (cellobiosyl GP) that 
do not associate with Gal-1. When lactosyl GP was incubated with mammary epithelial cells 
cultured on top of collagen, we found a marked decrease in nuclear GAL-1 after 1 day (Figure 
5.8f,g). In contrast, untreated cells and cells treated with cellobiosyl GP showed greater levels of 
nuclear GAL-1. When lactosyl GP was added to 3D CL-I cultures, we found an abrogation of 
branching/invasive phenotype (Figure 5.8h,i). Gal-1 was not visible after washing lactosyl GP-
treated cells. In contrast, Gal-1 staining was evident in branching cultures of cells treated with 
cellobiosyl GP.  
 The addition of α2,6-SA residues is known to negatively regulate Gal-1’s binding to 
LacNAc epitopes20,21. We found that engineering the levels of extracellular sialic acid residues 
capping terminal LacNAc structures increases the translocation of Gal-1 to the nucleus. Through 
the use of two independent methods, exogenous addition of Ac4ManNAc, a metabolic precursor 
of sialic acid, and overexpression of GNE, the rate-limiting enzyme in sialic acid synthesis, we 
were able to vary the extent of cell surface sialylation22 (Figure 5.9a). In both methods, α2,6-SA 
levels, measured by staining of Sambucus nigra lectin (SNA)22 increased (Figure 5,9b) and so 
did the nuclear Gal-1 levels (Figure 5.9c). We also knocked down GNE with shRNA in EpH4 
cells, which caused a decrease in branching and invasion in 3D (Figure 5.9d). 
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Figure 5.9. α2,6 SA regulates nuclear localization and mammary patterning by Gal-1. a, 
Fluorescence micrographs of EpH4 cells overexpressing GNE (middle panel), the rate limiting 
enzyme in sialic acid biosynthesis, or treated with the small molecule Ac4ManNAc (right panel), 
which is processed by the sialic acid salvage pathway. EpH4 cells were stained with Sambucus 
nigra lectin (SNA), which is specific for α2,6 linked SA , and with an α-Gal-1 antibody. Scale 
bar, 50 µm. b, Overexpression of GNE and Ac4ManNAc administration increases α2,6 linked 
SA levels in EpH4 cells. c, Quantification of Gal-1 nuclear:extranuclear ratio of EpH4 cells with 
varying levels of cell surface sialylation. d, Fluorescence micrographs of GNE KD EpH4 cells 
cultured in a 3D collagen I gel and stained with SNA and DAPI. Branching and invasion is 
absent in EpH4 cells lacking α2,6 SA residues. Scale bar, 50 µm. e, Model of extracellular 
glycan patterns regulating nuclear Gal-1 in mammary epithelial cells. In a LacNAc-rich 
environment containing intact ECM proteins, Gal-1 is mainly concentrated in the extracellular 
space (left). However, α2,6 sialylation of LacNAc structures causes Gal-1 to accumulate in the 
nucleus, resulting in an invasive phenotype (right). f, Immunofluorescence micrographs of 
murine mammary gland stained with Erythrina Crystagalli lectin (ECL) (top, right), which is 
specific for terminal LacNAc disaccharides, an α-Gal-1 antibody (bottom, left), and DAPI (top, 
left). LacNAc appears to line the ductal epithelia, whereas Gal-1 is heavily concentrated in the 
invasive end bud. Scale bar, 150 µm. g, Fluorescence micrographs of murine mammary gland 
stained with SNA (bottom) and DAPI (top) show high levels of α2,6 SA residues in the invasive 
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end bud of the mammary gland. Scale bar, 200 µm. For all bar graphs, error bars represent s.e.m. 
Statistical significance is given by ***P < 0.001; ****P < 0.0001. 
 
 Our data therefore point to a dynamic reciprocity between the glycan microenvironment 
and nuclear Gal-1 levels. In the case when the extracellular environment contains an excess of 
Gal-1 ligands, e.g. terminal LacNAc epitopes, the ‘equilibrium’ favors the accumulation of Gal-1 
outside of the cell (Figure 5.9e). Here, the extracellular glycan environment acts as a molecular 
sink for Gal-1, trapping it. On the other hand, when Gal-1 is unable to bind extracellular glycan 
ligands, e.g. GAL-1(N46D) or due to presence of α2,6-SA residues, the ‘equilibrium’ shifts to a 
higher abundance of nuclear Gal-1, promoting epithelial invasiveness. 
 We sought to determine if this mechanism is relevant to, and operative during, in vivo 
mammary branching morphogenesis. Towards this end, 5 week-old fixed mammary gland whole 
mounts were stained with a FITC-Erythrina Crystagalli lectin (ECL), which recognizes 
unmodified terminal LacNAc residues,23 and for Gal-1. Fluorescence microscopy displayed 
mutually exclusive signals for nuclear Gal-1 and extracellular LacNAc: nuclear Gal-1 was 
strongly present in the TEBs whereas LacNAc levels were highest in the ducts (Figure 5.9f). 
Sections of 5-week mammary gland ducts stained for LacNAc showed strong colocalization with 
the basement membrane and low levels of extracellular Gal-1 (Figure 5.10). We also confirmed 
our in vivo glycan findings with branching mammary epithelia clusters in culture (Figure 5.11): 
fixed branching mammary epithelia showed high levels of LacNAc, except at the invasive tips 
which showed little to no LacNAc. These tips, on the other hand, had high levels of nuclear Gal-
1.  
 
 
 
 
Figure 5.10. Gal-1 colocalizes with terminal LacNAc and laminin in mammary ductal epithelia. 
Immunofluorescence micrographs of a five-week murine mammary gland section showing 
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mammary ductal epithelia stained with DAPI (top, left), α-Gal-1 antibody (bottom, left), ECL 
(top, right), and α-pan-laminin antibody (bottom, right). Scale bar, 20 µm. 
 
 
 
Figure 5.11. Localization of Gal-1 and terminal LacNAc in EpH4 cells cultured in 3D. 
Immunofluorescence micrographs of branching Eph4 cells cultured in 3D CL-I gels stained with 
DAPI (top, left), α-Gal-1 antibody (bottom, left) and ECA (top, right). Scale bar, 50 µm. 
 
 Consistent with our model, we also detected high levels of α2,6-SA in the terminal end 
buds in vivo and the branching mammary epithelia in 3D cultures (Figure 5.9g). This result is in 
agreement with data from a microarray set which showed higher gene expression for ST6Gal1, 
an enzyme that adds α2,6-SA and blocks Gal-1 binding, within end bud epithelia compared to 
ductal epithelia24,25.  
 
Conclusion 
 
 In summary, we have demonstrated that glycans of the mammary tissue 
microenvironment determine the invasive and branching behavior of mammary epithelia by 
regulating the nuclear localization of Gal-1. LacNAc, the cognate glycan ligand for Gal-1, acts as 
a sink to retain Gal-1 in the extracellular mileu. We found significant levels of unmodified 
LacNAc and low nuclear Gal-1 levels in the quiescent ductal epithelia of mammary glands. α2,6-
siaylation increased nuclear Gal-1 levels by disrupting the binding of Gal-1 to glycoconjugates. 
We found significant levels of α2,6-SA and high nuclear Gal-1 levels in the proliferating 
epithelia at the invading edge of mammary end buds. The induction of invasion and branching by 
Gal-1 in the nucleus could be mediated by its positive regulation of Erk1/2, a mitogen activating 
protein kinase (MAPK), levels and activity26 (Figure 5.12).  
 
	   93 
 
 
Figure 5.12. Nuclear Gal-1 enhances Erk1/2 activity. Immunoblot (left) showing levels of 
endogenous Gal-1, ectopically expressed GAL-1, Erk1/2 and phosphorylated Erk1/2 (from 
bottom to top) in control (scrambled shRNA) cells, Gal-1 KD cells, Gal-1 KD cells ectopically 
expressing GAL-1, Gal-1 KD cells ectopically expressing NLS-GAL-1, and GAL-1 KD cells 
ectopically expressing SEC-GAL-1 (from left to right). Tubulin levels indicate uniform loading. 
 
 In vitro studies have shown that nuclear Gal-1 is involved in pre-mRNA splicing27. We 
observed that Gal-1 localizes to the spliceosomes of mammary epithelia (Figure 5.13a), 
suggesting that it may be part of Gemin-4-containing spliceosomal complexes. A knockdown of 
Gemin-4 expression in mammary epithelia using shRNA (Figure 5.13b) resulted in an abrogation 
of branching: the cells remained alive and formed noninvasive spherical clusters, phenocopying 
Gal-1 KD cells (Figure 5.13c). This strongly suggests that the interaction of Gemin-4 and Gal-1 
within the nucleus can modulate mammary epithelial invasiveness. This interaction could also be 
the mechanism by which nuclear Gal-1 regulates the levels of proteins such as MAPK and in 
turn promotes differential mammary end bud proliferation. Invasive breast cancer cells have high 
levels of α2,6-SA3,28,29, which blocks Gal-1 binding, as well as an increase in Gal-1 protein 
levels30,31. Our results provide insight into this paradoxical finding. Translocation of Gal-1 to the 
nucleus of malignant breast cancer due to hypersialylation may provide a path to cancer cell 
invasion, which has implications for the future of Gal-1 specific inhibitors in breast cancer 
treatment.  
 
	   94 
 
 
Figure 5.13. Association of Gal-1 and Gemin-4 in mammary epithelial nuclei. a, 
Immunofluorescence micrographs of EpH4 cells depleted of soluble nuclear chromatin fraction, 
cytoplasmic fraction and DNA, stained with an α-Gal-1 antibody and an α-Gemin-4 antibody. 
Scale bar, 200 µm. b, Immunofluoresence micrographs of EpH4 cells, control (top) and with 
Gemin-4 KD, cultured in 2D and stained with DAPI and α-Gemin-4 antibody. Scale bar, 50 µm. 
c, Immunofluorescence micrographs of control and Gemin-4 KD EpH4 cells cultured in 3D and 
stained with Phalloidin and DAPI (left) to assess branching morphology and Calcein AM vital 
dye (right) to assess viability. Scale bar, 200 µm. 
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Experimental Procedures 
 
Immunofluorescence 
 
 Freshly dissected mammary glands were fixed with 4% paraformaldehyde for 15 minutes 
and then with Carnoy’s fixative (75% ethanol and 25% glacial acetic acid) overnight. This was 
followed by serial dehydration and overnight treatment with xylene.  Dehydrated tissues were 
processed for paraffin embedding and sectioning. H&E stained and unstained 5 mm tissue 
paraffin sections were generated by the UCSF Helen Diller Family Comprehensive Cancer 
Center Mouse Pathology Core. Deparaffinized sections were subjected to microwave-based 
antigen retrieval using citrate buffer (pH 6) for 10 min. The sections were then blocked with PBS 
containing 5% normal goat serum, 1% BSA and 0.05% Tween-20 for 1 hour at rt, followed by 
incubation with rabbit polyclonal α-Gal-1 antibody (Abcam ab25138), diluted 1:200, overnight 
at 4°C. All images were obtained using a laser scanning confocal microscope LSM710 (Zeiss).  
 
Immunostaining of mammary whole-mounts 
 
 Mammary whole-mount of 5-week-old C57BL/6 mice was used. The mammary tissue 
was processed as previously described11 with some modifications in order to perform 
immunostaining. The antigen retrieval was performed as described earlier. Then, the mammary 
whole-mount was incubated with Triton-X 100 (0.1%) for 25 min and blocked (5% normal goat 
serum + 1% BSA + 0.05% Tween-20) overnight at 4°C. This was followed by incubation with 
anti-heparanase antibody, diluted at 1:15, overnight at 4°C. The tissue was washed for 24 hours. 
The secondary antibody used was Alexa Fluor 633-conjugated goat anti-rabbit (1:100), incubated 
overnight. Finally, the tissue was washed for 24 hours, dehydrated and mounted in Permount 
(Fisher Scientific, PA). Images were obtained using a confocal microscope (LSM710, Zeiss) 
using 10X and 40X lens. The lambda scan mode in the confocal was utilized to determine the 
maximum emission of the autofluorescence and from the secondary antibody.  
 
EpH4 cell culture and preparation of cell clusters 
 
 EpH4 cells were maintained in 1:1 DMEM/F12, supplemented with 10% fetal bovine 
serum (Invitrogen, Carlsbad, CA) and 50 µg/ml gentamycin (EpH4 media). The EpH4 cells were 
used between passage 10 and 20. EpH4 cells suspended in growth medium were plated in six-
well polyHEMA-coated plates (2x105 cells per well) and incubated overnight at 37°C, yielding 
rounded clusters. Single cells were removed by differential centrifugation, and the final pellet 
was plated again in six-well plates overnight. Finally, cell clusters were centrifuged and 
resuspended in the desired amount of the medium described above. 
 
Three dimensional (3D) collagen I (CL-1) gel 
 
 For 3D cell cultures, EpH4 cell clusters were embedded in CL-1 gels. Briefly, acid-
soluble collagen (900 µl of a 5 mg/ml solution), Cellagen (AC-5, ICN, Koken, Tokyo, Japan) 
was gently mixed on ice with 112.5 µL 10X DMEM/F12, followed by 85 µL of 0.1 N NaOH and 
375 µL of DMEM/F12. Around 250 clusters were plated in each well. Two layers of collagen 
were poured into each well: a basal layer consisting only of CL-1 and an upper layer containing 
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clusters of EpH4 cells. To allow solidification of the basal CL-1 layer, 75 µL of the CL-1 
solution was poured into each well of a 48-well dish and incubated at 37 °C for 15 min. A 
second layer of 220 µL of CL-1 containing 250 EpH4 clusters was added to each well and placed 
immediately at 37°C. After gelation, 300 µL of chemically defined medium (DMEM/F-12 
containing 1% insulin/transferrin/selenium, 1% penicilin/streptomycin) with 9 nM bFGF (Sigma) 
was added to each well and replaced every other day. Where indicated, Calcein AM dye (Life 
Technologies) was used to assess for cell viability. As exogenous treatments, we used 25 µM 
Ac4ManNAc (controls were treated with an appropriate amount of vehicle DMSO). In 
experiments with exogenous Gal-1, human recombinant Gal-1, either unconjugated, or 
conjugated with Alexa Fluor 633 using a Protein labeling kit (Life Technologies), was used.  
 
Analysis of branching morphogenesis 
 
 The branching phenotype of EpH4 clusters embedded in collagen I gel was determined 
after a 5-day culture period. The branching phenotype was defined as a cell cluster having at 
least two processes extending from its central body. Quantification of EpH4 cell branching was 
carried out by counting the number of branching clusters in each well.  In addition, we analyzed 
the number of branches in each cluster. All experiments were repeated at least three times. 
 
shRNA and constructs of expression 
 
 To transduce FLAG-tagged human GAL-1F, NLS-GAL-1F (with nuclear localization 
signal sequence, PHPPKRLRSDPDAC, from Gemin-4 as predicted by cNLSMapper32), NES-
GAL-1F (with nuclear exclusion signal sequence, INQMFSVQLSL, from Staufen-233), SEC-
GAL-1 (with signal peptide sequence, MYSMQLASCVTLTLVLLVNS, from Interleukin-2), 
N46D GAL-1 and myc-tagged GNE, each cDNA was made by PCR, confirmed by sequencing 
and ligated into pLenti-EF1α-puro, generated in our laboratory. Lentivirus plasmids containing 
shRNA (Mission shRNA; Sigma, St Louis, USA) against mouse Gal-1, Gemin-4 and GNE or 
lentivirus plasmids containing GAL-1 or variant constructs were transfected into 293FT cells 
using FuGene6 (Roche, Basel, Switzerland). Transfected cells were cultured in DMEM 
containing 5% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin. Culture media was 
replaced after 24 hours with fresh media. Forty-eight hours later, recombinant lentivirus was 
concentrated from filtered culture media (0.45 µm filters) by ultracentrifugation at 100,000 g for 
90 minutes (SW41Ti rotor; Beckman Coulter, Brea, USA). To transduce EpH4 cells, 1.0×105 
cells were plated in each well of a six-well plate, infected with the lentivirus, treated with 
polybrene for 30 minutes and selected by adding 5 µg/ml puromycin to growth medium for 4 
days. Lentivirus with scrambled sequence was used as an shRNA control. Template plasmids for 
Ypet and mCherry were purchased from Addgene (http://www.addgene.org) and alanine 206 
mutated to lysine (monomeric). Monomeric Ypet or mCherry were fused, respectively, with the 
C terminus of GAL-1F or its variants by PCR. All the sequences were confirmed by sequencing. 
 
Western blotting 
 
 To check knockdown and overexpression, EpH4 cells were cultured in EpH4 media or in 
CL-1 gel (3 mg/ml) for 48 hours in serum-free media (DMEM/F-12 containing 1% 
insulin/transferrin/selenium, 1% penicilin/streptomycin) with 9 nM bFGF (Sigma). For protein 
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isolation, media was removed, and the cells were washed with PBS and then lysed with a buffer 
containing 20 mM Tris (pH 7.5), 150 mM NaCl, 0.5% Tween with protease and phosphatase 
inhibitor cocktails (EMD Millipore, Billerica, USA). Protein concentration was determined using 
the BCA Protein Assay kit (Thermo Scientific, Waltham, USA). Protein samples were mixed 
with Laemmli sample buffer and heated at 95°C for 5 minutes. Samples were loaded into a pre-
cast 4-20% tris-glycine polyacrylamide gel (Invitrogen) using the NOVEX system (Invitrogen). 
Resolved proteins were transferred to nitrocellulose membrane (Whatman, Maidstone, UK) 
followed by blocking in PBS, 0.05% Tween-20 with 3% BSA for 1 hour at room temperature. 
Membranes were incubated overnight at 4°C in 5% BSA, 0.1% Tween-20 in PBS containing α-
Gal-1 antibody (Abcam), anti-α-tubulin antibody (Sigma), anti-Erk1/2 antibody and anti-
PhosphoErk1/2 antibody (Cell signaling). Primary antibodies were detected with the Pierce 
SuperSignal detection kit (Rockford, IL) and signal was captured with the FluorChem 8900 
analysis system (Alpha Innotech, San Leandro, CA).  
 
Glycopolymer treatment  
 
 Soluble lactosyl and cellobiosyl GPs were synthesized as previously described.19 Briefly, 
polymerizations were carried out using standard Schlenk techniques. CTA 2.21 (4.09 mg, 4.55 
µmol), lactosyl ethyl acrylamide 2.17 or cellobiosyl ethyl acrylamide 2.20 (0.100 g, 228 µmol), 
4,4′-azobis(4-cyanovaleric acid) (319 µg, 1.14 µmol), DMF (200 µl) and H2O (800 µl) were 
added to the Schlenk tube. The solution was degassed by sparging with N2 for 30 min. The 
Schlenk flask was placed in a 70 oC bath to start the polymerization. After 16 h, the reactions 
were stopped by exposure to oxygen. The conversion for the glycosyl monomer was calculated 
by comparing the integrals of the alkene proton peaks of the monomer (5.7 ppm, 1H) and those 
of the backbone methylene protons on the glycopolymer (1.87- 1.00 ppm, 2H). Glycopolymers 
were purified by dialysis against H2O for 72 h and lyophilized. 
 
Lactosyl GP. According to the above procedures, lactosyl GP was obtained as a light yellow 
solid (90.2 mg, 89%). Conversion (NMR) = quant. PDI (SEC) = 1.1. 1H NMR (500 MHz, D2O): 
δ 4.61 – 4.33 (m, 100H), 4.12 – 3.20 (m, 800H), 2.33 – 1.87 (m, 47H), 1.87 – 1.38 (m, 77H), 
1.10 (s, 12H).  
 
Cellobiosyl GP. Cellobiosyl GP was prepared using the above procedure to yield a light yellow 
solid (87.9 mg, 87%). Conversion (NMR) = quant. PDI (SEC) = 1.2. 1H NMR (500 MHz, D2O): 
δ 4.65 – 4.36 (m, 100H), 4.15 – 3.12 (m, 800H), 2.35 – 1.87 (m, 41H), 1.87 – 1.38 (m, 73H), 
1.38 – 1.09 (m, 26H). 
 
EpH4 cells cultured on top or embedded within CL-1 gels were incubated with lactosyl GP, 
cellobiosyl GP, or no GP for 1- 3 days. After 1 day, GAL-1 expressing EpH4 cells on top of CL-
1 gels were imaged using confocal fluorescence microscopy. After 3 days, EpH4 cells embedded 
within a CL-1 were washed extensively and then treated with α-Gal-1 antibody (Abcam), 
phalloidin, and DAPI. The cells were then imaged using confocal fluorescence microscopy.  
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Visualization of intranuclear bodies 
 
 For visualization of nuclear matrix proteins, extraction of soluble nuclear and 
cytoplasmic fractions was performed as previously described34. After washing with PBS, cells 
were extracted for 3 min with ice-cold cytoskeletal (CSK) buffer (10 mM PIPES, 300 mM 
sucrose, 100 mM NaCl, 3 mM MgCl2, 0.5% Triton X-100, pH 6.8) with protease inhibitors 
(Roche). Next, DNA was digested by DNAse I (Boehringer, Indianapolis, IN) in CSK buffer, 50 
mM NaCl, for 1 h at 32 °C. Chromatin was then washed out with CSK buffer. Chromatin 
removal was confirmed with DAPI staining. Cells were then washed with 0.25 M ammonium 
sulfate in CSK followed by a 2M NaCl wash. Finally, cell were washed three times with PBS, 
fixed in 4% ultrapure paraformaldehyde as described above, immunostained (for endogenous 
Gal-1 and Gemin-4), and imaged with a laser scanning confocal microscope (LSM710, Zeiss) 
using 40X water immersion lens. 
 
Statistics 
 
 Data were analyzed using the unpaired student’s t test and error bars indicate the standard 
error of the mean.  
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Appendix 
 
1H, 13C, 31P, and 19F NMR and UV-Vis Spectra, GPC Traces 
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